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ABSTRACT 
The detection of the Bcr-Abl gene in chronic myeloid leukaemia (CML) has resulted in the development 
of novel tyrosine kinase inhibitors (TKIs), such as imatinib that particularly interfere with the ATP binding 
pocket of the Abl kinase domain of the Bcr-Abl protein. Imatinib is currently used as a frontline therapy, 
with impressive outcomes at producing long-term clinical remission among many CML patients; however, 
resistance to imatinib has been reported in patients due to the development of Bcr-Abl mutations and/or 
intolerance to the drug. Potent second generation TKIs, namely nilotinib and dasatinib, have since been 
developed and approved to address this therapeutic challenge. With their prompt and noticeable deep 
molecular and haematological remission properties, dasatinib and nilotinib have provided a significant 
effect and efficiency against leukaemic cells. However, due to the side effects and challenges linked to 
dasatinib, imatinib, and nilotinib, ponatinib which is a new third generation TKI inhibitor multi-kinase drug 
has been developed to be effective against leukemic cells containing the Bcr-Abl resistance mutation T315I. 
Nevertheless, ponatinib can inhibit T315I Bcr-Abl mutant enzymes selectively especially the ones which 
are not sensitive to new Bcr-Abl inhibitors obtainable at clinics. 
 
The management of malignancy in a significant proportion of patients and their survival is improved using 
these later generation drugs, therefore, recent studies have concentrated on their toxicity. For instance, in 
the case of ponatinib and nilotinib, clinical studies have revealed excessive and unnecessarily severe 
vascular problems, such as peripheral arterial occlusive disease (PAOD) and arterial occlusive events 
compared with other TKIs. Consequently, this had led to an increased desire to limit the pathophysiology 
of cardiovascular risk factors. 
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Cardiovascular disease is a major clinical issue and a leading cause of illness, disability and mortality in 
the world, specifically in industrialised countries. Platelets are essential in normal haemostasis as they 
prevent blood loss following trauma by blood clot formation and they sustain vascular integrity. They also 
play a crucial role in the pathophysiological processes of atherosclerotic plaque and arterial thrombotic 
disease by contributing to vaso-occlusive thrombotic mechanisms that generate ischaemic traumatic 
damage in cardiovascular and peripheral blood vessel disease. Platelets’ attachment under some extreme 
conditions of excessive flow shear forces in stenotic blood arteries enhances the reaction of platelets leading 
to increased in vivo arterial coagulation. 
 
In the context of vasculature, the pro-atherothrombotic role of platelets is presently well defined and 
involves pro-incendiary viscid particles in the interface between endothelium and platelets at sites of 
ruptured atherosclerosis plaques. This promotes the recruitment and adhesion of leukocytes, thereby leading 
to enhancement of atherosclerotic plaque formation and development of arterial thrombosis. The anti-
leukaemic therapies, such as TKIs, are commonly associated with modifications of platelets and endothelial 
function that lead to the production of pathological thrombi. 
 
The primary purpose of this study was to determine the effect of ponatinib, nilotinib, dasatinib and imatinib 
on the function of platelets and thrombus growth in mouse and human arteries by in vitro, ex vivo and in 
vivo methods. The overarching goal was to provide a comprehensive analysis that would improve the 
understanding of potential mechanisms by which the TKI, ponatinib, potentiates a prothrombotic state. 
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In vitro experiments demonstrated that dasatinib and imatinib, but not ponatinib or nilotinib, inhibited ADP-
, CRP-, and collagen-induced platelet aggregation. Ponatinib also potentiated PAR-1-mediated alpha 
granule release, whilst imatinib and dasatinib showed inhibitory effects on platelet alpha granule exocytosis 
following agonist stimulation. 
 
In this study, we demonstrated using intravital microscopy of vascular injury of mesenteric arterioles and 
carotid arteries induced by ferric chloride (FeCl3) that there was a significant increase in in vivo thrombus 
formation over time in mice treated with ponatinib (3 mg/kg), nilotinib (25 mg/kg), but not with imatinib 
(25 mg/kg) or dasatinib (5 mg/kg). In addition, the effect of ponatinib was independent of platelet 
glycoprotein surface expression. Ponatinib potentiated alpha granule exocytosis in humans and mice.  
 
The data presented in this thesis confirmed the prothrombotic effects of ponatinib and nilotinib in humans 
where it was shown that in whole blood from drug-treated CML patients there was increased ex vivo platelet 
adhesion under flow conditions and increased plasma levels of soluble P-selectin (sP-selectin) and pro-
inflammatory cytokines. 
 
The results from this study also demonstrated that ponatinib and nilotinib TKIs have a prothrombotic effect 
that can be reversed by pretreatment with the L-type calcium channel blocker, diltiazem and the COX-2 
inhibitor, diclofenac, and to a lesser extent by the eNOS synthase inhibitor, L-NNA. However, the study 
suggested that nilotinib or ponatinib-treated CML patients who develop vascular complications of coronary 
artery vasospasm or cerebrovascular accident (CVA) could potentially be treated with L-type calcium 
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channel blockers to reduce arterial occlusive events. Further clinical trials are indicated to examine the 
efficacy and safety of using calcium channel blockers in the clinical setting of ponatinib and nilotinib-
treated CML patients. 
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 INTRODUCTION 
 
Blood has four main components in the body. These components are red blood cells, white 
blood cells, plasma and platelets [1]. Haematopoiesis is the process of blood cell production 
and formation from haematopoietic stem cells (HSCs) which occurs during embryogenesis and 
throughout life. It occurs mainly in bone marrow within adults but also occurs in liver, spleen 
and thymus [2]. The haematopoietic stem cell (HSC) is a multipotent stem cell that resides in 
the bone marrow and produces all of the cells of the blood and immune system [3]. In addition, 
HSC is a rare population of cells that gives rise to all of the cells comprising the two main 
differentiation pathways of the haematopoietic lineage: the myeloid arm and the lymphoid arm 
(Figure 1). However, defects can occur in the haematopoietic system leading to serious 
haematologic diseases such as anaemia and leukemia [4]. Leukemia is divided into two main 
types which are acute and chronic based upon onset of the disease, and various types of 
leukaemia including acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), 
chronic myeloid leukaemia (CML), and chronic lymphocytic leukaemia (CLL) occur in adults 
[5]. However, CML is rare accounting for only 0.3 % of all adult cancers in Australia [6]. 
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Figure 1. Haematopoietic stem cell system. The HSC differentiate into two different kinds of 
progenitors common myeloid progenitors (CMP) and common lymphoid progenitors (CLP), 
which further differentiate to various blood cells including platelets, granulocytes, lymphocytes 
and monocytes [7]. 
 
Chronic Myeloid Leukaemia (CML) is a malignancy of haematopoietic stem cells caused by 
the formation of the  Philadelphia (Ph) chromosome that carries a reciprocal translocation of 
chromosomal 22 and 9 [8].  The translocation leads to a Bcr-Abl (breakpoint cluster region 
gene-Abelson gene) fusion gene which results from a portion of the Abl gene from 
chromosome 9 fusing with the remaining portion of the Bcr gene on chromosome 22 [9] (Figure 
2). The classic fusion in CML is b3a2 or b2a2 fusion of exon 13 (b2) or exon 14 for b3 of Bcr 
to Abl’s exon 2 (a2) [10]. However, the reciprocal translocation of the chromosome results in 
a constitutively active tyrosine kinase (TK) protein producing myeloid hyper-proliferation 
associated with pathogenesis of CML. The reciprocal translocation can be identified through 
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routine karyotyping. TK activates several downstream signaling pathways resulting in 
uncontrolled proliferation and survival of myeloid cells [11]. 
CML progresses in multiple stages that include a long initial chronic phase that is able to last 
for more than ten years (CP-CML) [11]. The next stage (AP-CML) is an accelerated phase 
which is then followed by the blastic phase (BP). The survival rate of patients in the chronic 
phase is approximately 68% a year [10]. A number of patients are asymptomatic during the 
first stage where the diagnosis occurs by incidental discovery of elevated white cell counts [12]. 
In a number of cases, the dysfunction of the myeloid cells mostly results in a more severe, 
prolonged infection. The condition can be diagnosed in any person at any age; however, it is 
more common in older people aged above fifty years [13]. It is also reported that the 
susceptibility of CML is increased by family leukemic history and Down syndrome which 
increase the chances for DNA mutations and of development of precursor leukaemia cells [10]. 
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Figure 2. Formation of the philadelphia chromosome in chronic myeloid leukaemia. A 
part of chromosome 9 (9q) and a part of chromosome 22 (22p) breaks off and site places. The 
bcr-abl gene is formed on chromosome 22 where the piece of chromosome 9 attaches. The 
changed chromosome 22 is called the Philadelphia chromosome which is a hallmark of adult 
CML [14]. 
 
Ubiquitous intracellular TK pathways regulate basic cellular pathways such as proliferation, 
progression of cell cycle, survival, apoptosis and differentiation through phosphorylated signal 
transduction molecules. Dysregulation of tyrosine kinase expression by mutations in promoters 
governing their expression, or, as in Bcr-Abl, by mutations creating novel protein tyrosine 
kinases (PTKs), often contribute to dysregulated cell division, survival and metastatic 
properties as seen in cancer cells [15]. Some cancer therapies involve small-molecule inhibitors 
that target TKs, although there are others that are directed against serine and threonine kinases 
[16]. Under normal conditions the level of TK phosphorylation is closely controlled through 
antagonistic actions of SH2 domain containing protein-tyrosine phosphatases. Genetically 
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mutated or over-expressed TK results in unwarranted tyrosine phosphorylation and gene 
transcription changes that leads to tumorigenic processes [17]. 
TKs are classified into two receptors: receptor TK and non-receptor TK (Figure 3). Receptor 
tyrosine kinases (RTK) are made up of transmembrane domain, extracellular ligand-binding 
and intracellular TK catalytic domains. Most RTKs have a single polypeptide chain and are 
monomeric due to a lack of ligands (Figure 3) [18]. On the other hand, non-receptor TK relay 
intracellular signals given that they are found within the cell. An example of non-receptor TK 
is Abl [19]. A constitutive TK activity occurs through CML Bcr-Abl fusion gene. The activity 
is characterised by predominant proliferation of mature granulocytes within the bone-marrow 
and myeloid cells’ unregulated growth [20]. 
 
 
 
 
 
 
 
Figure 3. Receptor protein tyrosine kinase families (RTKs).  Domain structures of human 
receptor tyrosine kinases determine their sub-classification into different families. The name of 
each family is shown above with the members listed below. A key indicates the various motifs 
common to individuals within that family. 
There is a likelihood that CML starts through mutation of a pluripotential stem cell. If true, this 
implies that the treatment of clonal haematological malignancy may occur through a single 
pathway. Consequently, the generation of a discerning tyrosine kinase inhibitor (TKI) is a 
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representation of a promising therapeutic strategy in the treatment of CML [21]. While 
targeting the Abl kinase domain using TKIs is generally effective, the genetic instability in 
primitive CML stem cells leads to abnormalities in DNA repair mechanisms. As a result, 
additional mutations in these primitive stem cells develop leading to resistance with some TKI 
therapies. 
Other TKs such as epidermal growth factor receptor (EGFR) are involved in tumours like 
prostate, colon and breast cancer. Application of specific  tyrosine kinase inhibitors block 
tyrosine phosphorylation mediated by protein dimerization (Figure 3.1) [22]. The resultant 
effect is the blocking of the initiation of signaling cascade and stops the cell for proliferating 
and dividing. Compound cancer growth inhibitors can block one or more type of RTK.  
 
 
 
 
 
 
 
 
Figure 3.1. Epidermal growth factor receptor (EGFR) pathway. Ligands, such as epidermal growth 
factor (EGF), transforming growth factor (TGF)-α, or others, bind to the homo- and heterodimer kinase 
domain (TK), resulting in activation and receptor transphosphorylation. This creates docking sites for 
the adaptor proteins, Grb2 and Sos, which recruit Ras and phosphatidylinositol 3-kinase (PI3K), leading 
to the formation of two major signalling pathway branches, Ras/MAPK and PI3K/Akt. These networks 
result in, amongst others, proliferation, evasion of apoptosis and angiogenesis. MAPK: mitogen-
activated kinase-like protein [23].  
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1.1.1 Protein tyrosine kinase involvement 
 
Protein tyrosine phosphorylation (PTP) has been implicated as one of the essential cell-
signaling pathways. The transfer of phosphate groups by adenosine triphosphate (ATP) on 
tyrosine residues within proteins encoded by multicellular organisms gives rise to intracellular 
connections through biochemical signaling [24]. PTP is mediated and regulated by specific 
enzymatic molecules called protein-tyrosine kinases (PTKs), which catalyse the transfer of the 
terminal phosphate of ATP to tyrosine residues on protein substrates [25, 26]. PTKs belong to 
a heterogeneous superfamily of proteins with specific importance in numerous physiological 
events, including the mediation and regulation of numerous responses, such as cell growth, 
proliferation, differentiation, metabolism, migration and apoptosis [24]. PTKs can be 
subdivided into two broad families based on their supposed structures [27]. Receptor tyrosine 
kinases (RTKs), are characterised by having both an intracellular and an extracellular domain.  
This family includes platelet-derived growth factor receptor (PDGFR), vascular endothelial 
growth factor receptor (VEGFR), and the c-Kit receptor [28]. The second family, non-receptor 
protein tyrosine kinases (NRTKs), is characterised by a lack of extracellular sequences.  
NRTKs contain modular domains, which play an important role for subcellular objectives and 
the regulation of catalytic actions (Figure 4).  NRTKs include distinct families such as the Src 
family kinases (SFK) (Figure 4.1), Abl and spleen tyrosine kinase (Syk) play a critical role as 
a cytosolic enzymes that catalyse  the transfer of phosphate  group from ATP to tyrosine 
residues in proteins  [29]. 
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Figure 4. Non-receptor protein tyrosine kinase families (NRTKs). This figure shows 
domain structures of the main subfamilies of NRTKs. The carboxyl group is on the right side 
and the amino group is on the left. Adapted from [26, 30]. 
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Figure 4.1. Diagram of Src kinase activation. Diagram represents the inactive (left) and 
active (right) conformations for comparison. The two intramolecular interactions that regulate 
Src activation are indicated by arrows. Upon phosphorylation of the autoinhibitor site (Y529 
for mouse Src, see text for more details) the C-terminus of Src binds to the SH2 domain and 
the linker region binds to the SH3 domain, resulting in a closed molecular structure. This closed 
(inactive) conformation reduces the access of Src substrates to the kinase domain. On the other 
hand, dephosphorylation of Y529 results in an open (active) molecular structure, giving Src 
substrates access to the kinase domain. Full Src activation requires the autophosphorylation of 
Y418 (in mouse; see text for more details). Binding to other molecules such as CAS (Crk-
associated substrate) or FAK (focal adhesion kinase) displaces the intramolecular inhibitory 
interactions and results in activation of Src (not shown in the figure). The gray line indicates 
myristoylation sites important for membrane localization. 
 
 
1.1.2 The Efficacy, Safety, and Complication of Tyrosine Kinase Inhibitor Therapy 
 
In the past, treatment of chronic myeloid leukemia was ineffective for the majority of patients 
[31]. Historically, there are different types of treatment for CML including chemotherapy with 
hydroxyurea, cytarabine, cyclophosphamide and stem cell transplantation which has improved 
survival of leukemia patients [32-34]. The treatment of CML utilises tyrosine kinase inhibitors 
which has increased the 10 years survival rate of chronic phase CML patients to more than 80 
percent [35]. Imatinib (Gleevac) was introduced in 2000 as the first TKI for treatment of CML. 
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Imatinib has been clinically approved in all clinical phases of CML and has provided an 
efficient and  advantageous safety profile [36]. It revolutionised therapy for chronic phase CML 
significantly improving quality of life and survival outcomes. Some of the TKIs developed for 
the treatment include second generation compounds such as nilotinib and dasatinib. Despite the 
high 10 year survival rate of patients who are treated with TKIs such as imatinib, there are 
emerging issues on the treatment of CML using these TKIs [37]. Some of the emerging issues 
include increase in the development of resistance to dasatinib, nilotinib and imatinib. There are 
factors that have made the outcomes of  between 20 and 30 percent of CML patients insufficient 
leading to “multi-TKI-insensitivity” due to mutations of the Abl tyrosine kinase ATP binding 
pocket [38].  
 
Imatinib, a 2-phenylaminopyrimidine is the first CML-targeted TKI. Imatinib works to inhibit 
ATP binding to Bcr-Abl kinase domain resulting in the stabilisation of an inactive, closed 
conformation (Figure 5). Most CML patients treated with imatinib are capable of achieving 
complete cytogenetic response (CCyR) and complete haematological response (CHR). 
However, there are number of forms of resistance to imatinib messylate (IM) based therapies 
described in CML patients [39]. 
 
One of the related resistances to the therapy comes from leukaemic stem cells develop a 
residual cancer cell population that is capable of surviving the therapy [40]. This is often 
referred to as minimal residual disease. When therapy is stopped, the residual cells rebuild the 
population of the leukaemic cells leading to relapse of the disease. Imatinib fails to effectively 
target dormant CML stem cells. There is a high likelihood that quiescent cells can retain 
proliferation potential together with being reservoir for the relapse of disease. These quiescent 
cells can as well lead to progression of the condition to an advanced stage. This also shows a 
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possibility of the recurrence of the disease caused by the amplification of Bcr-Abl gene. On the 
other hand, second (nilotinib & dasatinib) and third (ponatinib) generations were developed as 
a solution to imatinib-resistant CML and has a higher linking affinity than imatinib producing 
a >30-fold greater effectiveness [41]. Recent reports suggest that chronic phase CML patients 
treated with nilotinib remain in remission after withdrawal of drug but not imatinib [42]. 
However, the two drugs demonstrate different side-effects and target selectivity. 
 
 
 
 
 
 
 
 
 
Figure 5. Mechanism of action of the Bcr-Abl TKI. (A) The Bcr-Abl tyrosine kinase (Bcr-
Abl TK) is a constitutively active kinase that binds ATP. Transfer a phosphate from ATP to 
tyrosine residues on different substrates lead to an alteration in cellular activation which leading 
to myeloid hyper-proliferation CML development. (B) The imatinib TKI blocks the binding of 
ATP to the Bcr-Abl and inhibits the TK phosphorylation of Bcr-Abl-mediated signaling 
pathways. (C) In imatinib resistant CML, ATP binds Bcr-Abl TK that leads to hyperactivity of 
tyrosine kinases resulting in relapse of CML. The second & third generation of TKI, nilotinib, 
dasatinib and ponatinib effectively overcomes imatinib resistance via potent inhibition on Bcr-
Abl TK phosphorylation and ponatinib will be effective for all Bcr-Abl mutations including 
T315I. 
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Nilotinib is a structural analogue of imatinib that interacts with both active and inactive 
conformation of Bcr-Abl [43]. Nilotinib inhibits cells that express kinase-activating mutants in 
a variety of tyrosine kinases such as c-Kit. Moreover, nilotinib is well tolerated in patients with 
CML-CP after imatinib failure or intolerance [12].  However, nilotinib-treated CML patients 
have been observed with side effects of impaired glucose metabolism, hypercholesterolaemia 
and cardiotoxicity [44]. The rapid development of progressive peripheral arterial occlusive 
disease (PAOD) with patients who were treated by nilotinib 300 or 400 mg twice daily within 
8 months after moving from imatinib to nilotinib is of major concern [45]. The common 
tyrosine kinase inhibitor drugs details are shown in Table 1. 
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Table 1. Common tyrosine kinase inhibitor drugs; branded name, market authorisation holder, 
target tyrosine kinases, indications. INN: International Nonproprietary [46]. 
TKI (INN) Branded Market 
authorisation 
Target tyrosine Indication(s) 
Imatinib 
 
 
 
 
 
 
 
Glivec 
 
 
 
 
 
 
 
Novartis 
 
 
 
 
 
 
 
BCR-ABL, 
KIT, PDGFR-A, 
PDGFR-B. 
 
 
 
 
CML, GIST, BCR-ABL- 
positive ALL,  
dermatofibrosarcoma 
protuberans, 
myeloproliferative 
neoplasms,  
hypereosinophilic syndromes 
 
Nilotinib Tasigna Novartis 
BCR-ABL, 
KIT, PDGFR-A, 
PDGFR-B 
 
                CML 
Ponatinib Iclusig 
 
 
 
 
 
Ariad 
 
 
 
 
 
BCR-ABL 
 
 
 
 
 
Patients with CML for which 
Imatinib, Nilotinib and 
Dasatinib are not appropriate 
(or patients carrying a T315I 
single-point mutations 
 
Dasatinib Sprycel 
 
 
 
Bristol-
Myers 
Squibb 
 
BCR-ABL 
 
 
 
 
 
CML 
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The initial design of dasatinib was as a Src family kinase (SFK) inhibitor which targets mutated 
Bcr-Abl by a distinct binding to inactive and active Abl-tyrosine kinase [47].  However, studies 
have shown that the drug affects activation of platelets induced by thrombin, collagen and ADP 
[48]. The platelet activation is possibly a contributory factor towards inhibition of SFK 
including Fyn and Lyn induced by vWF/GP1b-IX-V complex [49]. In addition, increased 
gastrointestinal bleeding has been linked to dasatinib treatment [50]. As a result of these 
challenges and the side effects associated with imatinib, dasatinib and nilotinib, a new 
multikinase inhibitor drug named ponatinib has been developed for T315I-based resistance 
(Figure 6). T315I Abl-Bcr mutant is a common mutation occurring in 15% CML patients. 
However, ponatinib has the ability to selectively inhibit cells carrying the T315I Bcr-Abl 
mutant that are insensitive to other clinically available Bcr-Abl inhibitors [51].  Ponatinib, a 
third generation TKI, uses a different interaction mode as compared to other TKI [52]. It binds 
with higher affinity and stronger than other TKIs. 
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Figure 6. Molecular structure of nilotinib, imatinib, dasatinib and ponatinib. Nilotinib is 
an analogue of imatinib. However, nilotinib is characterised by incorporating alternative 
linking groups to the N-methylpiperazine moiety and conserving an amide pharmacophore to 
maintain four H-bond associations with Glu286 and Asp381. Dasatinib and ponatinib are 
structurally distinct from imatinib and nilotinib. Both nilotinib and ponatinib contains trifluoro 
groups in their chemical structure designed to increase biological activity.  Adapted from [53].  
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  Ponatinib 
1.2.1 Mechanism of action and contribution to the development of vascular 
complications. 
This drug was designed through a structure-based and computational approach to generate a 
pan Bcr-Abl primary target enzymatic activity that includes T315I which is the most common  
resistance mutation detected in CML [54] (Figure 7). T315I forms hydrogen bonds between 
Abl and imatinib at an allosteric site resulting in a conformational change at the active site. The 
structure permits the drug to link to isoleucine T315I in the mutated side chain through van der 
Waals bonding [51, 55]. Recently, a T315L mutation of Abl kinase was described that is 
associated with ponatinib resistance and poor prognosis [56]. Ponatinib also has an inhibitory 
activity against platelet derived growth factor receptor alpha (PDGFR) families, fibroblast 
growth factor receptor (FGFR) members and vascular endothelial growth factor receptor 
(VEGFR) [57]. A major factor reducing the utility of ponatinib is that, 22% of patients 
receiving ponatinib experience arterial thrombosis that may induce a stroke or heart attack in 
patients receiving it [58].   
The increased risk of the thrombotic complications can lead to a patient’s death unless a 
concurrent use of anti-platelet agents, such as 100 mg of aspirin per day, is applied [12]. It may 
be argued that the thrombotic events are as a result of a number of cardiovascular risk factors 
such as diabetes mellitus, smoking, advanced age, or arterial hypertension [59]. However, the 
thrombotic events have been observed in both the absence and presence of the risk factors [45]. 
This is an indication of a direct drug effect of ponatinib to produce prothrombotic effects. 
Following the observed increase of 19 % in arterial thrombotic events, ponatinib was 
withdrawn and suspended from the market by the FDA and Ariad Pharmaceuticals in October 
2013 [60]. Following introduction of safety measures, ponatinib was reintroduced into the 
market in January 2014 with recommendations for drug dose reduction strategies, patient 
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selection, the need to evaluate cardiovascular and thrombotic risk before use and dosage was 
reduced from 30 mg to 15 mg QD. 
 
 
 
Figure 7: Ponatinib with Triple bond (yellow) unique structural feature evades the T315I 
gatekeeper mutation (blue) [61]. 
 
1.2.2 The Management of Side Effects 
The side effects of Bcr-Abl inhibitors can be debilitating to some CML patients. Even side 
effects defined as low-grade may affect a patient after a prolonged period of time [62]. For this 
reason, it is important to have a long-term plan for the management of side effects to maintain 
the patient’s quality of life. In all the Bcr-Abl inhibitors, the most common side effects seen in 
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CML patients are low blood counts such as anaemia 22% and thrombocytopenia 4% while 
different drugs have a different spectrum of other side effects (Table 2) [63]. 
 
Table 2: Safety profiles of TKI. CNS: central nervous system; TKI: tyrosine kinase inhibitors. 
INN: International Nonproprietary Name x: rare, xx: uncommon [46]. 
 
 
       TKI 
 
CNS 
 
 
Heart disorders 
 
Vascular disorders 
 
Renal disorders 
 
 
Imatinib X X X  
Nilotinib X X X X X X 
Ponatinib  X X X X X X 
Dasatinib X XX X X 
Gefitinib   X X X 
Sorafenib X X X X 
Sunitinib X X X X X 
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Oncologists and other clinicians are, therefore, required to assist their patients to understand 
the benefits of reporting the side effects such that they can be managed prior to becoming 
serious. This would allow the treatment of CML to continue uninterrupted [62]. Most of the 
side effects are generally managed through reduction of the drug dosage or the interruption of 
the treatment, but in some cases, the discontinuation or change to another TKI of the treatment 
is needed [64]. Oncologists and other clinicians should provide guidance to their patients to 
manage side effects resulting from additional medications (30% of elderly patients) e.g to 
follow their instruction to avoid any complications. They are required to reassure the CML 
patients with regard to the effects of the medication on Bcr-Abl inhibitor efficacy [62]. 
However, CML patients with cardiovascular risk factors are not given nilotinib or ponatinib as 
frontline treatment to avoid thrombotic complications [65]. Data obtained in October 2013 from 
the ongoing PACE trial with ponatinib-treated CML patients showed that after a median of 24 
months of follow-up, ponatinib was associated with an increased frequency of 19 % serious 
arterial occlusive events, compared with the frequency reported after 11 months of follow-up. 
Recommendations for dose reduction were implemented in October 2013 to mitigate the risk 
of additional serious adverse events [66].  
 
 PLATELET OVERVIEW 
 
Platelets are well identified that play crucial role in the pathogenesis of CVD, particularly 
involving arterial thrombosis. Platelets are tiny disc shaped cell fragments that are derived from 
precursor megakaryocytes. Platelets were discovered in 1882 by Giulio Bizzozero, who 
described these unique cells as granular, irregular and anuclear discs [67]. Platelets in 
mammalian blood systems are required for the formation of blood clots, healing of wounds and 
for maintaining haemostasis [68]. Platelets are also involved in angiogenesis in both adults and 
embryos. Insufficient platelets in the blood stream (thrombocytopenia) can result in excessive 
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bleeding. Platelets are also involved in certain diseases such as atherosclerosis, and 
thrombophlebitis [69]. Moreover, the angiogenic properties of platelets promote metastatic 
diseases like tumour spreading. Anti-platelet therapies are geared toward the prevention of 
myocardial infarction and excessive clotting [70]. Platelets are a main source of growth factors 
and their proteins used in the healing of wounds. These factors include transforming growth 
factor beta (TGFB), platelet derived growth factor (PDGF), vascular endothelial growth factor 
(VEGF), and epidermal growth factor (EGF) [71]. During the clot formation process, the 
shedding of platelets occurs releasing the growth factors together with chemotactic signals [70]. 
 
Megakaryocytes are the precursor of platelets which originate from haematopoietic stem cells. 
These are the rarest (0.01 percent) as well as the largest cells (50-100 micrometer) found in the 
bone marrow.  It is through endomitosis that platelets are released from the megakaryocytes 
[72]. This process involves several replications of the DNA without cell division. In addition, 
the other process that follows the replication of DNA includes the synthesis of protein and 
formation of granules [72]. 
 
Platelets are formed from proplatelets which are long cytoplasmic extensions of the 
megakaryocyte plasma membrane. In the cytoplasmic expansion phase, immediately after 
endomitosis, megakaryocytes synthesise specific organelles [73]. The resultant process is the 
assembly of microtubules at the centrosome (Figure 8). They run parallel to the cell membrane 
as they spread out towards the cell’s periphery. Prior to the initiation of the proplatelet, 
microtubules are assembled under the cell surface [74].  They assist in forming pseudopods 
that enlarge into becoming processes of proplatelets. Organelles are then moved within tracks 
of the microtubule toward the proplatelets ends in which the assembling of platelets occur [75]. 
Proplatelets are then constricted, resulting in a beaded appearance. The process results in the 
  
26 
 
conversion of megakaryocytes into proplatelets which divide and fragment to produce 
individual platelets [76]. It is estimated that about 1011 platelets are produced daily in an 
average human at circulating concentration of about 150-400 x 109 per litre of blood [77] 
(Figure 7). The platelet development and formation process are influenced by growth factors 
such as thrombopoietin (TPO) that regulate the formation of megakaryocytopoiesis [78]. It is 
believed that the differentiation processes and maturation of MK are promoted by various 
interleukins (IL-11, IL-6, and IL-3) that work in association with TPO and cytokines [79]. 
 
Endoreduplication, polyploidisation, polyploidy and addition of the cytoplasmic mass 
distinguish the maturation process, proliferation, and terminal differentiation of MK [80]. 
Immature MKs are characterised by rough endoplasmic reticulum and high levels of ribosomes 
as well as ribonucleic acid (RNA) content [81]. As the MKs mature, their cytoplasm continually 
develops, which includes platelet organelle amplification, intricate membrane system 
formation, and the production of specific platelet proteins such as fibrinogen and von 
Willebrand Factor (vWF) [82] (Figure 8). The amplified platelet organelles include alpha 
granules, dense granules, lysosomes, and T granules. After the maturation process, the 
centrosomes are disassembled and form microtubules which move to the cortex of the cell. 
Thick pseudopods are then produced from the tough cytoplasmic mass of the MK [83].  
 
During the expansion of organelles and microtubules into the proplatelet ends, the assembly 
point of the elongated proplatelets begin to develop. Mature platelets are later released after the 
conversion of MK cytoplasmic fragments into proplatelets [78]. Platelets are estimated to 
circulate for an average of between 7 to 10 days in the human body before macrophages situated 
in the spleen and liver remove them from the blood stream. 
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Figure 8. (A-E) Several stages promote megakaryocyte transition from immature cells to 
produce platelets. (A-B) The first stage, the immature megakaryocyte undergoes nuclear 
endomitosis, organelle synthesis and cytoplasmic maturation and expansion. (C-D) The next 
stage involves dissociation of the centrosomes and formation of microtubules, which move to 
the cell cortex and the proplatelet generation that also occurred with the development of thick 
pseudopods. Slipping of overlapping microtubules leads to proplatelet elongation as organelles 
are moved independently at proplatelet ends, where emerging platelets assemble. (E) The 
complete megakaryocyte cytoplasm is altered into a mass of proplatelets and new platelets are 
produced from proplatelet ends. Adapted from [84].       
                                                                                                                                                                                                                                                                                                                                                                                                                                                      
1.3.1 PLATELET ULTRASTRUCTURE 
Platelets are the smallest of all blood cells with average diameters ranging from 2.0 to 5.0 
micrometers [85]. Although they are characterised by the absence of genomic DNA, they often 
contain the translation apparatus essential for the synthesis of proteins as well as 
megakaryocyte-derived messenger RNA (mRNA) [86]. Platelets do not have a fixed shape 
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[87]. While in a resting physiological state, platelets have a discoid shape as they flow freely 
in the blood stream. When platelets are stimulated, their cytoskeleton is modified to result in 
the platelet becoming a small sphere with numerous long extensions from its discoid shape to 
enhance adhesion through activation and then aggregation of platelets [88]. The ultra-structure 
of platelets can be divided into four zones: the structural zone, the peripheral zone, membrane 
systems, and the organelle zone [89] (Figure 9). 
 
 
 
Figure 9. Platelet ultrastructure: The three main structural zones are peripheral, 
membranous, organelle and T-granules. Function of peripheral zone is adhesion and 
aggregation. In addition, the membranous zone play as a main role in structure and support and 
finally, the organelle zone is for the secretion and storage of platelets [90]. 
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1.3.2 The Peripheral Zone Structure 
The peripheral zone comprises a coagulation layer, a unit membrane, a phospholipid 
membrane, and glycocalyx [91]. This zone has a key role in the transport of substances from 
the surface of the platelet into the cell and in the release of alpha granule products secreted 
throughout platelet activation. The platelet membrane has two main components, 
phosphatidylserine, and phospholipids which facilitate and act as the place for configuration of 
the prothrombinase complex of coagulation, and the membrane also contains tissue factor that 
are exposed during the activation process with the production of microparticles [92]. At the 
same time, the membrane contains tissue factor that is exposed during the activation of platelets 
[93]. The process also results in the production of microparticles. Underneath the peripheral 
zone sits the glycocalyx, a dynamic surface that facilitates the adhesion and aggregation of 
platelets [94]. It is covered by integrin αIIbβ3 molecules and glycoprotein GPIb-V-IX complex 
receptors. The complex cytoskeleton located underneath the membrane of the platelet contains 
microfilaments and microtubules that facilitate the dynamic morphological changes of the 
platelet during the activation process. The primary inner structure of the platelet contains the 
platelet cytoskeleton that comprises a rigid network of actin cross filaments and central 
microtubules that strengthen the spectrin mesh [95]. Thus, it is evident that the cytoskeleton is 
pivotal in maintaining the platelet’s discoid morphology as well as safeguarding the integrity 
of the platelets from extensive shear stress when they are forced by the flow of the blood against 
the endothelium [96]. Additionally, the cytoskeleton takes part in the process of platelet 
activation by facilitating continual shape variations and the interactions that occur when 
platelets spread over an injured endothelial surface [97]. 
1.3.3 The Organelle Zone 
Platelets have secretory organelles such as lysosomes, dense granules, alpha granules and T 
granules (Table 3). Platelets contain high granule concentrations which are essential for platelet 
adhesion, activation and for thrombus formation. In response to the secretion of calcium during 
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the activation of platelets, dense bodies and alpha granules release their contents [98]. To 
promote platelet aggregation, all the secretory organelles are specialised to release their 
contents during the activation process [98].  
 
Table 3. The contents of organelles of platelets. 
 
Granules Contents of Granule 
   
  Secretion of ions 
1. Dense granules Guanine: GTP, GDP. 
  Nucleotides: Adenine: ATP, GTP, ADP, GDP 
  Serotonin (Transmitters), Histamine, Bivalent cations, Amines. 
   
2. Alpha-granules Adhesion molecules: P-selectin (CD62P), Glycoprotein IIb/IIIa 
  (GPIIb/IIIa, integrin αIIbβ3, CD41/CD61), Platelet endothelial cell 
  adhesion molecule-1 (PECAM-1/CD31), vWF, Thrombospondin-1 
  (TSP1), Vitronectin, Fibronectin. 
   
  Protease inhibitors; Plasminogen activator inhibitor-1 (PAI-1), 
  Tissue factor pathway inhibitor (TFPI), C1 inhibitor. 
  Coagulation factors: Fibrinogen, Kininogen, Factors V, VII, XI, 
  XIII. 
   
3. Lysosomes Glycosidases, Proteases. Cationic proteins. Digestive enzymes. 
  Acid hydrolases, cathepsins D, LAMP-1, LAMP-2 and WAMP-1. 
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1.3.4 The Structural Zone 
The sol-gel zone is the matrix of the cytoplasm of the platelets. Situated at the platelet’s center, 
it comprises various fibre systems in numerous polymerisation configurations and maintains 
the appearance of the platelet [89]. Its central function is the supply of a contractile system 
involved in the alteration of the morphology of the platelets, granule release, platelet activation, 
and the expansion of pseudopodia during the commencement of spreading [99]. 
1.3.5 Membrane Systems 
The plasma membrane of the platelet contains a phospholipid bilayer, with several tiny 
indentations. Each platelet contains a dense tubular system (DTS) and an open canalicular 
system (OCS) [100]. The OCS comprises numerous tortuous invaginations on the surface of 
the platelet that are evenly interposed along its structure [101]. It helps in improving the direct 
association between the interior surface of the platelet to create a path for the cells to access 
plasma substances and ingredients. At the same time, it provides a passage that helps in the 
transportation of particulate and chemical substances useful in the discharge reaction [102]. 
The platelet membrane is the primary site for the storage of calcium and cyclooxygenase, an 
enzyme responsible for converting arachidonic acid to thromboxanes and prostaglandins 
endoperoxide precursors [103]. Previous studies suggested that there is a close connection 
between the platelet membrane and the two platelet channels and highlighted that the platelet 
membrane might be essential in the activation of cells, which is achieved via direct 
communication with signals from the plasma. The transfer occurs through the OCS to DTS 
elements containing calcium ions and enzymes responsible for the synthesis of thromboxanes 
and prostaglandins [104]. Additionally, the membrane contains glycoprotein receptors such as 
fibronectin, collagen, and vWF that aid in the enhancement of platelet adhesion and activation 
pathways as well as platelet shape change [100]. The DTS helps in regulating the activation of 
platelets by controlling the release of calcium. It exists as thin elongated membranes in resting 
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platelets. Ten seconds after the addition of thrombin, there is a distinct ultrastructural change 
in the platelet’s DTS; from the thin elongated form to a rounded vesicular form [105]. 
1.3.6 Alpha Granules 
Alpha granules are the majority of the organelles found in platelets with 50 to 80 granules in 
every platelet. They have an elliptical shape with a diameter ranging between 200 to 500 nm 
[106]. The electron density of granules varies with granules in the outer zone have less electron 
density than the granules situated in the central zone. Produced within MK cells, alpha granules 
have high functional protein concentration as they comprise anti-coagulants, coagulation 
proteins, adhesion molecules (such as P-selectin, CD40L), growth factors, angiogenic factors, 
and chemokines [107]. When stimulated, proteins such as CD40L and P-selectin are 
translocated and expressed on the platelet’s surface membrane. Furthermore, proteolytic 
enzymes can cleave these proteins into soluble forms resulting in their secretion into the plasma 
[108]. It is worth noting that the expression of CD40L and P-selectin is essential to various 
atherosclerotic and inflammatory pathways that are involved in different pathophysiological 
processes. Alpha granules also contain vWF, a large multimeric glycoprotein that is synthesised 
specifically in the MKs and endothelial cells [109]. It is situated in the subendothelial matrix 
and is responsible for the regulation of platelet activation and aggregated at vascular injury 
sites. Primary and secondary haemostatic  processes are regulated by the release of the contents 
of alpha granules [108]. During primary haemostasis, fibrinogen acts as the αIIbβ3’s ligand 
functioning as an adhesive protein. Fibrinogen is also cross-linked in some of the stimulated 
platelets to aid in stabilising the growth of the thrombus. The release of coagulation factors V, 
VII, XI, and XIII is useful in mediating fibrin thrombi formation for the initiation of coagulation 
and stabilisation of a clot [110]. 
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1.3.7 Dense Granules 
Dense granules are also formed in the MK. However, their number is about ten-fold lower than 
that of alpha granules [111]. Each platelet is estimated to have 3 to 8 dense granules. Some 
dense granules are elongated in shape while others are spherical [112]. Additionally, dense 
granules contain specific non-protein components, unlike alpha granules. A key distinguishing 
trait of these granules is their high electron density that is attributed to the high concentration 
of substances such as phosphate, serotonin, calcium, adenosine triphosphate (ATP), 
nucleotides, magnesium, and adenosine triphosphate (ADP) [113]. These molecules are 
essential in platelet activation and aggregation as well as thrombus formation. Furthermore, 
dense granules influence the phosphorylation of protein kinase C and other tyrosine kinases 
useful in the aggregation of platelets by the release of calcium and ATP granules [114]. 
1.3.8 Lysosomes 
In addition, primary platelet lysosomes are formed in the MK. They are found in small numbers, 
about 1-3 lysosomes in each platelet [115]. They contain a variety of different enzymes; acid 
hydrolases such as proteases, glycosidases, and cathepsins [116]. They function as a reservoir 
of different digestive enzymes. In addition, they play a role in digesting phagocyted particles 
following their fusion with phagosomes and formation of phagolysosomes. Platelet receptors 
that localise to lysosomes contain a lysosomal targeting sequence in their cytoplasmic domain, 
Tyr XX hydrophobic residue such as the lamp proteins and CD63 tetraspanin superfamily 
member [117].  
1.3.9 T- Granules  
Toll-like receptors (TLRs) were first described in 1994 by Nomura and colleagues [118]. TLRs 
are proteins that play a main role to stimulate the innate immunity system. TLRs are pattern 
recognition receptors that recognise pathogen associated molecular patterns (PAMPs) 
expressed on pathogens and induce an inflammatory response on binding these PAMPs [119]. 
These responses normally, involve sentinel cells such as dendritic cells and macrophages [120]. 
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TLRs are expressed by platelets resulting in a link between innate and adaptive immune 
response. In addition, they help the immune system to recognise molecules that are found by 
pathogens which lead to activated immune cells [121]. 
1.3.10 Platelet Function 
The basic role of platelets is to offer vascular system integrity and maintain normal 
haemostasis. These functions rely on the ability of the platelets to provide particular receptors 
to bind type 1 collagen and vWF exposed form extracellular matrix in order to activate 
signaling pathways [122]. It has been shown that vWF, fibronectin, and collagen are capable 
of stimulating platelet adhesion and aggregation. Platelets are generated and activated by 
locally- produced agonists to induce a change in their shape from discs to tiny spheres with 
reorganised cytoskeleton and filopodia as discussed in 1.3.1 [123] (Figure 9). These activated 
platelets release their alpha granule contents including P-selectin that translocates to the 
surface. It basically mediates the rolling and tethering of leucocytes that are needed for strong 
extravasation and adhesion. Upon the release of platelet contents, other granules such as 
lysosomes cause the aggregation of platelets eventually forming platelet plugs at injury sites 
that assist to stem bleeding [124].  
1.3.11 Platelet Activation 
Following injury of endothelial cells, when the blood vessel is damaged or diseased, collagen 
and vWF becomes exposed and serve as substrate for adherence of platelets at the injury site. 
Platelets are then recruited, activated and aggregated [125]. The activation of platelets can 
occur via thrombin stimulation, a process assisted by subendothelium tissue factor [126]. 
Activated platelets change in shape to develop pseudopods. They then elongate to cover the 
injured or diseased endothelium. The contents of dense and alpha granules are released into the 
plasma [70]. Dense bodies secrete calcium, serotonin and ADP which then stimulate 
aggregation. In the same way, serotonin weakly accelerates the aggregation of platelets and 
also enables glycoprotein IIb/IIIa receptor binding to a number of agents [127]. On the other 
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hand, alpha granules secrete fibronectin, vWF, fibrinogen, and thrombospondin that serve as 
agents of connection during aggregation. In addition, GPVI, GPIa and vWF bind to GPIb-V-
IX which firmly attaches the platelets to the injured or diseased endothelium (Figure 10) [128]. 
Eventually, aggregated platelets develop a plug at the site of the wound to stop the blood flow 
[129] . 
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Figure 10. Stages of platelet activation and thrombus formation. Platelets adhere to a von 
Willebrand factor (vWF)/collagen matrix, get activated, secrete granular contents, aggregate 
via integrins, produce thrombin after developing a procoagulant surface, and form a contracted 
thrombus with fibrin. Heat map with color codes from green (low Ca2+signal) to red (high 
Ca2+ signal). Interactions of platelets with coagulation factor are indicated, as described. Note 
that procoagulant platelets provide a phosphatidylserine (PS)-exposing surface for the tenase 
complex (activated FVIII and FIX) and the prothrombinase complex (activated FV and FX). 
Formed thrombin provides positive-feedback reactions to activate platelets via GPCR and 
secretion of ADP and TXA2, which bind to their ligands, the P2Y12 and TP receptors, 
respectively to activate coagulation factors, and to convert fibrinogen into fibrin [130]. 
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 PLATELET RECEPTORS AND INTEGRINS 
 
Platelets contain numerous receptors which are important for normal function of platelets 
including platelet activation, adhesion, spreading and platelet aggregation [131]. These 
receptors include direct collagen-binding proteins, G-Protein coupled, thromboxane receptor 
(TP), integrins, immunoglobulin superfamily receptors, ADP purinergic receptors, leucine-rich 
superfamily member receptors and tyrosine kinase receptors (Figure 11) [132]. 
 
 
 
 
 
 
 
 
 
 
Figure 11. Diagram of platelet agonists and their receptors. Platelet agonists involved in 
platelet activation pathways on the site of vascular injury [133]. 
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1.4.1 Glycoprotein Ib-IX-V complex (GPIb-IX-V).   
Glycoprotein Ib-IX-V complex comprises the subunits: GPIbα, GPIbβ, GPV and GPIX. Each 
of these subunits contain a variable number of leucine-rich repeats. GPIbα and GPIbβ are 
linked by disulfide bridges, while the GPV and GPIX associate non-covalently with the 
complex with a ratio of 1:2:1 [134] (Figure 12). The binding between GPIbα and vWF mediates 
the capture of platelets to the injured vascular wall. In addition, GPIbα subunit bears the binding 
site for  von Willebrand factor (vWF), α-thrombin, leukocyte integrin αMβ2 and P-selectin 
[135]. GPIb-IX-V complex plays an important role in the initiation of tethering and adhesion 
of platelets at high shear stress [136].  
A deficiency or abnormal glycoprotein Ib-IX-V complex synthesis created by structural 
mutations in functionally important sites of platelet GPIb-IX-V complex leads to Bernard 
Soulier Syndrome (BSS) [137]. This is a congenital bleeding disorder that is characterised by 
macrothrombocytopenia and an inability of these platelets to aggregate in response to ristocetin, 
an antibiotic that normally causes platelets to aggregate in vitro by binding and activating vWF 
[138]. In addition, this complex plays a main role in thrombosis, metastasis, the life cycle of 
platelets, and is implicated in a number of thrombotic pathological processes such 
as ischaemic stroke and myocardial infarction [139]. 
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Figure 12. GPIb-IX-V structure. The GPIb-IX-V complex composed of GPIbα disulfide-
linked to two GPIbβ subunits, and associated with GPIX and GPV. Disulfide bonds within 
domains either side of leucine-rich repeat domains are depicted as solid black bars. The position 
of sulphated tyrosine residues (Sulfo-Tyr at 276, 278 and 279 of GPIbα), phosphorylated serine 
residues (Phospho-Ser) and palmitylated Cys residues of GPIbβ and GPIX are indicated. C, C-
terminus; N, N-terminus; TM, transmembrane domain [140]. 
 
1.4.2 Glycoprotein VI (GPVI)  
Glycoprotein VI (GPVI) is one of the main important members of the immunoglobulin 
superfamily expressed on the surface of platelets. There are approximately 2,000-4,500 copies 
of GPVI per resting platelet and this protein is exclusively expressed on platelets. [141]. GPVI 
is a major receptor on the platelet membrane surface as a direct collagen-binding protein, which 
plays role in platelet activation and aggregation upon vascular injury [142]. GPVI forms 
functional bonds with the GPIb-IX-V complex through a direct association between the 
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extracellular sequences of GPVI and GPIbα. As a result, the binding of GPVI/GPIb-IX-V 
complex with extracellular matrix ligands-vWF and collagen quickly induces platelet integrin 
activation, such as αIIbβ3 that binds vWF or fibrinogen to mediate platelet aggregation and 
integrin α2β1 that attaches to collagen [141]. GPVI has two extracellular immunoglobulin 
domains, a mucin-like domain, a transmembrane domain and a short cytoplasmic tail [143].  
 
 
  
  
 
 
 
 
 
Figure 13. Structure of GPVI. It has two extracellular immunoglobulin domains, a mucin-
like domain, a transmembrane domain, and a short cytoplasmic tail. The proline rich region is 
linked to the Src homology domains (Fyn and Lyn). Basic region within C-terminal region is 
connected to calmodulin and associated with FcRγ-chain. Modified from [144]. 
 
A salt bridge between an arginine residue in the transmembrane sequences of the GPVI and an 
aspartic acid residue in the transmembrane sequences of the FcRγ chain leads to linkage of 
GPVI with FcRγ subunit that contains an immunoreceptor tyrosine-based activation motif 
(ITAM) [145]. The FCR gamma chain provides the ITAM motif that is required for GPVI 
signaling pathway. The Fc receptor pathway of GPVI activation involves FcR γ chain (GPVI 
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transmembrane domain associates with FcR γ chain), Src kinase Fyn / Lyn, and LAT adaptor 
protein, all participating in phospholipase C activation [146] (Figure 14). When collagen binds 
to GPVI, platelets are activated initially by tyrosine phosphorylation of the immunoreceptor 
tyrosine-based activation motif of FcR-γ- chain [147]. Cross-linking FcRγ subunit with GPVI 
leads to the activation of Syk, PI3K, PKC and PLCγ. The phosphorylated FcRγ-chain-ITAM 
is subsequently associated with the Syk via SH2 domains, and Syk is phosphorylated by Src 
family kinases (SFKs) which promotes its major activation and initiates interactions with other 
signaling pathways [148] (Figure 13). However, deficiency in GPVI on the human platelet 
membrane results in impaired collagen adhesion, thrombus formation and is associated with 
prolonged bleeding [149]. On the other hand, increased GPVI expression is associated with 
thrombotic events [150]. GPVI plays a  main role for the initiation of early inside-out signaling 
through platelet activation involving integrins αIIbβ3 and α2β1 that modulates platelet 
adhesion and aggregation [151]. 
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Figure 14. Immunoreceptor tyrosine-based activation motif (ITAM) receptors in 
platelets. Glycoprotein VI (GPVI) is a type I transmembrane protein that is constitutively 
associated with the Fc gamma chain receptor γ (FcR-γ) chain, which bears an ITAM. It consists 
of two extracellular immunoglobulin domains, a mucin-like domain, a transmembrane domain, 
and a short cytoplasmic tail. The proline rich region is linked to the Src homology domains 
(Fyn and Lyn). Basic region within C-terminal region is connected to calmodulin and 
associated with FcRγ-chain [152]. 
 
1.4.3 Integrin α2β1  
The integrin α2β1 works as a direct receptor for collagen type I and IV [153]. It consists of two 
subunits (α2 and β1) with approximately 2000-4000 copies occurring per resting platelet. 
Integrin α2β1 is expressed mainly on epithelial cells and platelets. The α2 subunit includes a 
domain homologous to von Willebrand factor domain attaching to collagen [154]. However, 
the β1 subunit has four cysteine-rich regions and a structure similar to other β-integrins. The 
interaction of integrin α2β1 with collagen is essential for form platelet adhesion (Figure 15)  
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[155]. The surface expression of this complex shows high variability, particularly in relation to 
the polymorphism of GPIa subunit gene [156].  
 
 
 
 
 
 
 
 
Figure 15. Structure, activation and inhibition of integrin α2β1. The upper Left image is 
inactive conformation of integrin α2β1 which bound to collagen with the C-terminal α7 helix 
of the I-domain (red) displaced downward to engage the metal ion (purple) in the I-like domain. 
The upper Right Inactive conformation of integrin α2β1 with stabilising salt bridges formed by 
the pair E318 and R288 as well as R310 and E338 (Lower) Inhibitor (orange) attached into 
integrin α2β1 I-like domain locking the compound into the inactive conformation [157]. 
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GPVI-collagen binding plays a role in the increasing the affinity of integrin α2β1 for collagen 
from a low-affinity state to intermediate or high-affinity states. However, platelet integrin α2β1, 
αIIbβ3 or others promote firm adhesion and further support GPVI-mediated signaling pathways 
leading to pro-coagulant activity [158].  
 
 
 
 
 
 
 
 
 
  
 
Figure 16. Diagram of platelet adhesion to collagen by interaction of GPVI and integrin 
α2β1. GPVI-collagen interactions initiate cellular activation followed by shifting of integrins 
to high-affinity state and the release of second agonists, most importantly ADP and TxA2 . 
Adapted from [159]. 
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1.4.4 Integrin αIIbβ3  
This integrin attaches to fibrinogen and thus plays an important role in platelet adhesion and 
aggregation to damaged endothelial surfaces. Activation of this complex prescribes the platelet 
aggregation and the formation of the primary platelet plug, a fibrin clot [160]. The GPIIb/IIIa 
complex otherwise known as Integrin αIIbβ3 is a major platelet membrane component. There 
are around 80000 copies of αIIbβ3 found on the surface of unstimulated platelets [161]. 
Integrin αIIbβ3 is composed of a heterodimeric complex consisting of an αIIb and β3 subunit 
linked by disulphide bridges [162]. These subunits form Ca2+ - dependent complexes on the 
surface of platelet membrane in a 1:1 ratio [162].  
Integrin αIIbβ3 plays an important role in haemostasis and thrombosis in clot retraction, 
cytoskeletal reorganisation (platelet spreading) and stabilisation of platelet aggregates [163] 
(Figure 17). In the resting platelet state, the integrin is thought to be expressed in a low-affinity 
state and that the conformation of αIIbβ3 switches to a high-affinity state in response to specific 
agonist-induced platelet activation, such as ADP and thrombin, through ‘inside-out signaling’ 
events [164]. Activated αIIbβ3 is able to bind its ligand fibrinogen, which essentially induces 
important processes involving ‘outside-in’ signaling events. [163]. In addition, integrin  αIIbβ3 
and the immunoglobulin family receptor GPVI signal through similar but distinct tyrosine 
kinase-based signaling cascades causing activation and aggregation development [165].  
Dysfunction or lack of integrin αIIbβ3 due to structural mutations result in Glanzmann 
thrombasthaenia which is a bleeding syndrome characterised by impaired adhesion and failure 
of platelet aggregation [166]. In vivo experiments using β3-knockout mice or αIIb-knockout 
mice elucidated that β3-deficient mice have significantly prolonged tail bleeding times and 
show defective thrombus formation [156].  
Intravital microscopy investigations also verified that β3 deficiency causes defective binding 
of the integrin to fibrinogen which leads to abnormal platelet aggregation and spontaneous 
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haemorrhage [167]. Integrin αIIbβ3 clearly has an important role in haemostasis and 
thrombosis through platelet adhesion, cytoskeletal reorganisation and aggregation events [168]. 
 
 
  
 
 
 
 
 
 
  
Figure 17. Structure & Inside out signaling to induce activation of the integrin αIIbβ3. 
The three major conformational states of integrin αIIbβ3. It contains αIIb domains and β3 
subunits. The conversion of integrin αIIbβ3 from low-affinity (a bent state) into high-affinity 
conformation and stabilisation of high-affinity conformation (an extended closed headpiece 
state)[169]. 
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1.4.5 G-protein Coupled Receptors 
G-protein Coupled Receptors components comprise seven transmembrane receptors that bear 
different features for use in controlling the actions of thrombin. Specifically, G-protein coupled 
receptors (GPCRs) have both extracellular and intracellular loops that function as domains that 
link to G-protein signaling pathways [170]. One vital characteristic common to all GPCRs is 
the existence of a large cytoplasmic tail that may interact with protein kinase A, or C, or GPCR 
kinase. When a blood vessel is damaged due to injury, blood usually flows out. Thrombin-
mediated platelet activation engages GPCR to initiate the GP signaling pathway. Released 
secondary mediators of platelets, like TXA2 and ADP, amplify the process that leads to 
enhanced platelet aggregation of the blood tissue [171]. Specific forms of platelet activators 
can be used to engage respective ADP receptors, thrombin protease-activated Receptor (PAR) 
for PAR-1, PAR-2, and PAR-4, TXA2 receptor, and P2Y12. These elements respond differently 
to particular functions of the blood clot control process [172]. 
 
1.4.6 Thrombin Receptors 
GPCR comprises seven members that includes thrombin. Unlike other components of GPCR 
and other receptors that may be activated multiple times, thrombin receptors can be activated 
only once due to the fact that their activation involved a protease cleavage step [173]. Thrombin 
catalytic activity targets the N terminal  of GPCR receptor leading to its cleavage and activation 
of the receptor [174] (Figure 18). However, studies indicate that PAR receptors are not just 
restricted to platelets but also in the vasculature in smooth muscle cells and endothelial cells 
[175]. PAR receptor was found to have a significant role in the control of the spread of tumour 
growth. Specifically, PAR is composed of four components that include PAR-1 to PAR-4 that 
varies in expression in different parts of the body. For instance, PAR-1 appears on the plasma 
membrane of the platelets, which is very sensitive in humans but less efficient in mice [176].  
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In addition, PAR-1 is the predominant thrombin receptor mediating platelet activation 
especially in humans with expression of approximately 1,000-2,000 copies per platelet. Mice 
express PAR-4 and PAR-3, while humans express PAR-1 and PAR-4 that work as signaling 
systems. However, PAR-4 only becomes more sensitive when PAR-3 is absent which works 
as a co-factor in the activation of platelets [177].  
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Figure 18. Structure of G-Protein coupled receptors. GPCRs display a common structure 
consisting of seven transmembrane domains with three intracellular and three extracellular 
loops in these long proteins. GPCRs also contain a long cytoplasmic tail which may interact 
with protein kinase C, protein kinase A or GPCR kinase. GPCRs are generally highly 
conserved. Of the 367 human and 392 mouse GPCRs studied by Vassilatis and colleagues, 343 
were found to be common to both species [178]. 
 
1.4.7 ADP Receptors 
Some of the very first platelet agonists discovered were adenosine diphosphate (ADP) 
receptors. ADP is stored within platelet dense granules as discussed above and are secreted 
when platelets are activated [179]. ADP is largely kept at high concentrations in dense granules. 
It is released in reaction to P2Y1 and P2Y12 receptors mediated by platelet activation. Among 
the seven members of the transmembrane ADP purinergic receptors are P2Y1 and P2Y12 [180]. 
Platelet procoagulant activity is activated by the two receptors [25]. On the other hand, P2Y1 
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is solely responsible for shape change control [181]. It has been shown that the absence of 
P2Y12 results in an impaired ADP-induced aggregation which eventually leads to an unstable 
thrombi and excessive bleeding in-vivo [182]. One striking feature of ADP is its aggregating 
properties that allow it to change shape of platelets [183]. This observation implies that one can 
apply P2Y1 receptor to act as moderator. An assessment of the scenario revealed that when 
ADP participates in the activation of P2Y1, the ultimate effect is further activation of 
phospholipase under control of a Gq protein [184]. Uniquely, platelets in Gp knockout mice 
fail to undergo shape changes in the presence of ADP [185]. Thus, expression of ADP 
purinergic receptors is restricted to certain parts of the body including neuronal cells,  platelets 
and smooth muscle cells [180]. ADP is recognised by nucleotide receptors (P2 purinergic 
receptors) consisting of the P2X ion-channel family and the P2Y GPCR family [186].  
 
Briefly, ADP mediates platelet activation through binding to two P2Y receptors, P2Y1 and 
P2Y12 which link to Gαq and Gαi, respectively. In brief, P2Y1 is responsible for Ca2+ 
mobilisation, thus mediating platelet shape change and transient aggregation in response to 
ADP [187]. In contrast, P2Y12 plays an important role in inhibition of adenylyl cyclase which 
reduces the level of cAMP synthesis and promotes the activation of platelets. This occurs by 
dephosphorylation of vasodilator-stimulated phosphoprotein which carries out activation of 
integrin αIIbβ3 and increases the cyclic Ca2+ flux and platelet granule release. The signal 
transductions pathway downstream of P2Y1 and P2Y12 receptors have revealed an involvement 
of Src tyrosine kinase (Figure 19) [188]. A lack of platelet shape change, impaired platelet 
aggregation was demonstrated in P2Y1 knockout mice in response to ADP [118]. In contrast, 
P2Y12 -/- mice demonstrated normal platelet shape change but impaired ADP-induced 
aggregation. The P2Y12 -/- mice experienced significantly increased bleeding times and 
unstable thrombus formation [189]. 
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Figure 19. Different subtypes of ADP receptors. P2Y1 and P2Y12 are GPCRs. There are two 
main ADP receptors. The P2Y12 receptor leads to inhibition of adenylyl cyclase (AC) and a 
decrease in cyclic AMP (cAMP), resulting in platelet secretion of thrombotic mediators and in 
platelet aggregation. The P2Y1 receptor leads to improved calcium influx (Ca
2+), resulting in 
platelet shape change. MRS-2179 and Cangrelor (formerly AR-C9931MX) are selective P2Y1 
or P2Y12 antagonists, respectively [190]. 
 
1.4.8 Thromboxane A2 receptors 
Thromboxane A2 (TXA2) is a platelet agonist. It is a member of the prostanoid family of 
arachidonic acid metabolites which is generated by the sequential action of three enzymes – 
phospholipase A2, COX-1 or COX-2 and TXA2 synthase (TXAS) [191]. It is produced during 
platelet activation through a series of actions of cyclo-oxygenase-1 (COX-1) stimulation in 
platelets and is synthesised following arachidonic acid generation [192]. TXA2 amplifies 
platelet activation signals causing shape change, protein phosphorylation, secretion, and 
aggregation. TXA2 is lipid soluble, therefore it diffuses across the platelet membrane to recruit 
more platelets for promoting platelet plug formation via binding to its receptor [193]. The 
blockade of TXA2 secretion that occurs via inhibition of COX-1 by aspirin results from the 
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conversion of arachidonic acid into prostaglandin H2 which serves to prevent thrombotic 
diseases such as atherosclerosis, myocardial infarction and pulmonary embolism. The TXA2 
receptor (TP) presents two splice variants (TPα and TPβ), which differ only at their C-terminal 
domains and both are generated from a single gene. In human platelets, TPα expression has 
been identified at the protein level and has been suggested to possibly stimulate adenylyl 
cyclase. In contrast, TPβ has also been identified at the protein level but it inhibits adenylyl 
cyclase (Figure 20) [194]. When the TP receptor is activated by prostaglandin endoperoxides 
PGG2 and prostaglandin H2 predominantly couples to Gq and G12/13, and TP receptor has a 
minimal involvement in tyrosine kinase signal transduction [195]. TP-deficient mice are 
unresponsive to TXA2 and show an impaired response to collagen. TP-/- mice show delayed 
bleeding times and are unable to generate stable thrombi. These data suggest that the decreased 
activation of platelets in TP-/- mice might contribute to a reduction in cardiovascular risk [196]. 
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Figure 20. Arachidonic acid metabolism. Arachidonic acid (AA) is oxidised by 
lipoxygenases (LOX), cyclooxygenases (COX), ETE- Eicosanoid, LTA and LTB-leukotriene 
A and B, LXA-lipoxin A  and cytochrome P450 (CYP 450) to produce either pro-inflammatory 
(red border) or anti-inflammatory and pro-resolving (green border) metabolites. Adapted from 
[197]. 
 
 Role of coagulation cascade in Haemostasis 
The coagulation cascade is triggered to produce a stable clot through crosslinking of fibrin 
clotting factor complex by factor XIIIa. According to the  in vivo cell-based theory, the process 
takes place in four overlapping stages [198]. The stages include initiation and amplification as 
the first and second stages and propagation and stabilisation of the formation of thrombus as 
the third and fourth stages [26]. The coagulation is essentially initiated by the injury of 
  
54 
 
endothelium resulting in the release of tissue factor [199]. The tissue factor activates the 
extrinsic pathway resulting in fibrinogen being converted to fibrin. The amplification stages 
involve aggregation of platelets, activation of protein C, coagulation factors including  XIa, Va 
and VIIIa and endothelial cell effects [70]. Thrombin then cleaves fibrinogen to develop fibrin 
clots with platelets [70]. There are a number of different receptors for vWF for the mediation 
of platelet adhesion and involvement in leukocyte binding [199] (Figure 21).  In conditions 
associated with hypertension with high shear stress, platelet can become activated, predisposing 
to thrombosis. In addition, hypercoagulability results in elevation of coagulation factors; factor 
VII, vWF and prothrombin [200].  Clotting of blood occurs either in veins or arteries. Arterial 
thrombosis always occurs from deposition of platelets under high shear flow rates and the 
presence of the collagen reach atherosclerotic plaque. Venous thrombosis is mainly linked to 
reduce blood flow stasis and hypercoagulability with large amounts of fibrin deposited at the 
vascular injury site [199, 201]. 
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Figure 21. The coagulation cascade. Proposed cell-based model of coagulation in three steps: 
initiation, amplification and propagation occurring at the surface of TF-bearing cells and 
platelets.  Adapted from [202]. 
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 Gap In knowledge: 
The mechanisms by which ponatinib TKI contributes to vascular occlusive events remains 
unclear. Whether ponatinib directly induces arterial thrombotic episodes or accelerated 
atherosclerosis or pathological induction of vasospasm is unclear. By defining the mechanism 
will help to define ways of ameliorating the prothrombotic effects of ponatinib. These gaps in 
knowledge provide a basis for the hypothesis and study aims of the project. 
 Hypothesis: 
Ponatinib has a prothrombotic effect that leads to thrombotic complications. 
 
Aims: 
• To determine the effect of ponatinib on platelet function and haemostasis in vitro (Use 
nilotinib, imatinib and dasatinib as comparison). 
• To assess the acute effect of TKI treatment (ponatinib, nilotinib, imatinib and dasatinib) 
on platelet and endothelial activation and thrombus formation ex vivo and in vivo using 
a C57BL/6 mouse model. 
• To determine strategies to ameliorate the prothrombotic effects of ponatinib ex vivo and 
in vivo thrombus formation in mouse models (calcium channel blocker, COX-2 
inhibitor and L-NNA inhibitor). 
• To examine the ex vivo thrombus formation and pro-inflammatory markers of 
ponatinib-treated CML patients versus healthy human controls and other TKI treated 
CML patients. 
  
57 
 
 
 
 
 
 
 
 
  
 
Chapter 2: MATERIALS AND METHODS 
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 MATERIALS&METHODS 
 Materials 
2.2.1 Chemicals and reagents 
Sodium chloride (NaCl), potassium chloride (KCl), sodium bicarbonate (NaHCO3), glucose, 
tri-sodium citrate, magnesium chloride hexahydrate (MgCl2-6H2O), disodium hydrogen 
phosphate (Na2HPO4) were purchased from Merck, Kilsyth (Victoria, Australia). Potassium, 
Iron (III) Chloride (FeCl3), quinacrine, dimethyl sulfoxide (DMSO) and Rhodamine G6 dye 
(Rh6G) were purchased from Sigma Aldrich (St Louis, MO, USA). Type I collagen fibrils were 
purchased from Nycomed (Linz, Austria). Ketamine was purchased from Pfizer, (Auckland, 
New Zealand) and xylazine was purchased from Ilium, Troy Laboratories Pty Ltd (Smithfield, 
NSW, Australia) TRAP peptide SFLLRN, PAR-4 agonist peptide, AYPGKF-NH2 was 
purchased from GL-Biochem, Shanghai, China. Thrombin was purchased from Sigma Aldrich 
( St.Louis, MO, USA). ADP was purchased from DKSH (Hullam, Victoria, Australia).  
 
2.2.2 Antibodies 
FITC-conjugated anti-mouse CD62P antibodies, PE-labeled mouse IgG isotype control, anti-
mouse integrin β3-FITC conjugated (CD61) - FITC conjugated and anti-mouse CD3e were 
purchased from BD Biosciences Pharmingen (Franklin Lakes, NJ). PE-conjugated JON/A 
monoclonal antibodies, anti-mouse GPIbα- FITC conjugated anti-mouse GPVI (JAQ-1), anti-
mouse integrin α2-FITC conjugated and anti-mouse CD9- FITC conjugated antibodies were 
purchased from Emfret Analtics (Würzburg, Germany).  
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2.2.3 Preparations of stocks of tyrosine kinase inhibitors 
Ponatinib was provided from ARIAD/Takeda Pharmaceuticals Company (Boston, USA) as a 
pure powder. Both nilotinib and imatinib were purchased from Novartis Pharmaceuticals as a 
pure powder. Dasatinib was purchased from Bristol Myers Squibb (BMS) (Mulgrave, VIC) as 
a pure powder form. They were dissolved in DMSO to give a 10 mM stock solution in 
phosphate buffer solution (PBS) pH 7.4 and stored at -200C. Fresh dilutions of TKIs were made 
in phosphate buffered saline (PBS) pH 7.4 that was prepared by dissolving (137 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) in 1000 mL total volume of Milli-Q water 
(Millipore, Australia). The maximum final concentration of DMSO in the TKI mixture was 
less than 0.2% (v/v). 
 
2.2.4 Preparation of tyrosine kinase inhibitors for in vivo work 
The following procedure was used to prepare 1 mL of dosing formulation at a 2.5 mg/mL 
concentration of compounds. 2.5 of each mg of compound was added to 500 μL of 25 mM 
citrate buffer (pH 2.75) and warmed for one minute in hot water (60-70 deg C).  Then extra 
500 μL of 25 mM citrate buffer; pH 2.75 was added and the solution stirred for another 5 min 
until a clear dose solution was obtained.  Final concentration of the solution was 2.5 mg/mL of 
compound. All daily aliquots intended for dosing were administered within 2 hours of 
preparation. To prepare 1 mL of a 0.5 mg/mL dosing solution, we took 200 μL of the 2.5 mg/mL 
dosing solution and mixed thoroughly with 800 μL of 25 mM citrate buffer; pH 2.75.  The 
volume of dosing solution to be administered was based on the weight of each individual 
mouse. For example, 250 μL of a 2.5 mg/mL dosing formulation administered to a 0.025kg 
(25g) mouse, will yield a dose of 25 mg/kg; 300 μL of a 2.5 mg/mL dosing formulation 
administered to a 30g mouse, will yield a dose of 25 mg/kg; 250 μL of a 0.5 mg/mL dosing 
formulation administered to a 0.025kg (25g) mouse, will yield a dose of 5 mg/kg. The dosing 
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of mice TKI drugs was based on achieving in in vivo plasma drug Cmax concentrations within 
the four time frame (provided by Ariad/Takada Pharmaceuticals). 
 
2.2.5 Healthy human donors 
The collection of healthy human blood for this research project was approved by RMIT 
University Human Research Ethics Committee (HREC/14/Austin/404). Each blood donor 
voluntarily gave informed consent prior to blood collection. Eligible donors were healthy adults 
of both sexes between 18-58 years of age without known history of disease and donors must 
not have taken any anti-platelet medications such as aspirin and clopidogrel within the last 7 
days. Venous blood was obtained from healthy human volunteers using a 21-gauge needle into 
a syringe containing 3.2% (w/v) trisodium citrate (9 parts blood to 1 part anti-coagulant). 
2.2.6 Animal Model 
Male and female (age- and sex matched) C57BL/6 mice were obtained from Animal Resource 
Centre (Perth, Western Australia). These mice were accommodated and monitored at RMIT 
University animal house facility in accordance with the National Health and Medical Research 
Council animal guidelines. Four to eight-week-old WT mice were used in the experiments. The 
experiments procedures conducted on these mice were approved by the RMIT University 
animal ethics committee (#AEC 1333) or (#AEC 1704). For ex vivo and in vivo model studies, 
cohorts of C57BL/6 mice were orally administrated by oral gavage once as a single dose with 
certain concentrations of TKIs according to mouse body weight. Mice were treated with 3, 10 
and 30 mg/kg of ponatinib, 25 mg/kg of imatinib, 25 mg/kg of nilotinib and 5 mg/kg of 
dasatinib. Vehicle control mice were orally given PBS pH 7.4 or 25 mM citrate buffer pH 2.75 
alone using the same method of TKIs-treated mice with similar corresponding doses of drugs 
vehicle- and TKI- treated mice were left for 4 hours (C max peak drug concentration) and had 
free access to fresh water and food supplement. 
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 METHODS 
2.3.1 Preparation of human platelets 
Whole blood samples obtained from either healthy volunteers or CML patients were 
immediately collected into tubes containing 3.2 % (w/v) tri-sodium citrate. Platelet rich plasma 
(PRP) was generated by centrifuging the citrate blood at 190 ×g for 10 minutes without brake 
at room temperature using an Allegra X-15R centrifuge (Beckman Coulter, Brea, USA). 
Washed platelets were generated from PRP by centrifugation at 1000 ×g for 15 minutes without 
brake in the presence of 50 ng/mL PGE1. The platelet pellet then was washed twice in Ringer-
citrate-dextrose (RCD) buffer (108 mM NaCl, 38 mM KCl, 1.7 mM NaHCO3, 21.2 mM sodium 
citrate, 27.8 mM glucose and 1.1 mM MgCl2-H2O, pH 6.5) in the presence of 50 ng/mL of 
PGE1 gently resuspended in RCD buffer. Finally, the platelet pellet was then resuspended in 
RCD buffer, pH 7.4, to give a final concentration of 100×109/L of platelets [203]. The 
remaining citrate blood was further centrifuged at 1000 ×g for 10 minutes without brake at 
room temperature to obtain platelet poor plasma (PPP) from the top layer of the centrifuged 
blood sample to be used as an optical baseline standard for platelet aggregation studies.  
 
2.3.2 Preparation of mouse platelets 
Blood was collected from C57BL/6 mice under universal anaesthesia using inhalation of 2% 
isoflurane from an Isotec3 vaporiser linked with two litres/minute oxygen flow to initiate a 
deep plane of anaesthesia. Whole blood was collected from mice by cardiac puncture using a 
26-gauge needle attached to a 1 mL syringe and immediately placed into 100 μL 3.2% (w/v) 
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trisodium citrate in a ratio of 9 parts blood to 1 part anti-coagulant. Approximately 600 to 900 
μL blood was collected from each mouse. PRP was obtained through centrifugation of the 
whole blood at 115 ×g for 8 minutes at room temperature without brake in the presence of 50 
ng/mL of PGE1. Washed platelets were obtained via re-centrifuged PRP at 640 ×g for 10 
minutes without brake at room temperature. The platelet pellet was then resuspended gently in 
RCD buffer, pH 7.4, at a concentration of 100×109 platelets/liter. Finally, mice were killed by 
cervical dislocation immediately following cardiac puncture. Mouse plasma samples were 
generated from whole blood for measurement of soluble levels of P-selectin and other 
cytokines. Plasma was isolated from whole blood by centrifugation at 1000 ×g for 15 minutes 
at room temperature, and this process was repeated twice. Finally, plasma was separated by 
aliquoting into microcentrifuge tubes and immediately frozen at -80oC until analysis. 
 
2.3.3 Platelet aggregation studies 
As described in section 2.2.1 for the separation of PRP from human whole blood. Platelet 
aggregation responses were recorded by measuring the changes in light transmission using a 
four channel lumi-aggregometer (Chrono-Log Co, Havertown, PA) [403]. PRP was normalised 
to 100×109/L in RCD buffer, pH 7.4 using a Cell-Dyn Emerald haematology analyser (Abbott 
Diagnostics, Abbott Park, Illinois). PRP aggregation was performed in the presence of 1 mM 
CaCl2 with continuous stirring (1000 rpm) at 37
oC. Human PPP was set as baseline diluted 1:2 
in ringer citrate dextrose (RCD) buffer, pH 7.4. PRP was pre-incubated with different 
concentrations (0.05, 0.1, 1, 2.5, 5 and 10 µM) of ponatinib, imatinib, nilotinib or dasatinib for 
10 minutes at 37oC. Subsequently, platelet aggregation was initiated by adding certain agonist, 
including 1 µg/mL collagen, 0.5 µg/mL CRP or 5 µM ADP. The platelet aggregation response 
was measured as the maximal increase of light transmittance platelet aggregation over 10 
minutes was recorded. 
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2.3.4 Measurement of alpha granule exocytosis 
 Washed platelets (100×109/L; 50 µL) were pre-incubated with or without different 
concentrations of ponatinib, nilotinib, imatinib or dasatinib at 37oC for 10 min. Platelets were 
then fixed in 1% (w/v) paraformaldehyde with RCD buffer pH 6.5 for a 10 min at room 
temperature followed by termination of the reaction with 1 mL of RCD buffer pH 6.5 
containing 0.2% (w/v) BSA and the samples were centrifuged at 640 ×g for 10 minutes without 
brake. Fixed platelets were pre-labelled with 10 μg/mL P-selectin antibody (FITC-conjugated 
- anti-mouse-CD62P antibody) for 30 min at room temperature in the dark. Following, samples 
were washed in RCD buffer pH 6.5 with 0.2% (w/v) BSA and centrifuged at 640 ×g for 10 
minutes without brake. Lastly, platelets were then diluted with 300 μL of RCD buffer pH 7.4. 
Platelet alpha granule secretion (P-selectin expression) was recognised using platelet 
population characteristic side and forward light scatter channels. A total of 10,000 platelet 
events were analysed for each individual sample using FACS Canto II flow cytometer and 
Weasel software Version 3.0.2 (Walter Eliza Hall Institute, Victoria). 
 
2.3.5 Measurement of platelet dense granule exocytosis 
Washed human platelets (100×109/L; 50 µL) were pre-labelled with 100 µM quinacrine dye 
for 30 minutes in the dark at 37oC, allowing the platelet dense granules to take up the dye. The 
reaction was terminated by adding 1 mL RCD, pH 6.5 containing 0.2% (w/v) BSA and 
centrifuged the samples at 640 ×g for 10 minutes at room temperature without brake. Platelets 
were then incubated with or without various dose responses of ponatinib, nilotinib, imatinib or 
dasatinib at 37oC for 10 minutes. A range of platelet agonists such as 0.25 U/mL thrombin, 
1.25 µM TRAP peptide SFLLRN and 1.25 µg/mL CRP were added to samples and incubated 
at 37oC for 10 minutes to stimulate platelet activation and trigger dense granule exocytosis. The 
stimulation was stopped by adding 300 μL of RCD buffer, pH 7.4. Immediately, platelet dense 
granule release was quantitated as the percentage of decrease in quinacrine fluorescent intensity 
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compared to resting platelets using flow cytometry. The flow cytometer settings were 
recognised for the acquisition of platelets via logarithmic signal intensification. The dot-plot 
template was configured specifically for platelet-FITC/PE protocol based on characteristic side 
and forward light scatter channels and fluorescence parameters in log scale. A total of 10,000 
platelet events were analysed for each individual sample using FACS Canto II flow cytometer 
(BD Biosciences, San Jose, CA) and Weasel software Version 3.0 
 
2.3.6 Analysis of PAC-1 mAb binding 
The ability of PAC-1 monoclonal antibody binding to the active conformation of integrin 
αIIbβ3 (GPIIb/IIIa) on human platelets was tested as previously described [204]. In brief, 50 
µL of washed platelets (100×109/L) derived from normal human donor blood were incubated 
with PE-conjugated PAC-1 mAb (1:50 dilution) for 1 hour at room temperature in the dark. 
Platelets were then terminated with 0.2% (w/v) BSA-RCD buffer pH 6.5, and then centrifuged 
at 640 × g for 10 minutes without brake. Labelled-platelets were then stimulated with certain 
agonists such as thrombin (0.25 U/mL) for 60 minutes at room temperature. Platelets were then 
washed in 0.2% (w/v) BSA-RCD buffer pH 6.5, and then centrifuged at 640 ×g for 10 minutes 
without brake. The activation of platelets was terminated by the addition of 1% (w/v) 
paraformaldehyde for 10 min at room temperature. Finally, platelets were diluted in 300 μL of 
RCD buffer, and a total of 10,000 events were quantified using FACS Canto II flow cytometer 
and Weasel software Version 3.0.2. 
 
2.3.7   Analysis of JON/A-PE mAb binding 
The ability of JON/A monoclonal antibody binding to the active conformation of integrin 
αIIbβ3 (GPIIb/IIIa) on murine platelets was tested as previously described [205]. In brief, 50 
µL of washed platelets (100×109/L) derived from mice untreated or treated TKIs were 
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incubated with PE-conjugated JON/A mAb (1:50 dilution) for 1 hour at room temperature in 
the dark. Platelets were then terminated with 0.2% (w/v) BSA-RCD buffer pH 6.5, and then 
centrifuged at 640 × g for 10 minutes without brake. Labelled-platelets were then stimulated 
with certain agonists such as thrombin and CRP for 60 minutes at room temperature. Platelets 
were then washed in 0.2% (w/v) BSA-RCD buffer pH 6.5, and then centrifuged at 640 ×g for 
10 minutes without brake. The activation of platelets was terminated by the addition of 1% 
(w/v) paraformaldehyde for 10 min at room temperature. Finally, platelets were diluted in 300 
μL of RCD buffer, and a total of 10,000 events were quantified using FACS Canto II flow 
cytometer and Weasel software Version 3.0.2. 
 
2.3.8 In vitro and ex vivo flow thrombus formation onto immobilised type I collagen 
Briefly, glass μ-slide VI 0.1 with specific dimensions (0.1×1.0×45 mm, H×W×L) (Ibidi 
Company, Martinsried, Germany) was coated with 500 μg/mL type I equine ligament collagen 
(Nycomed, Linz, Austria) for two hours at 37oC followed by rinsing with PBS pH 7.4 to remove 
non adherent collagen.  
 
For in vitro arterial thrombus growth studies, anticoagulant whole blood from human or mice 
were normalised with RCD pH 6.5 to 200×109/L and 300×109/L respectively. Blood was then 
pre-incubated with different concentration of drugs including 0.1 μM ponatinib, 5 μM imatinib, 
5 μM nilotinib, or 0.1 μM dasatinib or vehicle control for 10 minutes at 37oC.  
 
For ex vivo thrombus formation studies, mice were treated with ponatinib (3, 10 and 30 mg/kg), 
imatinib (25 mg/kg), nilotinib (25 mg/kg) or dasatinib (5 mg/kg) or vehicle for 4 hours before 
blood collection that is a Cmax peak drug concentration [206]. Whole blood from both human 
and mice in vitro or ex vivo thrombus formation studies were fluorescently labelled with 0.05 
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% (w/v) rhodamine 6G dye at 370C for 30 minutes to allow visualisation of platelets. Labelled 
platelets in whole blood were then perfused over a matrix of type I collagen-coated μ-slide VI 
0.1 microcapillaries for 6 minutes at shear stress rate of 1800 seconds-1 using a infuse/withdrew 
PHD 22/2200 syringe pump (Model 999; Ha rvard Apparatus, Holliston, MA). The flow system 
was rinsed with PBS pH 7.4 subsequently each perfusion at the same shear rate for 6 minutes. 
The intact thrombus formation derived from initial platelet adhesion with type I fibrillar 
collagen and accumulation of platelet aggregation on coated surface was directly visualised in 
real time using a Zeiss Axiovert 135 M1 microscope (Carl Zeiss, Gottingen, Germany) 
(objective LD 20×/0.4 NA) equipped with Halogen 100-W bright light and HBO 100-W 
fluorescent light lamp source. Image series of the time-lapse recording and examination of the 
extent of platelet thrombi production on the surface were carried out off-line from digital photos 
of the microchannel surface using Axiovision Rel version 4.6 software (Carl Zeiss Imaging 
Solution GmbH, Munich, Germany). The fluorescent profile of platelets attached in each image 
was determined and expressed as an arbitrary ‘pixel unit’ which is the total surface area of the 
thrombi on the surface in a 3D deconvolved thrombus area. The determination of fluorescent 
platelet thrombus generation on a recognised surface coverage area is basically utilised for 
comparing thrombus formation between different TKI phenotypes on human and mouse 
samples. Z-stack slices of fluorescent images of aggregated platelets were captured and 
recorded by an AxioCam MRm camera (Carl Zeiss, Gottingen, Germany). Deconvolution 
process was carried out from the three dimensional (3D) reconstructed rendered Z-stack images 
using the AxioVision Rel4.6 software (Carl Zeiss). Following deconvolution, the threshold was 
adjusted to be lower intensity for distinguishing platelets from the background and the same 
threshold characteristic was applied for all Z-stack images to keep analysis consistent. The 
thrombus volume (μm3) was determined from the surface coverage area (μm2) multiplied by 
the height (μm) of the platelet thrombi. 
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2.3.9 In vivo thrombosis model experiments 
The ferric chloride (FeCl3) induced vascular injury is well-defined and extensively performed 
to examine arterial thrombosis and thrombogenesis in experimental mouse models in vivo 
[207]. The FeCl3 mechanically induces arterial thrombosis through oxidative injury to 
vasculature without complete damage to the inner layers of vessel wall, leading to endothelial 
cell denudation and exposure of the basement of membrane elements including collagen and 
tissue factor, resulting in platelet and leukocyte adhesion as well as development of occlusive 
thrombus formation. Characteristically, FeCl3 contains pro-oxidative properties (redox-active 
iron) which trigger endothelial denudation. The moving of ferric ion (Fe3+) to the lumen 
initiates lipid peroxidation of erythrocyte membrane leading to direct red blood cell (RBC) 
haemolysis [208]. The haemolytic cells secrete haemoglobin that is oxidised by iron generating 
reactive oxygen species. RBC haemolysis and oxidative haemoglobin generation are required 
for endothelial cell denudation exposing their molecules e.g. type I collagen [209]. 
 
2.3.10 Ferric chloride-induced vascular injury model of mesenteric arterioles 
Male and female C57BL/6 mice (4-6 weeks old) were orally administrated with the TKIs, 3, 
10 and 30 mg/kg ponatinib, 25 mg/kg imatinib, 25 mg/kg nilotinib, 5 mg/kg dasatinib or vehicle 
control PBS pH 7.4 (vehicle control mice) or 25 mM citrate buffer pH 2.75 using an oral gavage 
procedure. Treated mice were left for 4 hours (peak drug concentration) before surgical 
procedures were performed. Mice were anaesthetised with a ketamine/xylazine (100:10 mg/kg) 
mixture intraperitoneally (IP). Mice were tested to ensure for receiving sufficient anaesthesia 
by using the pedal reflex test by pinching the front/hind paw of the mice with a pair of forceps 
to confirm the mouse is suitably anaesthetised. Once the mice were sufficiently anaesthetised, 
FeCl3 induced injury and intravital microscopy (IVM) were performed. A midline incision was 
made in the abdomen exposing the intestines. Mesenteric arterioles of the ideal diameter (80-
100 μm) were then selected and visualised with a Zeiss Axiovert 135 microscope (Carl Zeiss, 
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Gottingen, Germany) and Z-stack slices of the arterioles were captured with AxioCam MRm 
camera (Carl Zeiss, Gottingen, Germany) and projected onto the computer screen. The selected 
vessels were visualised under a long distance lens 20 ×/0.4 NA. A strip of Whatman filter paper 
(4 mm x 1 mm) was soaked in freshly prepared (7.5% w/v) FeCl3 solution for around 3 seconds, 
applied to a 2-to-5-mm length of mesenteric arterioles for 4 minutes and then removed. A 
volume of 75 μL of 0.05 % w/v rhodamine 6G dye was injected through the jugular vein 
catheter for platelet labelling. The monitoring of blood flow and thrombus development within 
vessels was recorded in real time over 10 minutes. Z-stack images of the artery were 
progressively captured over 10 minutes in 2 minute cycles (defined as the artery vessel starts 
to occlude).  
 
The rendered Z-stack images were deconvolved with Zeiss Axiovert Rel 4.6 software to 
generate 3D reconstructions (Carl Zeiss Imaging Solution GmbH, Munich, Germany). Analysis 
of thrombus growth parameters including thrombus area (μm2), thrombus height (μm) and 
thrombus volume (μm3) were carried out, excluding any thrombi less than 50 μm2. The 
threshold was adjusted to be lower consistently for distinguishing platelets from the 
background and the same threshold typical was applied for all Z-stack images to analyse in 
similar conditions. The calculations of thrombus volume and the percentage of vessel occlusion 
and stability scores were performed using Zeiss Axiovert Rel 4.6 software. Thrombus area was 
determined by measuring the selected surface average of the thrombus by scaling outline in 
μm2. Thrombus volume (μm3) was calculated as thrombus area (μm2) multiplied by thrombus 
height (μm) of the platelet thrombi. The vessel volume was calculated based on this formula 
(The vessel volume= π × (vessel diameter ÷ 2)2 × vessel length).  
2.3.11 Ferric chloride-induced vascular injury model of carotid arteries 
C57BL/6 mice (sex and age-matched 8 weeks; weight 20±2 g) were orally administrated with 
TKIs, 3 mg/kg ponatinib, 25 mg/kg imatinib, 25 mg/kg nilotinib, 5 mg/kg dasatinib or PBS pH 
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7.4 (vehicle control) using an oral gavage. Treated mice were left for 4 hours (peak drug 
concentration) prior to the surgical procedure. The animals were anaesthetised by IP injection 
of ketamine and xylazine (100:10 mg/kg). The right common carotid artery was completely 
exposed utilising surgical scalpel and blunt dissection. A Doppler flow probe was placed 
proximal to surface of the carotid artery allowing to Doppler monitoring and baseline blood 
flow was recorded on a laser Doppler perfusion monitor using Moor Instruments Ltd (Millwey, 
Axminster, Devon, UK). Following surgical incision and the blood flow baseline adjusted, a 
piece of filter paper (0.5 × 1.0 mm) was saturated in 20 % (w/v) FeCl3 for 3 seconds and placed 
on the adventitial surface of carotid artery for 4 minutes (to initiate sufficient injury mediated 
thrombus formation). The filter paper was carefully removed after 4 minutes and blood flow of 
carotid artery was recorded. The blood flow reading persisted till flow recording dropped to 50 
AU (corresponding to 95 % vessel occlusion). The initial time of artery injury to 95% vessel 
thrombotic occlusion was calculated [210]. 
 
2.3.12 Enzyme linked immunosorbent assay 
Levels of soluble P-selectin (sP-selectin) were measured by solid phase sandwich enzyme 
linked immunosorbent (ELISA) assay according to manufacturer’s instructions. The purpose 
of ELISA tests of multiple cytokines (IL-6, sP-selectin, TNF-α and IFN-γ) to examine the effect 
of TKIs on the inflammatory biomarkers of platelets and endothelium for ex vivo studies. 
Plasma was isolated from whole blood of TKI treated human patient or mice treated with PBS 
7.4, either 3 mg/kg ponatinib, 25 mg/kg imatinib, 25 mg/kg nilotinib or 5 mg/kg dasatinib. The 
samples were separated by double-centrifugation at 1000 ×g for 10 minutes to obtain platelet 
poor plasma. Plasma was collected from upper half volume of sample and aliquoted in portions 
of 20 microliters and the PPP samples are quickly frozen at -80OC. The frozen plasma samples 
were thawed at room temperature prior to processing. 
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2.3.13 Soluble P-selectin measurement  
Mouse sP-selectin/CD40 Quantikine ELISA kit and human sP-Selectin ELISA kit were 
purchased from (R&D Systems, Minneapolis, MN, USA) and performed according to the 
manufacturer’s instructions. Briefly, for measuring sP-selectin in mouse plasma, wells of 96 
well polystyrene microplates have been pre-coated with monoclonal anti-mouse P-selectin 
antibodies. Plasma samples were diluted in 1:50 in ‘Calibrator Diluent’ and 100 μL of diluent 
was added to wells in duplicates. A standard curve ranging from 0 to 10 ng/mL (mouse sP-
selectin standard) was generated and a lyophilised control was used. The plate was incubated 
at room temperature for 2 hours. After five washes with 400 μL ‘Wash Buffer’ containing PBS, 
100 μL of a polyclonal antibody against mouse P-selectin (conjugated) was then added and 
incubated at room temperature for 2 hours. The plate was then washed five times and colour 
was developed by adding 100 μL of substrate solution (tetramethyl-benzidine). After 30 
minutes, 100 μL of stop solution (NaOH) was applied for terminating the reaction. For 
measuring sP-Selectin levels in patient plasma, ELISA plate was pre-incubated with anti-
human sP-selectin monoclonal antibody. Plasma diluted in 1:20 in ‘sample diluent’ human sP-
selectin standard and a lyophilised control was added. Subsequently, the ‘sP-selectin conjugate’ 
containing a polyclonal anti-human sP-Selectin antibody cross-linking with human P-selectin 
was then applied to each well and incubated for 1 hour at room temperature. The plate was 
washed three times with 400 μL ‘wash buffer’ and incubated with 100 μL of substrate in the 
dark. After 15 minutes, the reaction was stopped by adding 100 μL of stop solution (NaOH). 
Optical density (OD) 450 nm was determined with wavelength correction set to 650 nm using 
A PerkinElmer’s Victor™ X3 Multilabel Plate Reader (Waltham, Boston, USA). 
 
2.3.14 Mouse sTNF-α measurement 
This mouse TNF-α ELISA test is designed to enable the quantitative measurement of natural 
and/or recombinant TNF-α in serum, plasma and cell culture media. It contains one strip-well 
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plate pre-coated with mouse TNF-α capture antibody along with sufficient key reagents for 
plate development. Firstly, solutions were prepared as required by following the manufacturer’s 
instructions. Then, 50 μL of assay diluent 1B were added to each well. Then, we added 50μL 
of standards, samples and zero standard controls to each well and seal the plate with the 
adhesive cover provided and incubate for 2 hours at room temperature. Plates were then washed 
four times with wash buffer (250 μL). Then, 100μL of biotin labelled detection antibody was 
added to each well and incubated for 2 hours at room temperature.  The aspiration/wash steps 
were repeated as previous. Then, 100μL of freshly diluted streptavidin-HRP conjugate was 
added to each well and seal the plate with the adhesive cover provided and incubated for 45 
minutes at room temperature. The washing step were repeated as previous. Finally, 100μL of 
TMB substrate were added to each well and incubated for approximately 20 minutes at room 
temperature. The development process (blue colour) was monitored every 5 minutes to prevent 
over development of the plate. The reaction was stopped with 50 μL of stop solution. The wells 
colour changed from blue to yellow in colour. The optical density (OD) of the plate were 
determined using a micro-plate reader set at 450 nm and wavelength correction, set at 570 nm. 
 
2.3.15 Mouse sIL-6 measurement 
This mouse sIL-6 ELISA test is designed to enable the quantitative measurement of natural 
and/or recombinant IL-6 in serum and cell culture media. It contains one strip-well plate pre-
coated with mouse IL-6 capture antibody along with sufficient key reagents for plate 
development. Solutions were prepared according to manufacturer’s instructions. 100 µL of 
standards (2000 to 31.25 pg/ml), samples and zero standard controls were added to the plate 
and incubated for 2 hours at room temperature. Then, the plate wells were aspirated and washed 
with wash buffer (250 µL). 100 µL of biotin labelled detection antibody to each well and 
incubated for 2 hours at room temperature. The washing step was repeated followed by adding 
100 µL of freshly diluted streptavidin-HRP conjugate to each well and incubated for 45 minutes 
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at room temperature. Again, aspirating each well and washing of the plate five times with wash 
buffer (250 µL). 100 µL of TMB substrate was added to each well and incubated for 
approximately 15 minutes at room temperature. The development process (blue colour) was 
monitored every 5 minutes to prevent over development of the plate. The reaction was stopped 
by adding 50 µL of stop solution resulting in change the colour from blue to yellow. Finally, 
we determined the optical density (OD) of the plate using a micro-plate reader set at 450 nm 
and wavelength correction, set at 570 nm. 
 
2.3.16 Mouse IFN-γ measurement 
This mouse IFN-γ ELISA test is designed to enable the quantitative measurement of natural 
and/or recombinant IFN-γ in serum and cell culture media. It contains one strip-well plate pre-
coated with mouse IFN-γ capture antibody along with sufficient key reagents for plate 
development. Solutions were prepared according to manufacturer’s instructions. 100 µL of 
standards (2000 to 31.25 pg/ml), samples and zero standard controls were added to the plate 
and incubated for 2 hours at room temperature. Then, the plate wells were aspirated and washed 
with wash buffer (250 µL). 100µL of biotin labelled detection antibody to each well and 
incubated for one hour at room temperature. Washing step was repeated followed by adding 
100 µL of freshly diluted streptavidin-HRP conjugate to each well and incubated for 45 minutes 
at room temperature. Again, aspirating each well and washing of the plate five times with wash 
buffer (250 µL). 100 µL of TMB substrate was added to each well and incubated for 
approximately 15 minutes at room temperature. The development process (blue colour) was 
monitored every 5 minutes to prevent over development of the plate. The reaction was stopped 
by adding 50 µL of stop solution resulting in change the colour from blue to yellow. Finally, 
we determined the optical density (OD) of the plate using a micro-plate reader set at 450 nm 
and wavelength correction, set at 570 nm. 
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2.3.17 Human sTNF-α measurement 
Human TNF-α ELISA test is designed to enable the quantitative measurement of natural and/or 
recombinant TNF-α in serum, plasma and cell culture media. It contains one strip-well plate 
pre-coated with human TNF-α capture antibody along with sufficient key reagents for plate 
development. Firstly, solutions were prepared as required by following the manufacturer’s 
instructions. Then, 50 μL of assay diluent 1B were added to each well. Then, we added 50 μL 
of standards, samples and zero standard controls to each well and seal the plate with the 
adhesive cover provided and incubate for 2 hours at room temperature. Plates were then washed 
four times with wash buffer (250 μL). Then, 100μL of biotin labelled detection antibody was 
added to each well and incubated for 2 hours at room temperature.  The aspiration/wash steps 
were repeated as previous. Then, 100 μL of freshly diluted streptavidin-HRP conjugate was 
added to each well and seal the plate with the adhesive cover provided and incubated for 45 
minutes at room temperature. The washing step were repeated as previous. Finally, 100 μL of 
TMB substrate were added to each well and incubated for approximately 20 minutes at room 
temperature. The development process (blue colour) was monitored every 5 minutes to prevent 
over development of the plate. The reaction was stopped with 50 μL of stop solution. The wells 
colour changed from blue to yellow in colour. The optical density (OD) of the plate were 
determined using a micro-plate reader set at 450 nm and  wavelength correction, set at 570 nm. 
 
2.3.18 Human sIL-6 measurement 
This human sIL-6 ELISA test is designed to enable the quantitative measurement of natural 
and/or recombinant IL-6 in serum and cell culture media. It contains one strip-well plate pre-
coated with human IL-6 capture antibody along with sufficient key reagents for plate 
development. Solutions were prepared according to manufacturer’s instructions. 100 µL of 
standards (2000 to 31.25 pg/mL), samples and zero standard controls were added to the plate 
and incubated for 2 hours at room temperature. Then, the plate wells were aspirated and washed 
  
74 
 
with wash buffer (250 µL). 100 µL of biotin labelled detection antibody to each well and 
incubated for 2 hours at room temperature. The washing step was repeated followed by adding 
100 µL of freshly diluted streptavidin-HRP conjugate to each well and incubated for 45 minutes 
at room temperature. Again, aspirating each well and washing of the plate five times with wash 
buffer (250 µL). 100 µL of TMB substrate was added to each well and incubated for 
approximately 15 minutes at room temperature. The development process (blue colour) was 
monitored every 5 minutes to prevent over development of the plate. The reaction was stopped 
by adding 50 µL of stop solution resulting in change the colour from blue to yellow. Finally, 
we determined the optical density (OD) of the plate using a micro-plate reader set at 450 nm 
and wavelength correction, set at 570 nm. 
 
2.3.19 Human IFN-γ measurement 
This human IFN-γ ELISA test is designed to enable the quantitative measurement of natural 
and/or recombinant IFN-γ in serum and cell culture media. It contains one strip-well plate pre-
coated with human IFN-γ capture antibody along with sufficient key reagents for plate 
development. Solutions were prepared according to manufacturer’s instructions. 100 µL of 
standards (2000 to 31.25 pg/mL), samples and zero standard controls were added to the plate 
and incubated for 2 hours at room temperature. Then, the plate wells were aspirated and washed 
with wash buffer (250 µL). 100µL of biotin labelled detection antibody to each well and 
incubated for one hour at room temperature. Washing step was repeated followed by adding 
100 µL of freshly diluted streptavidin-HRP conjugate to each well and incubated for 45 minutes 
at room temperature. Again, aspirating each well and washing of the plate five times with wash 
buffer (250 µL). 100 µL of TMB substrate was added to each well and incubated for 
approximately 15 minutes at room temperature. The development process (blue colour) was 
monitored every 5 minutes to prevent over development of the plate. The reaction was stopped 
by adding 50 µL of stop solution resulting in change the colour from blue to yellow. Finally, 
  
75 
 
we determined the optical density (OD) of the plate using a micro-plate reader set at 450 nm 
and wavelength correction, set at 570 nm. 
 
2.3.20 Human sICAM-1 measurement 
 Human sICAM-1 ELISA test is designed to enable the quantitative measurement of natural 
and/or recombinant sICAM-1 in serum and cell culture media. It contains one strip-well plate 
pre-coated with human sICAM-1 capture antibody along with sufficient key reagents for plate 
development. Solutions were prepared according to manufacturer’s instructions. 100 µL of 
standards, samples and zero standard controls were added to the plate and incubated for 2 hours 
at room temperature. Then, the plate wells were aspirated and washed with wash buffer (250 
µL). 100µL of biotin labelled detection antibody to each well and incubated for one hour at 
room temperature. Washing step was repeated followed by adding 100 µL of freshly diluted 
streptavidin-HRP conjugate to each well and incubated for 45 minutes at room temperature. 
Again, aspirating each well and washing of the plate five times with wash buffer (250 µL). 100 
µL of TMB substrate was added to each well and incubated for approximately 15 minutes at 
room temperature. The development process (blue colour) was monitored every 5 minutes to 
prevent over development of the plate. The reaction was stopped by adding 50 µL of stop 
solution resulting in change the colour from blue to yellow. Finally, we determined the optical 
density (OD) of the plate using a micro-plate reader set at 450 nm and wavelength correction, 
set at 570 nm. 
 
2.3.21 Human sVCAM-1 measurement 
This human ELISA test is designed to enable the quantitative measurement of natural and/or 
recombinant sVCAM-1 in serum and cell culture media. It contains one strip-well plate pre-
coated with human sVCAM-1 capture antibody along with sufficient key reagents for plate 
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development. Solutions were prepared according to manufacturer’s instructions. 100 µL of 
standards, samples and zero standard controls were added to the plate and incubated for 2 hours 
at room temperature. Then, the plate wells were aspirated and washed with wash buffer (250 
µL). 100µL of biotin labelled detection antibody to each well and incubated for one hour at 
room temperature. Washing step was repeated followed by adding 100 µL of freshly diluted 
streptavidin-HRP conjugate to each well and incubated for 45 minutes at room temperature. 
Again, aspirating each well and washing of the plate five times with wash buffer (250 µL). 100 
µL of TMB substrate was added to each well and incubated for approximately 15 minutes at 
room temperature. The development process (blue colour) was monitored every 5 minutes to 
prevent over development of the plate. The reaction was stopped by adding 50 µL of stop 
solution resulting in change the colour from blue to yellow. Finally, we determined the optical 
density (OD) of the plate using a micro-plate reader set at 450 nm and wavelength correction, 
set at 570 nm. 
 
2.3.22 Statistical analysis 
Statistical analysis was conducted using GraphPad Prism software program version 7.02 
(GraphPad, San Diego, CA). All results are expressed as a mean ± standard error of mean 
(SEM). The statistical significance of differences was determined using unpaired students t-
test for two groups for multiple comparisons. A statistically significant difference was indicated 
by P values less than 0.05.  
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Chapter 3: THE IN VITRO EFFECTS OF DIFFERENT 
TYROSINE KINASE INHIBITORS IN REGULATING 
HUMAN AND MOUSE PLATELET FUNCTION 
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 INTRODUCTION 
 
The results of the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial showed 22% arterial 
thrombotic events, 12 cardiovascular events, 8% cerebrovascular events and 8% peripheral 
vascular events with ponatinib TKI therapy [211]. The complications of ponatinib treatment 
have led to clinical sequence of  heart attacks, hypertension, PAOD, and significant stenosis 
[212]. These finding suggest, TKIs exert several biological effects on the functioning of 
vascular endothelium and platelets [213]. Various clinical studies have shown that ponatinib 
has a potent significant impact on the vascular endothelium and platelets by development of 
arterial thrombotic events [65]. Similarly,  nilotinib TKI  can selectively potentiate in vitro 
thrombus formation on type I collagen for both human and mouse [214]. Conversely, imatinib 
and dasatinib inhibited platelet aggregation and reduced in vitro thrombus formation on type I 
collagen. However, other previous studies showed that essentially, dasatinib inhibited in vitro 
creation of thrombus on type I collagen under arterial shear conditions using either murine and 
human blood [215]. The same sources also revealed that CML patients who were subjected to 
the imatinib treatment demonstrated a reduced thrombus formation under arterial flow 
conditions.  
The process of unregulated platelet activation and aggregation has been found to contribute to 
the development of arterial thrombotic occlusion that could result in cerebral ischaemic stroke 
or myocardial infarction. Among patients with leukemia, thrombosis is linked to cancerous 
lesions and is the second highest cause of mortality [216]. This makes platelets a crucial 
component of blood to target during treatment [217]. Once a vascular injury has occurred, 
platelets, by binding vWF to GPIb-IX-V and collagen to GPVI, stick to exposed thrombogenic 
molecules of the subendothelial matrix. This consequently results in platelet adhesion, 
activation, and aggregation. A number of soluble agonists such as ADP and thrombin are 
secreted during platelet activation. These agonists can induce pathways for signaling, as well 
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as further activation of platelets [218].  After their activation, platelets undergo a series of 
biological alterations that prompt the initiation of intracellular signaling events that activate 
inside-out signaling pathways through the conversion of integrin αIIbβ3 from its low-affinity 
inactive condition to an active state. This conversion to a high-affinity state then enables the 
integrin αIIbβ3 to bind with fibrinogen that consequently triggers “outside-in” signaling 
pathways, hence resulting in an irreversible, stable platelet adhesion, cytoskeletal 
reorganisation, aggregation of platelets and thrombus development [219].  
Type I fibrillar collagen is the principal bonding moderator in the vascular subendothelium, 
and acts as a soluble agonist that can promote platelet adhesion, signaling events and 
aggregation. Thus, in most cases, in vitro and ex vivo research has employed the use of vWF-
coated or type I collagen-covered flow microcapillary chambers in studying the shear-induced 
formation of platelet thrombus with or without drugs in identifying characteristics of thrombus 
growth and stability, in real-time development of arterial thrombi [220]. Evidence from a 
particular study demonstrated that dasatinib therapy inhibited the activation and aggregation of 
platelets as well as impairing thrombus growth [221]. Other emerging clinical trials suggest 
that nilotinib and ponatinib potentiate arterial events [222]. However, it is notable that no single 
study has been able to demonstrate how TKIs affect platelet activation, secretion and 
aggregation of platelets. 
The objective of this chapter is to determine the ability of TKIs, in particular, ponatinib 
compared with other TKIs to regulate the formation of thrombus using either human or 
C57BL/6 mouse blood under in vitro physiological flow conditions and the effect of TKIs on 
platelet activation and aggregation.  
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 RESULTS 
3.2.1 Effect of TKIs on platelet alpha granule exocytosis 
In order to investigate the effect of TKI’s on alpha granule release, P-selectin expression was 
monitored by flow cytometry to determine whether ponatinib, imatinib, nilotinib or dasatinib 
can modulate agonist induced platelet alpha granule release. 
Flow cytometry detection using an FITC-labelled monoclonal antibody (mAb) against P-
selectin is one of most frequently used examinations for assessing the platelet alpha granule 
release following agonist stimulation as a marker of platelet activation. 
The ability of washed human platelets to release alpha (P-selectin) granules in response to 
soluble agonists with and without TKIs was determined by flow cytometric detection of 
CD62P-FITC mean fluorescence intensity. Interestingly, P-selectin exposure induced by 1.25 
µM TRAP peptide was significantly potentiated by ponatinib and nilotinib when compared to 
the vehicle control at 5 and 10 µM concentrations. Treatment with 0.25 U/ml thrombin or 1.25 
µM TRAP peptide and 1.25 µg/mL CRP significantly inhibited alpha granule secretion induced 
by agonists following treatment with dasatinib (Figure 22-24). In addition, inhibition of alpha 
granule release induced by 0.25 U/ml thrombin or 1.25 µM TRAP peptide was also observed 
with imatinib-treated platelets (Figures 22-24). Therefore, different TKIs exhibit opposing 
actions in modulating platelet alpha granule secretion.  
In these experiments, imatinib inhibited thrombin and TRAP peptide-mediated alpha granule 
release (P-selectin exposure) whilst ponatinib and nilotinib enhanced TRAP mediated alpha 
granule release at 5 and 10 µM concentrations (Figure 22 and 23). Our data also are consistent 
with the view that dasatinib had a potent inhibitory effect on agonist-mediated alpha granule 
exocytosis. 
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Figure 22. The effect of TKIs on thrombin-mediated platelet alpha granule exposure. 
Washed platelets incubated with dose responses of imatinib, nilotinib or dasatinib for 10 
minutes at 37oC following agonist activation of thrombin (0.25 U/mL) or unstimulated 
(resting). The platelets were then labelled with FITC-P-selectin monoclonal antibody. Flow 
cytometric analysis was used for determining platelet P-selectin expression. Results are 
represented as MFI±SEM from four independent experiments (**P<0.01 and ***P<0.001; 
n=4) using unpaired student’s t test. 
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Figure 23. The effect of TKIs on TRAP peptide-mediated platelet alpha granule 
exocytosis. P-selectin surface expression for washed human platelets was measured by flow 
cytometry. Platelets were either untreated or treated with various concentrations of ponatinib, 
nilotinib, imatinib or dasatinib and then stimulated by 1.25 µM TRAP peptide for 15 minutes 
at 37oC. Platelets were then stained with FITC-P-selectin CD62P monoclonal antibody. Data 
are expressed as MFI±SEM from four independent experiments (*P<0.05; **P<0.01 and 
***P<0.001; n=4) using unpaired student’s t test. 
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Figure 24. The effect of TKIs on CRP-mediated alpha granule exocytosis was assessed by 
flow cytometry. Washed human platelets were either untreated or treated with a dose-
dependent concentration of ponatinib, nilotinib, imatitib or dasatinib (0.05-10 µM) for 10 
minutes at 37oC and then stimulated with selective agonist CRP (1.25 µg/mL) for 15 minutes 
37oC. Platelets were stained with FITC-P-selectin CD62P monoclonal antibody for 30 minutes 
at room temperature. Platelet P-selectin CD62P expression was determined by flow cytometry. 
Results are cumulative data from four independent experiments and presented as mean±SEM 
(*P<0.05; **P<0.01 and ***P<0.001; n=4) using unpaired student’s t test. 
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3.2.2 Impact of TKIs on platelet dense granule exocytosis 
 
As TKI-treated platelets showed different agonist-mediated alpha granule release responses, 
the effect of ponatinib, imatinib, nilotinib or dasatinib over a dose-dependent range 0.05 to 10 
µM on agonist-induced dense granule exocytosis (quinacrine) in human platelets was 
examined. Quinacrine staining was performed that labels only dense granules and then flow 
cytometry analysis was used to evaluate agonist-induced dense granule release with and 
without TKI treatment.  
 
Analysis of dense granule secretion revealed that ponatinib, imatinib, nilotinib or dasatinib had 
no effect in the absence of platelet agonist when compared with the positive control (thrombin 
0.25 U/mL). Upon agonist stimulation, analysis of dense granule secretion revealed the dose 
dependency of ponatinib, imatinib and nilotinib had no detectable effect on dense granule 
exocytosis over a range of platelet agonists including thrombin (0.25 U/mL). In contrast, the 
secretion of platelet dense granules was significantly inhibited (*P<0.05; n=4) at different 
concentrations of dasatinib in response to thrombin (0.25 U/mL), TRAP peptide (1.25 µM) and 
CRP (1.25 µg/mL) when compared to untreated platelets (Figure 25, 26 and 27). These data 
indicate that ponatinib, imatinib and nilotinib treatment results in normal dense granule release 
in human platelets in the presence of soluble agonists, while dasatinib has an inhibitory effect 
on agonist-induced dense granule release (***P<0.001; n=4).  
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Figure 25. The effect of TKIs on thrombin-mediated dense granule release as determined 
using flow cytometry. Washed human platelets (platelet count normalised to 100×109/L) were 
labelled with 100 µM quinacrine at 37oC. Labelled platelets were either untreated or pre-
incubated with increasing concentrations of ponatinib, nilotinib, dasatinib or imatinib (0.05-10 
µM) for 10 minutes at 37oC and then stimulated by of 0.25 U/mL thrombin for 15 minutes 
37oC. The results of dose response-of various drugs were compared with baseline. Results are 
representative of four independent experiments and are shown as the mean±SEM (** P<0.01 
and *** P<0.001; n=4) using unpaired student’s t test. 
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Figure 26. The effect of TKIs on TRAP peptide-mediated dense granule release was 
assessed using flow cytometry. Quinacrine-labelled platelets (platelet count normalised to 
100×109/L) were either untreated or treated with ponatinib, nilotinib, dasatinib or imatinib in a 
dose-dependent manner (0.05-10 µM) for 10 minutes at 37oC and stimulated with 1.25 µM 
TRAP peptide for 15 minutes 37oC. Data were expressed as the mean±SEM from four 
independent experiments (*P<0.05 and ** P<0.01; n=4) using unpaired student’s t test. 
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Figure 27. The effect of TKIs on CRP-agonist peptide-mediated dense granule exocytosis 
was determined by flow cytometry. Washed platelets from normal human donors (platelet 
count normalised to 100×109/L) were stained with quinacrine (100 µM) for 30 minutes at 37oC. 
Quinacrine-labelled platelets were either untreated or treated with ponatinib, nilotinib, 
dasatinib or imatinib (0.05-10 µM) in a dose-dependent range and activated with 1.25 CRP 
µg/mL (B). Results are expressed as the mean±SEM from four independent experiments 
(*P<0.05 and **P<0.01; n=4) using unpaired student’s t test. 
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As shown in Figure 28, thrombin induced activation of platelets derived from imatinib-treated, 
ponatinib-treated, nilotinib-treated or untreated human platelets displayed a similar ability to 
bind with the fibrinogen mimetic PAC-1 mAb that recognises the active conformation of 
integrin αIIbβ3 on platelets. These results indicated that platelets from ponatinib-treated human 
platelets had normal conversion from a resting state of integrin αIIbβ3 to an activated 
conformation. In contrast, dasatinib-treated platelets showed reduced conversion from a resting 
to activated conformation of integrin αIIbβ3 (**P<0.01; n=4).  
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Figure 28. The effect of TKIs on PAC-1 mAb binding. Washed platelets (100×109/L) 
incubated with dose responses of ponatinib, imatinib, nilotinib or dasatinib for 10 minutes at 
37oC following agonist activation of thrombin (0.25 U/mL) or unstimulated (resting). The 
platelets were then labelled with PAC-1-FITC monoclonal antibody. Results are represented as 
MFI±SEM from four independent experiments (**P<0.01; n=4) using unpaired student’s t test. 
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3.2.3 Impact of TKIs on platelet aggregation 
A platelet aggregation study was performed to investigate the effect of ponatinib on human 
platelet function. Concentrations were determined for different aggregating agents in order to 
induce irreversible and sub-optimal platelet aggregation. ADP is considered a weak agonist due 
to reversible nature of the platelet aggregation. As shown in Figure 29, a dose-dependent 
increase in 5 µM ADP-induced platelet-aggregation was observed from 1-10 µM ponatinib 
concentrations. Ponatinib TKI promoted ADP-mediated platelet aggregation in 1 µM 
(37±2.6%, **P<0.01; n=4), 2.5 µM (38±3.84%, **P<0.01; n=4), 5 µM (36±0.88%, **P<0.01) 
and 10 µM (39±0.57%, **P<0.01;n=4) in a dose-dependent manner (0.05-10 µM), indicated 
that higher concentrations of ponatinib induced more pronounced aggregation potentiating 
effect. In contrast, both imatinib and dasatinib showed efficiently inhibited platelet aggregation 
at different concentrations (Figure 29).  
Danatinib demonstrated a more potent inhibitor shown by a significant inhibitory effect at all 
concentrations tested from 0.05 to 10 µM for all agonists including ADP, collagen and CRP 
(Figure 29-31). As showed in the Figure 30, ponatinib showed enhancement of collagen 
induced platelet aggregation at 5 and 10 µM drug concentrations. 
GPVI selective ligand, collagen-related peptide (CRP), on the other hand, is a stronger agonist 
that only required 0.5 µg/ml to induce platelet aggregation (Figure 31). From the experimental 
results, 5 and 10 µM ponatinib demonstrated a modest potentiation in platelet aggregation 
mediated by CRP 0.5 µg/ml (26±0.8%, *P<0.05; n=4) but did not achieve a statistically 
significant difference at lower concentrations of ponatinib.  
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Figure 29. The effect of TKIs on ADP-induced platelet aggregation. PRP from normal 
human blood was normalised to 100×109/L (platelet count). Ponatinib-treated PRP, nilotinib-
treated PRP, imatinib-treated PRP and dasatinib-treated PRP (dose-dependent drug response 
0.05-10 µM) for 10 minutes at 37oC. Aggregation responses of PRP were determined following 
agonist stimulation by ADP (5 µM). Note that ADP stimulated drug-treated PRP are compared 
relative to untreated control PRP. These results represent the mean±SEM from four 
independent experiments (** P<0.01 and *** P<0.001; n=4) using unpaired student’s t test. 
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Figure 30. The effect of TKIs on collagen-induced platelet aggregation. PRP from normal 
human blood was normalised to 100×109/L (platelet count). Ponatinib-treated PRP, nilotinib-
treated PRP, imatinib-treated PRP and dasatinib-treated PRP (dose-dependent drug response 
0.05-10 µM) for 10 minutes at 37oC. Aggregation responses of PRP were determined following 
agonist stimulation by collagen (1 µg/mL). Note that collagen induced drug-treated PRP are 
compared relative to untreated control PRP. These results represent the mean±SEM from four 
independent experiments (* P<0.05; ** P<0.01 and *** P<0.001; n=4) using unpaired student’s 
t test. 
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Figure 31. The effect of TKIs on CRP-induced platelet aggregation. PRP from normal 
human blood was normalised to 100×109/L (platelet count). Ponatinib-treated PRP, nilotinib-
treated PRP, imatinib-treated PRP and dasatinib-treated PRP (dose-dependent drug response 
0.05-10 µM) for 10 minutes at 37oC. Aggregation responses of PRP were determined following 
agonist stimulation by CRP (0.5 µg/ml). Note that CRP induced drug-treated PRP are compared 
relative to untreated control PRP. These results represent the mean±SEM from four 
independent experiments (* P<0.05 and *** P<0.001; n=4) using unpaired student’s t test. 
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Compared to other TKIs that were tested, dasatinib acted as a potent inhibitor and achieved a 
significant reduction in ADP, collagen and CRP mediated platelet aggregation at different drug 
concentrations (Figure 29-31). This is consistent with the previous studies that dasatinib acts 
as a potent inhibitor [223]. 
 
3.2.4 Assessment of platelet thrombus growth in ponatinib-treated normal human whole 
blood over type I collagen under in vitro arterial flow conditions. 
 
We hypothesised that the Bcr-Abl tyrosine kinase inhibitor, ponatinib modulates platelet 
activation, adhesion and aggregation for fibrillar collagen surface under arterial flow. As 
platelet adhesion and activation on collagen is driven by GPVI and α2β1 that activates integrin 
αIIbβ3, it was important to examine the effect of ponatinib TKI on this process.  Assays were 
conducted to examine the dose-dependent effect of TKIs on in vitro platelet thrombus 
formation in blood samples from healthy humans and C57BL/6 mice model. Citrated whole 
blood was treated with ponatinib (0.1 and 1 µM), nilotinib (5 µM), imatinib (5 µM) or dasatinib 
(0.1 µM) for 30 minutes at 37oC. Whole blood was fluorescently labelled with rhodamine 6G 
[untreated whole blood or whole blood treated with ponatinib (0.1 and 1 µM), nilotinib (5 µM), 
imatinib (5 µM) or dasatinib (0.1 µM)] was perfused through a collagen-coated microcapillary 
tube flow chamber at an arterial shear rate of 1800s-1. After six minutes of sample perfusion, 
thrombus images for ponatinib, imatinib, nilotinib and dasatinib-treated whole blood were 
recorded and determined in real time. Deconvolved Z-stack images of thrombi recorded in real 
time were analysed for thrombus parameters including thrombus area, thrombus height and 
thrombus volume in the TKI-treated whole blood samples.  
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As shown in Figure 32 and 33, ponatinib-treated human whole blood displayed increased 
thrombus height, thrombus surface coverage (area) and thrombus volume when compared to 
untreated whole blood at all ponatinib concentrations of 0.1 and 1 μM.  
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Figure 32. Ponatinib effect on in vitro human thrombus formation and growth on Type 
I collagen under arterial shear flow. Representative images of thrombus formation over 
type I collagen under arterial flow conditions. Fluorescently labelled whole blood from 
human in the presence of PON (0.1 µM), PON (1 µM) or vehicle control was perfused across 
500 µg/ml type I collagen at an arterial flow rate of 1800s 
-1
 in real time over a 6 minute time 
period.  
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Figure 33. Kinetics of ponatinib effect on in vitro human thrombus formation and growth on Type I 
collagen under arterial shear flow. (A) Thrombus height. (B) Thrombus area. (C) Thrombus volume. 
Fluorescently labelled whole blood from human in the presence of PON (0.1 µM), PON (1 µM) and vehicle 
control were perfused across 500 µg/ml type I collagen at arterial flow rate 1800s
-1
 in real time over a 6 minute 
time period. Results are presented as the mean ± SEM. (*P < 0.05 and ** P < 0.01; n=4) using unpaired student’s t-
test. 
B.   C.   
A.   
Thrombus Height  
Thrombus Area Thrombus Volume 
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3.2.5 Assessment of platelet thrombus growth in TKI-treated normal human whole blood 
over type I collagen under in vitro arterial flow conditions 
 
To determine the effect of Bcr-Abl inhibition on human platelet adhesion and aggregation on 
type I fibrillar collagen under arterial flow, a comparison of ponatinib was done with other 
TKIs. As shown in Figure 34 and 35, human whole blood treated with nilotinib showed 
increased thrombus formation for in vitro thrombus growth over type I collagen and the surface 
area covered by platelet thrombi and the thrombus volume were similar to ponatinib compared 
to control. In contrast, smaller thrombus formation was observed with dasatinib and imatinib 
compared to untreated control as shown in the thrombus height, area and volume. These results 
demonstrate different characteristics of TKIs including ponatinib versus control. Assays were 
conducted to examine the dose-dependent effect of TKIs on in vitro platelet thrombus 
formation in blood samples from healthy humans and C57BL/6 mice model. Citrated whole 
blood was treated with ponatinib (0.1 and 1 µM), nilotinib (5 µM), imatinib (5 µM) or dasatinib 
(0.1 µM) for 30 minutes at 37oC. Whole blood containing rhodamine 6G fluorescently labelled 
platelets [untreated whole human blood or whole  human blood treated with ponatinib (0.1 and 
1 µM), nilotinib (5 µM), imatinib (5 µM) or dasatinib (0.1 µM)] was perfused through a 
collagen-coated microcapillary flow chamber at an arterial shear rate of 1800s-1. After six 
minutes of sample perfusion, thrombus images for ponatinib, imatinib, nilotinib and dasatinib-
treated whole blood were recorded and determined in real time. Deconvolved Z-stack images 
of thrombi recorded in real time were analysed for thrombus parameters including thrombus 
area, thrombus height and thrombus volume in the TKI-treated whole blood samples. 
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Figure 34. TKI effect on in vitro human thrombus formation and growth on Type 
I collagen under arterial shear flow. Representative images of thrombus formation 
over type I collagen under arterial flow conditions. Fluorescently labelled whole blood 
from human in the presence of PON (0.1 µM), NIL (5 µM), IM (5 µM), DAS (0.1 µM) 
and vehicle control were perfused across 500 µg/ml type I collagen at an arterial flow 
rate of 1800s
-1
 in real time over a 6 minute time period.  
Vehicle NIL 5 μM PON 0.1 μM Time/min 
2 min 
6 min 
4 min 
DAS 0.1 μM IM 5 μM 
  
100 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
Figure 35. Kinetics of TKI effect on in vitro human thrombus formation and growth on Type I collagen 
under arterial shear flow. (A) Thrombus height, (B) Thrombus area, (C) Thrombus volume. Fluorescently 
labelled whole blood from human in the presence of PON (0.1 µM), NIL (5 µM), IM (5 µM) and DAS (0.1 
µM) were perfused across 500 µg/ml type I collagen at an arterial flow rate of 1800s 
-1
 in real time over a 6 
minute time period. (*P < 0.05,** P < 0.01 and *** P < 0.001; n=4) using unpaired student’s t-test. 
                                                                              
C.   
B.   
A.   
Thrombus Height  
Thrombus Area Thrombus Volume 
** 
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3.2.6 Assessment of platelet thrombus growth in ponatinib-treated murine blood over 
type I collagen under in vitro arterial flow conditions. 
We hypothesised that Bcr-Abl inhibitor ponatinib would modulate murine platelet adhesion 
and aggregation on type I fibrillar collagen surface under arterial flow conditions. Assays were 
conducted to examine the dose-dependent effect of TKIs on in vitro platelet thrombus 
formation in blood samples from C57BL/6 mice model. Citrated whole murine blood was 
treated with ponatinib (0.1 and 1 µM), nilotinib (5 µM), imatinib (5 µM) or dasatinib (0.1 µM) 
for 30 minutes at 37oC. Whole murine blood containing rhodamine 6G fluorescently labelled 
platelets [untreated whole murine blood or whole blood treated with ponatinib (0.1 and 1 µM), 
nilotinib (5 µM), imatinib (5 µM) or dasatinib (0.1 µM)] was perfused through a collagen-
coated microcapillary flow chamber at an arterial shear rate of 1800s-1. After six minutes of 
sample perfusion, thrombus images for ponatinib, imatinib, nilotinib and dasatinib-treated 
whole blood were recorded and determined in real time. Deconvolved Z-stack images of 
thrombi recorded in real time were analysed for thrombus parameters including thrombus area, 
thrombus height and thrombus volume in the TKI-treated whole blood samples. 
As shown in Figure 36 and 37, ponatinib-treated murine whole blood displayed increased 
thrombus growth in terms of thrombus height, surface area and thrombus volume when 
compared to untreated whole blood at all ponatinib concentrations tested at 0.1 and 1 μM.  
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Figure 36. Ponatinib effect on in vitro murine thrombus formation and growth 
on Type I collagen under arterial shear flow. Representative images of thrombus 
formation over type I collagen under arterial flow conditions. Fluorescently labelled 
whole blood from C57BL/6 mice in the presence of  PON 0.1 µM, PON 1 µM and 
vehicle control were perfused  across 500 µg/ml type I collagen at an arterial flow 
rate of 1800s 
-1
 in real time over a 6 minute time period.  
Vehicle PON 0.1 μM PON 1 μM 
Time/min 
2 min 
4 min 
6 min 
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Figure 37. Kinetics of ponatinib effect on in vitro murine thrombus formation and growth on Type I collagen 
under arterial shear flow. (A) Thrombus height, (B) Thrombus area, (C) Thrombus volume. Fluorescently labelled 
whole blood from C57BL/6 mice in presence of PON (0.1 µM), PON (1 µM) or vehicle control were perfused across 
500 µg/ml type I collagen at an arterial flow rate of 1800s 
-1
 in real time over 6 minute time period. (*P < 0.05 and ** 
P < 0.01; n=4) using unpaired student’s t-test. 
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3.2.7 Assessment of platelet thrombus growth in TKI-treated C57BL/6 mouse blood over 
type I collagen under in vitro arterial flow conditions. 
To determine the effect of Bcr-Abl inhibitors on murine platelet adhesion and aggregation on 
fibrillar collagen under arterial flow conditions, a comparison of ponatinib with other TKIs was 
performed. Assays were conducted to examine the dose-dependent effect of TKIs on in vitro 
platelet thrombus formation in blood samples using C57BL/6 mice model. Citrated whole 
murine blood was treated with ponatinib (0.1 and 1 µM), nilotinib (5 µM), imatinib (5 µM) or 
dasatinib (0.1 µM) for 30 minutes at 37oC. Whole murine blood containing rhodamine 6G 
fluorescently labelled platelets [untreated whole blood or whole murine blood treated with 
ponatinib (0.1 and 1 µM), nilotinib (5 µM), imatinib (5 µM) or dasatinib (0.1 µM)] was 
perfused through a collagen-coated microcapillary flow chamber at an arterial shear rate of 
1800s-1. After six minutes of sample perfusion, thrombus images for ponatinib, imatinib, 
nilotinib and dasatinib-treated whole blood were recorded and determined in real time. 
Deconvolved Z-stack images of thrombi recorded in real time were analysed for thrombus 
parameters including thrombus area, thrombus height and thrombus volume in the TKI-treated 
whole blood samples. 
As shown in Figures 38 and 39, both ponatinib and nilotinib-treated murine whole blood 
displayed increased thrombus growth in terms of thrombus height, thrombus surface area and 
thrombus volume when compared to untreated whole blood with increased development of 
thrombus growth over type I collagen under flow conditions. In contrast, the thrombus growth 
was reduced with imatinib and dasatinib revealing inhibition in thrombus formation when 
compared to thrombi formed by untreated control blood (Figure 38 and 39). 
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Figure 38. TKI effect on in vitro murine thrombus formation and growth on 
Type I collagen under arterial shear flow. Representative images of thrombus 
formation over type I collagen under arterial flow conditions. Fluorescently labelled 
whole blood from C57BL/6 mice in the presence of PON (0.1 µM,) NIL (5 µM), 
IM (5 µM), DAS (0.1 µM) and vehicle control were perfused across 500 µg/ml type 
I collagen at arterial flow rate 1800s
-1
 in real time over a 6 minute time period.  
Vehicle PON 0.1 μM NIL 5 μM 
Time/min 
2 min 
4 min 
6 min 
IM 5 μM DAS 0.1 μM 
  
106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Kinetics of  TKI effect on in vitro murine thrombus formation and growth on Type I collagen under 
arterial shear flow. (A) Thrombus height, (B) Thrombus area, (C) Thrombus volume.  Fluorescently labelled whole 
blood from mouse C57BL/6 in the presence of PON (0.1 µM), PON (1 µM), NIL (5 µM), IM (5 µM) and DAS (0.1 
µM) were perfused across 500 µg/ml type I collagen at arterial flow rate 1800s -1 in real time over 6 minute time 
period. (*P < 0.05 and ** P < 0.01; n=4) using unpaired student’s t-test. 
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3.2.8 Assessment of platelet thrombus growth in TKI-treated normal human whole blood 
of blinded studies over type I collagen under in vitro arterial flow conditions 
In order to remove any operator bias, blinded studies of two unknown TKIs compounds was 
performed for in vitro human thrombus formation on type I collagen. Assays were conducted 
to examine the dose-dependent effect of TKIs on in vitro platelet thrombus formation in blood 
samples from healthy humans and C57BL/6 mice model. Citrated whole blood was treated with 
compound A (0.1 and 1 µg/ml) and compound B (0.1 and 1 µg/ml) for 30 minutes at 37oC. 
Whole blood containing rhodamine 6G fluorescently labelled platelets (untreated whole blood 
or whole blood treated with compound A and B) was perfused through a collagen-coated 
microcapillary flow chamber at an arterial shear rate of 1800s-1. After six minutes of sample 
perfusion, thrombus images for compound A and B-treated whole blood were recorded and 
determined in real time. Deconvolved Z-stack images of thrombi recorded in real time were 
analysed for thrombus parameters including thrombus area, thrombus height and thrombus 
volume in the TKI-treated whole blood samples. 
Two unknown compounds A and B were supplied from ARIAD/Takeda pharmaceutical 
company, USA. As shown in Figure 40 and 41, compound A with different concentrations (0.1 
and 1 µg/ml) showed increased thrombus formation compared with the vehicle control. In 
contrast, the compound B (0.1 and 1 µg/ml) displayed reduced thrombus formation as shown 
in the decreased thrombus height, area and volume compared to vehicle human control sample. 
Note compound A and B samples that were received for testing for ARIAD and they confirmed 
identity of TKIs by LC-ms studies. They decoded compound A as ponatinib and compound B 
as imatinib.  
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Figure 40. Blinded studies of TKI effect on in vitro thrombus formation and growth on 
Type I collagen under arterial shear flow. Representative images of thrombus formation 
over type I collagen under arterial flow conditions. Fluorescently labelled whole blood from 
human in the presence of compound A (0.1 µg/ml), compound A (1 µg/ml), compound B 
(0.1 µg/ml), compound B (1 µg/ml) and vehicle control were perfused across 500 µg/ml type 
I collagen at arterial flow rate of 1800s
-1
 in real time over a 6 minute time period.  
Vehicle Time/min Comp A 1 μg/ml 
 
2 min 
4 min 
6 min 
Comp A 0.1 μg/ml 
 
Comp B 0.1 μg/ml 
 
Comp B 1 μg/ml 
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C.   B.   
Figure 41. Blinded studies of TKI effect on in vitro human thrombus formation and growth on Type I 
collagen under arterial shear flow. (A) Thrombus height, (B) Thrombus area, (C) Thrombus volume. 
Fluorescently labelled whole blood from human in the presence of compound A (0.1 µg/ml), compound A (1 
µg/ml), compound B (0.1 µg/ml), compound B (1 µg/ml) and vehicle were perfused across 500 µg/ml type I 
collagen at arterial flow rate 1800s
-1
 in real time over a 6 minute time period. Results are presented as the mean ± 
SEM. (*P < 0.05,** P < 0.01 and *** P < 0.001; n=4) using unpaired student’s t-test. 
 
A.   Thrombus Height  
Thrombus Area Thrombus Volume 
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 DISCUSSION 
 
Clinical studies have suggested that ponatinib and nilotinib may have an effect on arterial 
thrombotic event of the blood vessels and initiation of PAOD events over time. However, 
neither imatinib nor dasatinib have this effect. This study provides one of the first insights into 
the effect of ponatinib in platelet activation in vitro, also highlighting the possible mechanism 
by which the risk of vascular events is increased. We found that an acute single dose of 
ponatinib treatment contributed to platelet activation. 
ADP is known to be a weak agonist to induce platelet aggregation compared to collagen and 
CRP. At 5 µM ADP, ponatinib potentiated the ADP-mediated platelet aggregation response 
consistent with modulation of a weak agonist induced platelet aggregation. 
Platelet activation occurs in response to vessel injury and is triggered by different receptors, 
including thrombin, thrombin receptors, PAR-1 and PAR-4 [168]. It has previously found that 
PAR-1 is the primary thrombin receptor with high affinity on human platelets and couples to 
distinct sets of G-proteins for the regulation of signalling pathway [224]. Ponatinib and 
nilotinib appear to potentiate PAR-1 mediated α-granule release in normal healthy donor 
platelets. Although the mechanism remains unclear, it is possible that it has off targeting effects 
that selectively act on PAR-1 mediated α-granule pool release of P-selectin and impacts on 
haemostasis. In these studies, ponatinib was demonstrated to significantly promote platelet 
aggregation in response to adenosine diphosphate (ADP) in a dose-dependent manner, which 
was not seen in imatinib, nilotinib or dasatinib. In addition, both ponatinib and nilotinib were 
shown to potentiate exposure of platelet activation marker, P-selectin (CD62) from alpha 
granule (α-granule) in vitro upon PAR-1 stimulation, but it had no effect following thrombin 
and CRP stimulation. 
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Upon platelet activation, α- granules release their contents and P-selectin is rapidly translocated 
and expressed on platelet surface that influence the integrity of blood vessel wall [25]. It plays 
a role in triggering inflammation by mediates the adherence of leukocyte to endothelial cells, 
procoagulant release and tissue factor production [225]. Ponatinib potentiated P-selectin 
exposure suggesting platelet activation and is associated with the responses to endothelial 
injury or stimulation of vascular tissue. Interestingly, α-granule release was not potentiated in 
PAR-4 mediated platelet activation. Previous studies have indicated that human platelets 
contain different α- granule pools; PAR-1 mediated α-granule release of vascular endothelial 
growth factor (VEGF) and fibrinogen containing pro-angiogenic proteins whereas PAR-4 
mediated α-granule release of Endostatin and vWF-containing anti-angiogenic proteins [226]. 
This highlights the differential release of α-granule protein pools from platelets in these two 
independent groups. It has been well established that thrombin is the most potent physiological 
stimuli and has a pronounced pro-inflammatory character [227].  
However, ponatinib demonstrated no potentiating effect on α-granule release by thrombin-
mediated exposure of platelet activation. This could be explained by the fact that thrombin are 
coupled to multiple receptors, including PAR-1, PAR-4 and platelet glycoprotein (GP)1b-IX-
V receptor. It has to be taken into consideration that GP1b binding site for thrombin is abundant 
on platelet membrane and full platelet activation stimulated by thrombin is required. The 
stimulation effect is possibly counteracted to different receptors, hence minimising or masking 
the potentiation [228]. 
It is widely accepted that ruptured atherosclerotic lesions expose high concentrations of type I 
fibrillar collagen which initiates localised thrombosis through recruitment and adherence of 
platelets to exposed ECM constituents within the vascular wall followed by activation of 
coagulation that intensify thrombus formation. To examine the contribution of TKIs, 
specifically ponatinib in modulating platelet aggregation and arterial thrombus growth several 
complementary approaches were used. The findings achieved in this Chapter provided some 
  
112 
 
novel observations into the effect of ponatinib, imatinib, nilotinib and dasatinib on platelet 
thrombus formation in vitro from both normal humans and wild-type C57BL/6 mice. 
Unlike nilotinib, dasatinib and imatinib, the effect of ponatinib on platelet thrombus formation 
under in vitro flow conditions had not been extensively examined. In this Chapter, it was of 
interest to test and compare the ability of ponatinib and other TKIs to modulate platelet 
thrombus growth under arterial in vitro flow conditions by intravital microscopy that allowed 
capturing of real time images from human and C57BL/6 mouse samples. These experiments 
demonstrated that ponatinib and nilotinib significantly potentiated thrombus growth under in 
vitro arterial flow conditions over immobilised type I collagen at all doses tested. By contrast, 
imatinib and dasatinib inhibited platelet adhesion on type I fibrillar collagen and the thrombus 
area and volume was significantly reduced at 4 and 6 minutes of perfusion when compared 
with vehicle control of whole blood.    
Previous work by Loren et al., appears to contradict the results of my in vitro thrombus 
formation analysis induced by ponatinib [222]. The reason for this difference likely reflects 
differences in assay systems. These workers used a shear flow rate of 2200s-1 on type I collagen 
and coated surface was blocked with denatured BSA whereas in this study arterial shear flow 
rate of 1800s-1  ( average share flow rate in healthy arteries) on type I collagen without surface 
blocked by BSA [222]. Another factor relates to solubilisation of ponatinib. In this study, 25 
mM  citrate buffer pH 2.75 achieved maximal solubilisation of ponatinib for the experiments 
which would provide optimal bioactive ponatinib for stimulation of platelet activation and 
thrombus formation under arterial flow conditions [222]. 
Previous study by Gratacap et al., demonstrated that imatinib-treated patients significantly 
reduced thrombus formation on immobilised type I collagen under physiologic shear rate while 
dasatinib-treated patients formed smaller and less stable thrombi that was much more 
pronounced than imatinib. The same research group also reported that blood derived from 
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dasatinib-treated mice formed much smaller thrombi over type I collagen under arterial flow 
shear flow rate [47].  
In conclusion, clinical data have reported that treatment of CML patients with ponatinib is 
associated with increased rates of atherothrombotic events [229]. Data in this Chapter revealed 
insights and differential effects of various TKIs on platelet function profiles derived from 
healthy human donors and murine samples. The laboratory experiments demonstrated that 
imatinib and dasatinib treatments have inhibitory effects on platelet aggregation, platelet 
granule exocytosis and in vitro thrombus formation. While these studies revealed that ponatinib 
and nilotinib selectively potentiated platelet alpha granule release (P-selectin exposure) in 
response to PAR-1 in human platelets suggesting that ponatinib and nilotinib TKIs potentiate 
agonist induced platelet activation. 
This Chapter confirms a potential involvement of ponatinib treatment in the potentiation of in 
vitro thrombus formation for both human and murine on type I collagen under arterial flow 
conditions. In addition, these data provide strong evidence that ponatinib and nilotinib induced 
increased arteriolar thrombus development associated with fibrillar collagen as a thrombogenic 
substance exposed from the endothelium. These results support a direct effect of ponatinib and 
nilotinib TKI’s in modulating platelet activation, adhesion and aggregation events. In addition, 
it indicates a potential mechanism for supporting an increased rate of thrombus formation in 
vascular disease and atherosclerosis. Future strategies that involve pre-treatment or concurrent 
treatment to reduce prothrombotic effect of nilotinib or ponatinib therapy should be considered. 
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Chapter 4: INVESTIGATION THE ACUTE EFFECT OF 
TYROSINE KINASE INHIBITORS TREATMENT ON 
ARTERIAL THROMBUS FORMATION IN AN EX VIVO 
& IN VIVO MODEL 
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 INTRODUCTION 
 
A retrospective analysis of CML patients treated with nilotinib showed 2.1% of nilotinib-
associated vascular events of acute cases were vasospastic in nature with no evidence of 
atherosclerotic lesions [230].  It is also likely that ponatinib TKI has a similar effect on 
induction of vasospasm.  Consistent with this possibility is that ponatinib has been shown to 
augment vasoconstriction and attenuate vasorelaxation in mouse aortic rings 
[231].  Furthermore, the rapid onset of arterial events in CML patients on ponatinib suggests 
an acute vascular toxicity within a few weeks of drug exposure.  This suggested that ponatinib 
could have a direct effect on the blood vessel wall potentiating vasospasm leading to 
endothelial and platelet activation.   To investigate these possibilities, the acute effect of 
various TKIs was examined ex vivo and in vivo thrombus formation in C57BL/6 mouse model 
to examine thrombus characteristics.   
Platelet activation and aggregation can have a significant involvement in the development of 
arterial thrombotic occlusion and ultimately leading to myocardial infarction or cerebral 
ischaemic stroke [232]. Thrombosis related to cancerous lesions is the second major cause of 
death among leukaemic patients; therefore, platelets are an important blood component to target 
for treatment [233]. 
 Primarily, the adhesion is facilitated by binding P-selectin from platelets and endothelial cells 
to P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes, which eventually endorses the 
stability of thrombus in vivo after a vascular damage [234].  The arterial thrombi formed at the 
sites of the ruptured atherosclerotic plaque are rich in platelets and exposed to blood flow 
forces. 
 Platelets easily move in vivo in the bloodstream and do not interact with the non-activated 
endothelium. Nevertheless, in a damaged or diseased endothelial surface, the platelets respond 
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by tethering, adhering, and aggregating, resulting in the propagation of arterial thrombosis. 
Similarly, exposed tissue factor induces the stimulation of clotting cascade, leading to thrombin 
and fibrin accumulation that encourages the activation of platelets and potentiates the 
development of thrombus [235].  
However, using intravital microscopy analysis in real-time in vivo thrombus formation, have 
confirmed platelet aggregation to be an active process that has a major role in areas of vascular 
injury. 
Although, ponatinib was temporarily withdrawn from the market in 2013 due to arterial 
vascular occlusive events, it returned again in 2014 by FDA with new safety measures 
including dose reduction strategies from 45 mg QD to 30 to 15 mg QD [36]. However, a prior 
study indicated that blood from dasatinib-treated mice inhibited the formation of thrombus in 
vitro, ex vivo, and in vivo [236]. Moreover, the research also determined that primary 
haemostasis in vivo was impaired after treatment with dasatinib about four hours after ingestion 
[237]. A previous study in our laboratory examined the influence of TKI, imatinib, dasatinib 
or nilotinib but not ponatinib in mediating in vivo thrombus development in real time [238].  
In this Chapter, the aim is to test the ability of TKIs, specifically ponatinib, to modulate 
thrombus formation under ex vivo physiological flow conditions in a C57BL/6 model. In 
addition, cohorts of TKI-treated mice were subjected to FeCl3-mediated vascular induced 
injury of the mesenteric arterioles (80-100 µM) and in vivo microvascular thrombus growth 
was evaluated. Moreover, cohorts of TKI-treated mice were subjected to FeCl3-mediated 
vascular induced injury of the carotid artery as a mechanism for inducing arteriolar thrombosis 
in vivo. These approaches were taken to determine the effect of Bcr-Abl TKIs on platelet 
phenotype and ex vivo thrombus formation under arterial flow, and to assess microvascular and 
arteriolar thrombosis in vivo in a C57BL/6 mouse model. 
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 RESULTS 
 
4.2.1 Impact of TKIs on thrombus growth under conditions of ex vivo arterial flow on 
immobilised type I collagen 
 
The effect of TKIs on platelet function was further examined by comparing ex vivo thrombus 
formation by pre-treating C57BL/6 mice with various TKI for four hours followed by 
examination of thrombus growth characteristics under arterial flow conditions of mouse whole 
blood. Briefly, blood was collected from C57BL/6 mice which were treated with either 3 
mg/kg, 10 mg/kg or 30 mg/kg ponatinib, 25 mg/kg imatinib, 25 mg/kg nilotinib, 5 mg/kg 
dasatinib or 25 mM citrate pH 2.75 (vehicle control) by oral gavage and left for four hours from 
the initial dose (Cmax peak drug concentration). Whole blood with fluorescently labelled 
platelets was perfused onto immobilised type I collagen at an arterial shear rate of 1800s-1 for 
six minutes.  
The blood from ponatinib-, imatinib-, nilotinib- and dasatinib-treated mice were compared to 
the sham control and the images of thrombi formed were recorded in real time. Analysis of 3D 
deconvolved images revealed that surface coverage of platelet adhesion, thrombus height and 
the thrombus volume were significantly enhanced with ponatinib doses versus sham control. 
As shown in Figure 42 and 43, all doses of ponatinib showed a significant potentiation of 
thrombus height, area and thrombus volume over time compared vehicle control.  
 
 
 
 
  
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42.  The effect of a dose response of ponatinib on ex vivo murine thrombus 
formation and growth. Fluorescently-labelled whole blood of C57BL/6 mice 
untreated or treated with 3, 10 or 30 mg/kg ponatinib was perfused over 500 µg/mL 
type I collagen under arterial flow conditions at shear rate of 1800s 
-1
. Z-stack images 
were captured over 6 minutes duration with a digital Axiocam mRm camera (Carl 
Zeiss) and analysed with Zeiss Axiovision Rel4.6 software. 
Vehicle Time/min 
2 min 
4 min 
6 min 
PON 3 mg/kg PON 10 mg/kg PON 30 mg/kg 
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Figure 43. Kinetics of a dose response of ponatinib effect on ex vivo thrombus formation and growth on Type I collagen 
under arterial shear flow. (A) Thrombus height, (B) Thrombus area, (C) Thrombus volume. Fluorescently labelled whole 
blood from mouse in the presence of PON (3 mg/kg), PON (10 mg/kg), PON (30 mg/kg) and vehicle after treatment for 4 hours 
were perfused across 500 µg/ml type I collagen at arterial flow rate 1800s 
-1
 in real time over a 6 minute time period. Results 
are presented as the mean ± SEM. (*P < 0.05, ** P < 0.01 and *** P < 0.001; n=4) using unpaired student’s t-test. 
Thrombus Height  
Thrombus Area Thrombus Volume 
*** 
C.   B.   
A.   
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Similarly, mice treated with 3 mg/kg of ponatinib or 25 mg/kg nilotinib displayed a significant 
enhancement of thrombus growth in thrombus height, area and volume compared to vehicle 
control. In contrast, imatinib and dasatinib caused a significant inhibition of thrombus 
formation (Figure 44 & 45). 3 mg/kg treated mice correlates with 45 mg QD given to human 
CML patients. 
Based upon these results, C57BL/6-treated mice with ponatinib and nilotinib doses shows 
strong potentiation of platelet adhesion and thrombus growth in real time, while imatinib or 
dasatinib treatment had an inhibitory effect on platelet thrombus formation on immobilised 
type I collagen matrix under ex vivo physiologic arterial shear flow. These results indicate that 
the prothrombotic effect of ponatinib and nilotinib treatment of wild-type mice required the 
presence of the endothelium to prime the platelets in vivo to potentiate ex vivo thrombus growth 
under arterial flow conditions. 
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Vehicle DAS 5 mg/kg 
2 min 
4 min 
6 min 
NIL 25 mg/kg IM 25 mg/kg PON 3 mg/kg 
Figure 44. The effect  of  TKIs  on  ex  vivo  murine  thrombus  formation  and  
growth. Fluorescently-labelled whole blood of C57BL/6 mice untreated or treated 
with 3 mg/kg ponatinib, 25 mg/kg imatinib, 25 mg/kg nilotinib and 5 mg/kg dasatinib 
was perfused over 500 µg/mL type I collagen under arterial flow conditions at shear 
rate of 1800s 
-1
. Z-stack images were captured over a 6 minute duration with a digital 
Axiocam mRm camera (Carl Zeiss) and analysed with Zeiss Axiovision Rel4.6 
software. 
Time/min 
2 min 
4 min 
6 min 
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Figure 45. Kinetics  of TKI effect on ex vivo murine thrombus formation and growth on Type I collagen 
under arterial shear flow. (A) Thrombus height, (B) Thrombus area. (C) Thrombus volume. Fluorescently 
labelled whole blood from mouse in the presence of PON (3 mg/kg), NIL (25 mg/kg), IM (25 mg/kg), DAS (5 
mg/kg) and vehicle control after treatment for 4 hours were perfused  across 500 µg/ml type I collagen at arterial 
flow rate 1800s 
-1
 in real time over a 6 minute time period. Results are presented as the mean ± SEM. (*P < 
0.05, ** P < 0.01 and *** P < 0.001; n=4) using unpaired student’s t-test. 
Thrombus Height  
Thrombus Area Thrombus Volume 
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4.2.2 The effect of ponatinib on platelet glycoprotein surface expression 
 
Platelet glycoprotein receptors are known to play an important role in the regulation of platelet 
function and haemostatic mechanisms. In this study, this assay was conducted to examine 
whether ponatinib treatment would alter the expression of glycoproteins on the surface of 
resting platelets in wild-type C57BL/6 mice. Several glycoproteins, including GPVI, GPIb-IX-
V complex, integrin α2β1, integrin αIIbβ3 and CD9, were detected on resting platelets using 
well-characterised specific monoclonal antibodies. Wild-type C57BL/6 mice were orally 
administered with 3 mg/kg ponatinib and blood samples were collected by cardiac puncture 
four hours later. Washed platelets in the resting state derived from untreated or ponatinib treated 
mice were incubated with respective anti-mouse platelet glycoprotein-FITC conjugated. As 
shown in Figure 46, the surface expressions of all glycoproteins GPVI, GPIb-IX-V complex, 
integrin α2β1, integrin αIIbβ3 and CD9 on platelets derived from ponatinib-treated mice were 
normal when compared to untreated mice. Results were derived from four independent 
experiments and are represented as mean fluorescence intensity MFI±SEM. Therefore, a single 
acute dose of ponatinib TKI did not affect platelet glycoprotein expression despite inducing an 
ex vivo prothrombotic state under arterial flow conditions. 
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Figure 46. The effect ponatinib on surface expression of platelet glycoproteins in mice.    
Flow cytometric analysis on a FACS Canto II analyser of GPVI, Integrin α2β1, Integrin αIIbβ3, 
GPIb-IX-V and CD9 expression on resting platelets from C57BL/6 mice treated with 3 mg/kg 
ponatinib versus vehicle control using specific fluorescently labelled monoclonal antibodies 
for wild-type mouse platelets. The assay samples were performed in triplicate, and the results 
shown are representative of four independent experiments and presented as MFI±SEM 
(P>0.05; n=4) using unpaired student’s t test. 
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4.2.3 The effect of TKI on the conversion of integrin αIIbβ3 to its active conformation on 
platelets 
 
The formation of stable platelet aggregation and thrombus formation is dependent upon the 
conversion of integrin αIIbβ3 from its resting to an activated state where it will bind its soluble 
ligand fibrinogen. We studied the effect of ponatinib and other TKIs on the conversion of 
integrin αIIbβ3 to its active conformation in wild-type platelets detected using JON/A mAb-
PE binding. Washed platelets derived from ponatinib-treated (3 mg/kg), nilotinib-treated (25 
mg/kg), imatinib-treated (25 mg/kg), dasatinib-treated (5 mg/kg) or untreated C57BL/6 mice 
showed minimal binding of JON/A-PE under resting conditions, compared with agonist-
induced activation with thrombin (0.5 U/mL). As shown in Figure 47, thrombin induced 
activation of platelets derived from ponatinib-treated, nilotinib-treated, imatinib-treated or 
untreated mice displayed a similar ability to bind with the fibrinogen mimetic JON/A mAb that 
recognises the active conformation of integrin αIIbβ3 on platelets. In contrast, platelets from 
dasatinib-treated C57BL/6 mice displayed a reduced ability to bind the fibrinogen mimetic 
JON/A mAb. These results indicated that platelets from ponatinib and nilotinib-treated mice 
had normal conversion from a resting state of integrin αIIbβ3 to an activated conformation on 
platelets. 
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Figure 47. The effect of TKI on JON/A mAb binding in murine platelets. Flow cytometric 
analysis on a FACS Canto II analysis resting versus agonist induced active conformation of 
integrin αIIbβ3 on platelets from wild-type mice treated with 3 mg/kg ponatinib, 25 mg/kg 
nilotinib, 25 mg/kg imatinib, 5 mg/kg dasatinib or PBS using JON/A-PE mAb binding to 
platelets stimulated with thrombin (0.5 U/mL), or unstimulated (vehicle control). The assay 
samples were performed in triplicate, and the results shown are representative of four 
independent experiments and presented as MFI±SEM (*P < 0.05; **P < 0.01; n=4) using 
unpaired student’s t test. 
 
 
 
 
* 
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4.2.4 Assessment of microvascular thrombosis formation and stability in BCR-Abl TKI-
treated C57BL/6 mice subjected to FeCl3-induced vascular injury of the mesenteric 
arterioles. 
 
As the Bcr-Abl inhibitor, ponatinib and nilotinib displayed a potentiating effect on in vitro 
thrombosis formation under arterial flow, we wanted to examine thrombosis characterisation 
in an in vivo FeCl3 induced vascular injury of mesenteric arterioles in C57BL/6 mice.  It was 
clear that ponatinib and nilotinib TKI displayed a potentiating effect on in vitro and ex vivo 
thrombus formation, whereas imatinib and dasatinib exhibited an inhibitory role on in vitro and 
ex vivo thrombus growth under arterial flow conditions. Therefore, the effect of TKI’s 
(ponatinib, nilotinib, imatinib and dasatinib) drugs was examined on the formation of in vivo 
microvascular thrombi in mesenteric arterioles using FeCl3-induced vascular injury in a 
C57BL/6 mouse model. Thrombus formation and stability characteristics were analysed in real 
time by measuring the number of fluorescently-labelled platelets bound to injured endothelium. 
In this model, wild-type mice were treated with ponatinib (3, 10, 30 mg/kg), 25 mg/kg imatinib, 
25 mg/kg nilotinib, 5 mg/kg dasatinib or PBS pH 7.4 or 25 mM citrate buffer pH 2.75 by oral 
administration at four hours before surgery. The mice were then completely anaesthetised, the 
ideal diameter of the mesenteric arterioles (80-100 µm) was determined, and the animals were 
administered rhodamine 6G dye. Thrombus growth was observed and compared between TKI-
treated mice and citrate buffer pH 2.75-treated mice for 10 minutes in real time in vivo through 
intravital microscopy. The rendered Z-stack images were deconvolved with Axiovision Rel 4.6 
software, to construct 3D-images, and the volume of the thrombi was calculated from the area 
multiplied by the height of each thrombus. As shown in the representative images in Figure 48 
& 49, enhanced thrombus growth was observed in FeCl3-injured mesenteric arterioles of 3, 10, 
30 mg/kg of ponatinib-treated mice in four hours after ingestion when compared to vehicle 
control at each time point beyond four minutes.
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Figure 48. Ponatinib dose response on in vivo thrombus growth characteristics using 
FeCl3 injured mesenteric arterioles. Representative images of thrombus formation in 
mesenteric arterioles (80-100 μm) at 2,4,6,8,10 minutes after 7.5% FeCl3-induced vascular 
injury with ponatinib (3, 10 and 30 mg/kg) treated mice at 4 hours compared to vehicle control 
mice (n=4).  
Vehicle Time/min 
2 min 
4 min 
6 min 
PON 10 mg/kg PON 3 mg/kg PON 30 mg/kg 
8 min 
10 min 
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Figure 49. Kinetics of thrombus height, thrombus area and thrombus volume with different doses of 
Ponatinib TKI. (A) Thrombus height, (B) Thrombus area (C) Thrombus volume were determined over time for 
thrombi formed in mesenteric arterioles of ponatinib (3, 10, 30 mg/kg) treated mice after 4 hours. Results are 
presented as the mean ± SEM. (*P < 0.05,** P < 0.01 and *** P < 0.001; n=4/group) using unpaired student’s t-
test. 
C.   B.   
A.   Thrombus Height  
Thrombus Area Thrombus Volume 
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As shown in Figure 50, in contrast to the effects seen with ponatinib (3 mg/kg) and nilotinib 
(25 mg/kg), thrombus growth was reduced in mice treated with imatinib (25 mg/kg) and 
significantly diminished over a ten-minute period in 5 mg/kg dasatinib treated-mice following 
FeCl3-induced injury, when compared with the mouse vehicle control. The Z-stack analysis of 
thrombus growth over all time-points revealed that imatinib-treated mouse arterioles displayed 
slightly decreased thrombus formation. No statistically significant differences were observed 
for any thrombus formation parameters when compared with vehicle-treated mouse arterioles 
(Figure 50). At 6 minutes, the kinetics of thrombus volume in imatinib-treated mice was 
(26421±3256 µm3). However, mice treated with ponatinib exhibited a significant increase in 
the kinetics of thrombus volume at 6 minutes when compared to the control (70520±3352 µm3). 
Also, there was a significant increase in the kinetics of thrombus volume with nilotinib 
(65411±3327 µm3).   Nevertheless, significant inhibition was observed in the kinetics of the 
thrombus volume (22544±3215 µm3) at 6 minutes in mice treated with 5 mg/kg dasatinib 
compared to the wild-type vehicle ontrol. Overall, an increase in the kinetics of thrombus 
volume for mice treated with either ponatinib or nilotinib was observed at 6, 8 and 10 minute 
time points, whereas the inhibition of thrombus formation with both imatinib and dasatinib was 
observed when compared to the vehicle control at 6, 8 and 10 minute time points (Figure 51).  
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Figure 50. TKI effect on in vivo thrombus growth using FeCl3 injured mesenteric arterioles in C57BL/6 
mice model. Representative images of thrombus formation in mesenteric arterioles (80-100 μm) at 2,4,6,8,10 
minutes after 7.5% FeCl3-induced vascular injury in ponatinib (3 mg/kg), nilotinib (25 mg/kg), imatinib (25 
mg/kg) and dasatinib (5 mg/kg) treated mice at 4 hours compared to vehicle control mice. All microvessels are 
viewed at 200x magnification, and images acquired at a 1280x1024 pixel array using Axiovision Rel 4.6 version 
software attached to an Axiovert 135 M1 microscope (Carl Zeiss).  
Vehicle DAS 5 mg/kg NIL 25 mg/kg IM 25 mg/kg PON 3 mg/kg 
Time/min 
2 min 
4 min 
6 min
8 min 
10 min 
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Figure 51. Kinetics of TKI effect on in vivo thrombus growth and stability using FeCl3 injured mesenteric 
arterioles in C57BL/6 mouse model. (A) Thrombus height, (B) Thrombus area, (C) Thrombus volume were 
determined over time for thrombi formed in mesenteric arterioles of TKIs treated mice after 4 hours. Results 
are presented as the mean ± SEM. (*P < 0.05,** P < 0.01,*** P < 0.001, **** P < 0.0001; n=4) using unpaired  
student’s t-test. 
B.   C.   
A.   
Thrombus Height  
Thrombus Area Thrombus Volume 
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4.2.5 Assessment of arterial thrombosis formation in TKI-treated C57BL/6 mice 
subjected to FeCl3-induced vascular injury of the mesenteric in blinded studies. 
In order to remove operation bias, ARIAD/Takeda pharmaceutical company supplied two 
unknown TKI compounds to test the in vivo thrombus formation characteristics in mesenteric 
arterioles of C57BL/6 mice. The mice were anaesthetised, the ideal diameter of the mesenteric 
arterioles (80-100 µm) was determined, and the animals were administered rhodamine 6G dye. 
Thrombus growth was observed and compared between TKI-treated mice and vehicle-treated 
mice for 10 minutes in real time in vivo through intravital microscopy. The rendered Z-stack 
images were deconvolved with Axiovision Rel 4.6 software, to construct 3D-images, and the 
volume of the thrombi was calculated from the area multiplied by the height of each thrombus. 
The percentages of vessel occlusion and stability scores were also analysed for untreated wild-
type mice or those treated with TKIs. Thrombi formed were analysed at all time points (0-2, 2-
4, 4-6, 6-8 and 8-10 min).  
As shown in the Figure 52 and 53, the kinetics of thrombus height, area and volume in 
compound A (5 and 25 mg/kg) -treated mice at 6, 8 and 10 minutes showed a significant 
increase in the thrombus formation when compared to the vehicle control. In contrast, 
significant inhibition was observed in the kinetics of the thrombus volume at 6, 8 and 10 
minutes in mice treated with compound B (5 and 25 mg/kg) compared to the wild-type control. 
Overall, changes were observed in the kinetics of thrombus height, area and volume for mice 
treated with both concentration 5 and 25 mg/kg of compound A, whereas the inhibition with 
both concentration 5 and 25 mg/kg of compound B were observed when compared to the 25 
mM citrate buffer pH 2.75 control (Figure 52). The compounds A and B were tested by LC-
MS by ARIAD/Takeda pharmaceutical company. They recorded that compound A is ponatinib 
and compound B is imatinib. 
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Figure 52. TKI effect on in vivo thrombus growth and stability using FeCl3 injured mesenteric 
arterioles in blinded studies.  Representative images of thrombus formation in mesenteric arterioles (80-
100 μm) at 2,4,6,8,10 minutes after 7.5% FeCl3-induced vascular injury in compound A (5 mg/kg), 
compound A (25 mg/kg), compound B (5 mg/kg) and compound B (25 mg/kg) treated mice at 4 hours 
compared to vehicle control mice (25 mM citrate buffer pH 2.75). 
Vehicle A 5 mg/kg A 25 mg/kg B 5 mg/kg B 25 mg/kg 
Time/min 
2 min 
4 min 
6 min 
8 min 
10 min 
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Figure 53. Kinetics of TKI effect on in vivo thrombus growth and stability using FeCl3 injured mesenteric 
arterioles in blinded studies. (A) Thrombus height, (B) Thrombus area and (C) thrombus volume were determined 
over time for thrombi formed in mesenteric arterioles of TKIs treated mice after 4 hours. Results are presented as the 
mean ± SEM. (*P < 0.05 and ** P < 0.01; n=3/group) using unpaired student’s t test. 
B.   C.   
A.   Thrombus Height  
Thrombus Area Thrombus Volume 
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4.2.6 Evaluation of arterial thrombosis formation and time to vessel occlusion in TKI   
treated C57BL/6 mice through FeCl3-induced vascular injury of the carotid artery 
 
In order to investigate the effect of Bcr-Abl inhibitor ponatinib compared to other TKI’s in 
arteriolar thrombosis, we treated cohorts of C57BL/6 with respective doses of TKI’s for 4 hours 
then examined time to 95 % vessel occlusion by doppler laser flow probe.  
In the microvascular thrombosis studies, mice treated with a single dose of ponatinib and 
nilotinib exhibited more rapid vessel occlusion in vivo following FeCl3-induced injury of the 
mesenteric arterioles, whilst those treated with imatinib and dasatinib displayed reduced vessel 
occlusion compared to vehicle control mice. In this study, the possibility that ponatinib and 
nilotinib have comparable prothrombotic phenotypes, and that imatinib and dasatinib can 
inhibit thrombus formation in vivo were determined by measuring the time to achieve 95% 
vessel occlusion in real time. In this model, platelet recruitment and adhesion to form thrombi 
at injured sites is initiated by FeCl3-induced vascular injury of the carotid artery and monitored 
blood flow using a Doppler laser flow probe.  
As shown in Figure 54, the mean time to reach >95% vessel occlusion four hours after both 
ponatinib-treatment (3 mg/kg) of C57BL/6 mice was 888±22.51 seconds and nilotinib-
treatment (25 mg/kg) was 848.4±21.74 seconds which were significantly shorter than the time 
observed for imatinib-treated (25 mg/kg) (1453.2±34.26 seconds) and dasatinib-treated ( 5 
mg/kg) (1573.8±53.74 seconds) versus vehicle-treated (1113.8±28.39 seconds) C57BL/6 mice 
(Figure 54 & 55). These results suggest that a single acute dose of ponatinib and nilotinib can 
potentiate arteriolar thrombosis, whereas imatinib and dasatinib reduced arteriolar thrombosis 
in the carotid artery in vivo. 
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Figure 54. Examination of thrombus formation in the injured carotid artery in TKI-
treated C57BL/6 mice. (A-E) Representative graphs of blood flow restriction in the carotid 
artery due to thrombus formation following 20% (w/v) FeCl3 induced injury. (A) Vehicle-
treated mice, (B) imatinib-treated mice, (C) nilotinib-treated mice, (D) dasatinib-treated mice 
and (E) ponatinib-treated mice. The vertical lines indicate the time when the carotid artery 
reached 95% occlusion, and the arrows indicate when FeCl3 injury was initiated. 
 
A. B. 
C. D. 
E. 
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Figure 55. Time to 95 % vessel occlusion in the injured carotid artery in TKI-treated 
C57BL/6 mice. Time to 95% carotid vessel occlusion was determined from the initiation of 
FeCl3-induced injury in various TKI-treated mice. Each symbol represents one mouse, and all 
mice were sex-matched and weight-matched (20±2g). Data represent as mean±SEM and are 
representative of n=4 mice/group. (*P<0.05 and **P<0.01) using unpaired student’s t-test. 
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 DISCUSSION 
 
In the recent research on TKIs, it was observed that TKIs bear differential influence on the 
formation of platelet thrombus as an emerging subject matter. Furthermore, there are clinical 
studies which indicate that ponatinib might directly impact arterial thrombotic and trigger 
PAOD events in a dose dependent manner during CML treatment [239]. Nevertheless, there 
has been no other direct evidence that shows the role of ponatinib treatment in moderating 
pathological thrombus growth. We utilised a range of methods in this Chapter to assess platelet 
thrombi growth over time in C57BL/6 mice which are treated with an acute single dose 3, 10 
or 30 mg/kg ponatinib, 25 mg/kg nilotinib, 25 mg/kg imatinib, 5 mg/kg dasatinib or vehicle 
control. The methods included assessment of the formation of platelet thrombus after FeCl3-
induced vascular injury in either the carotid artery or mesenteric arterioles.  
In this Chapter, it was of interest to test and compare the ability of ponatinib and other TKIs to 
modulate platelet thrombus growth under ex vivo arterial flow conditions by intravital 
microscopy that allowed capturing of real time images from C57BL/6 mice. These experiments 
demonstrated that ponatinib and nilotinib had significant effects on thrombus growth under ex 
vivo arterial flow conditions over immobilised type I collagen at all doses tested. By contrast, 
dasatinib and imatinib inhibited platelet adhesion on type I collagen and the thrombus volume 
was significantly reduced at 4 and 6 minutes of perfusion when compared with untreated 
vehicle control. Furthermore, the ex vivo studies used drug concentrations that were optimised 
based on dose response curves, and the drug concentrations were similar to those used 
previously. As demonstrated in this Chapter, all concentrations 3, 10 and 30 mg/kg of ponatinib 
and 25 mg/kg of nilotinib significantly increased ex vivo thrombus growth on immobilised type 
I collagen over time when compared to vehicle control in real time. By contrast, thrombus 
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growth on type I collagen under ex vivo flow shear conditions was inhibited by imatinib and 
dasatinib TKIs. 
The existence of glycoprotein receptors on the platelet surface, such as GPIb-IX-V, GPVI, 
integrin α2β1, integrin αIIbβ and CD9, are important participants in the regulation of platelet 
function in both humans and mice. The expression of these receptors contributes directly to 
haemostatic processes through involvement by either coordinating adhesive receptors with 
exposed subendothelial molecules at vascular trauma, platelet stimulation in response to 
soluble agonists or aggregating growth for associating with other platelets or with other blood 
components, including leukocytes, which leads to formation of the haemostatic plug. However, 
up-regulation of receptor expression on platelet surfaces has been shown to play a critical role 
in platelet arterial thrombosis in both humans and mice [5, 64]. Previous research showed that 
dasatinib impaired the collagen/GPVI association and created subsequent defects in the ITAM-
mediated signaling pathways in platelets, particularly for FcγRIIa and collagen GPVI/FcR 
gamma chain that involve tyrosine kinase phosphorylation, PI3-kinase activation and 
PLC/DAG kinase activation, with the end result of increased bleeding events and prevention 
of thrombus growth [47]. 
Following identification that ponatinib treatment of C57BL/6 mice resulted in a prothrombotic 
phenotype under ex vivo arterial flow conditions. The next step therefore was to investigate 
whether this could be attributed to increased platelet glycoprotein expression or induced 
activated conformation of integrin αIIbβ3 in vivo. This Chapter’s results demonstrated that 3 
mg/kg ponatinib did not show a direct effect on the surface expression of glycoproteins on 
resting platelets in C57BL/6 mice. In addition, the results here demonstrated that ponatinib did 
not directly alter conversion of integrin αIIbβ3 to its active conformation in murine platelets 
upon agonist stimulation. 
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 Platelets from ponatinib-treated mice had a similar ability for binding with JON/A mAb as  
platelets from untreated mice, resulting in normal conversion of integrin αIIbβ3 from resting 
to activated conformation to bind its fibrinogen mimetic JON/A mAb. Collectively, these 
findings of the initial characterisation of ponatinib treatment suggest that ponatinib had no 
effect on modulation of platelet glycoprotein expression or conformation of integrin αIIbβ3 at 
a single acute dose. However, further studies could be of interest to ascertain the possibility of 
potential effects of multiple treatments of ponatinib (chronic model) on regulation of platelet 
glycoprotein receptors. 
In this study, the intravital microscopy was used to examine FeCl3 induced injury of mesenteric 
arterioles or carotid artery. The results show that the mice treated with ponatinib and nilotinib 
increased thrombus growth in vivo at 6, 8 and 10 minutes. This study and others have shown 
that dasatinib-treated mice yielded smaller thrombi [240]. Therefore, these studies highlight 
that dasatinib has the potential to inhibit the growth of platelet thrombus in vivo. In addition, 
mice treated with imatinib had smaller thrombi.  
Moreover, FeCl3 induced oxidation of haemoglobin, resultant in erythrocyte haemolysis that 
demanded denudation of the endothelium and subsequent exposure of ECM molecules 
including collagen [241]. Platelets circulating in the blood will tether and stick to 
subendothelial collagen at the vascular injury sites by binding with their receptors (the GPVI 
and GPIb-IX-V complexes). The receptors are expressed on the surface membrane of the 
platelet, thus engaging platelet attachment, activation, and promotion of platelet aggregation 
and growth of the thrombus [242]. 
Once the platelets are stimulated, adhesive proteins, such as CD40L and P-selectin are 
generated to support the activation of platelets and enhance the formation of arterial thrombus 
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in vivo [242]. In this study, through the use of intravital microscopy, there was an enhanced 
extent of FeCl3-induced injury of mesenteric arterioles ponatinib treated mice showed 
increased thrombus growth compared to those in the vehicle control. However, the differences 
were statistically significant (Figure 48 & 49). This proves that ponatinib and nilotinib TKIs 
potentiate the interaction of platelets and endothelium together with platelet-platelet interaction 
the formation of thrombus in vivo. Conversely, a FeCl3-induced vascular injury resulted in 
smaller thrombus growth among mice treated with imatinib as compared to those in vehicle 
control. As anticipated, there were smaller thrombi in dasatinib-treated mice than those in the 
sham control group after the FeCl3-induced injury which showed a significant difference 
compared to ponatinib, nilotinib or vehicle control (Figure 50 & 51). 
This study showed a ponatinib-mediated prothrombotic phenotype using a substitute 
experimental in vivo model that engaged a different type of vascular bed that contained a higher 
rate of shear. There was a measurement of time to achieve >95% C57BL/6 mouse carotid 
arteries vessel occlusion following treatment of ponatinib, imatinib, nilotinib, dasatinib, or 
vehicle (control). The process was preceded by FeCl3-induced injury of carotid arteries 
followed by monitoring with the use of a Doppler laser flow probe. Following TKI treatment, 
the time required to achieve >95% vessel occlusion was significantly shorter in ponatinib or 
nilotinib-treated mice than in the vehicle control, dasatinib or imatinib-treated mice. Although 
there was a delay in the mean time to 95% vessel occlusion, that was statistically significant in 
the imatinib or dasatinib-treated mice when compared with shorted time ponatinib, nilotinib 
compared to the vehicle control (Figure 54 & 55). 
The study proves the hypothesis, which indicated that treatment of mice with imatinib and 
dasatinib causes a delay in achieving 95% vessel occlusion following the FeCl3-induced injury 
of the carotid artery in comparison to the vehicle control. The FeCl3-induced thrombosis 
primarily happens as a result of the platelet activation at the spot where there is vascular injury 
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through contact between circulating platelets and the bare subendothelial adhesive proteins, 
like vWF and type I collagen, which attach themselves to their receptors (GPIb-IX-V and GPVI 
complexes correspondingly) [243]. The findings here are parallel to the observations made 
above as established from the model in the first experimental model indicating that ponatinib 
and nilotinib dose and not of dasatinib or imatinib enhance in vivo thrombus growth following 
the mesenteric arterioles’ FeCl3-induced injury. Consequently, the integration of the two result 
findings indicates that ponatinib and nilotinib therapy play a key role in increasing the 
recruitment of platelets at FeCl3-induced vascular injury sites, thus promoting progressive 
prothrombotic growth over time. 
Previous studies in our lab, Alhawiti et al., showed that nilotinib induced a prothrombotic state 
in vitro, ex vivo and in vivo following FeCl3-induced injury of  mesenteric arterioles, while both 
imatinib and dasatinib showed inhibition of thrombus growth [238]. 
A recent study demonstrated that ponatinib induced thrombus formation using Rose Bengal 
photoactivation technique in an in vivo mouse model. These studies correlated with my study 
despite using a photoactivation model that induces in vivo thrombus formation but also causes 
vessel blood cells to stagnate [244].  
In conclusion, this Chapter has provided novel insights into the influence of TKIs on arteriolar 
thrombus formation in vivo using different models. Ponatinib or nilotinib selectively induced a 
prothrombotic state in vivo four hours after a single dose (Cmax) of the drug in the context of 
blood vessels with different vascular beds. This included examining platelet thrombus 
formation following FeCl3-induced vascular injury in either mesenteric arterioles (80-100 µm 
in diameter) or in the carotid artery.  
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Chapter 5: EXAMINING THE AMELIORATION OF THE 
PONATINIB AND NILOTINIB INDUCED PROTHROMBOTIC 
EFFECTS ON HUMAN AND MICE USING DIFFERENT 
AGENTS INCLUDING CALCIUM CHANNEL BLOCKER, 
DILTIAZEM, COX2 INHIBITOR, DICLOFENAC AND eNOS 
SYNTHASE INHIBITOR, L-NNA. 
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 INTRODUCTION 
 
The endothelium refers to a monolayer of endothelial cells, which form the inner blood vessel 
lining and the lymphatic system. Moreover, the endothelium functions by regulating blood flow 
and preventing platelets from adhesion because of the anti-thrombotic surface that is created 
by the endothelial cells [245]. The functioning of the endothelium is controlled by several 
vasoactive substances, a mechanical network, and other mechanical forces such as pressure 
[246]. From this perspective, it is evident that the endothelium serves a primary role in ensuring 
enough flow of blood, which is regulated by other substances. Key vasodilators include nitric 
oxide and prostaglandin I2 that are aided by the secretion of other substances including C-type 
natriuretic peptide and the hyperpolarising factor that is derived from the endothelium [247]. 
NO and PGI2 serve as key bioactive secretions from endothelium that inhibit platelet 
aggregation. Anti-thrombotic and anti-aggregation of platelets is achieved through the 
increased secretion of the vasodilators, which increase adenylate cyclase and guanylate cyclase 
activity that are responsible for raising the levels of c-AMP and c-GMP in the body [248].  
 
The endothelium also secretes vasoconstrictors namely thromboxane A2, angiotensin II, 
reactive oxygen species (ROS), and endothelin-1 [249]. The natural anticoagulant nature of the 
endothelial cells is achieved through their cell surface expression of thrombomodulin that 
converts thrombin into an anticoagulant enzyme by binding and activating protein C that down 
regulates FVa and FVIIIa. [92].  
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Endothelial cell injury following vascular inflammation leads to shedding of endothelial micro 
particles into the blood circulating system, which can be measured with increased fragments of 
the endothelial cells in association with endothelial dysfunction and unstable coronary 
vasculitis. Imbalanced release of vasodilators and vasoconstriction-related elements result in 
endothelial dysfunction [250]. 
 
Calcium flux plays an important role during both platelet and endothelial activation [251]. In 
addition, the intracellular calcium communication mediates by co-operative interplay between 
integrin αIIbβ3 engagement and ADP activation [252]. Hence the co-ordination of calcium flux 
through platelet activation leads to an increase in the calcium signal contributing to the 
development of thrombus formation [253]. Since GPIb and integrin α2β1 aid in platelet 
adhesion that is essential for the growth of thrombus, the research findings unearth the 
possibility that calcium is responsible for signaling the downstream of the receptors and in the 
aggregation of platelets, which is vital in fluxing of calcium that facilitates the development of 
thrombus and aggregation of platelets on vWF [254]. 
 
Recent myograph studies of mouse aortic rings have demonstrated that ponatinib augmented 
norepinephrine enhanced vasoconstriction of the aortic rings compared to vehicle control 
treated [231]. Notably, vascular function is facilitated by two major regulating components that 
are produced by endothelial cells including endothelial nitric oxide synthase (eNOS) and 
cyclooxygenase-2 (COX-2). In normal circumstances, PGI2 synthesis and the expression of 
COX-2 is promoted by laminar flow, which acts as an eNOS stimulant [255]. In effect, optimal 
vascular control is attained coupled with balanced homeostasis that are essential in preventing 
the activation and aggregation of platelets. The imbalance between the endothelium relaxers 
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and contractors are the underlying mechanisms for endothelial dysfunction. This occurs when 
there is continuous reduction of NO caused by changes in eNOS activity and expression, 
increased COX factors, and increased oxygen-free radicals [256].  
 
In this chapter, cohorts of TKI-treated mice were subjected to FeCl3-mediated vascular induced 
injury of the mesenteric arterioles (80-100 µM) and in vivo microvascular thrombus growth 
was evaluated to examine the effect of calcium channel blocker (CCB) or COX-2 inhibitor, 
diclofenac or eNOS synthase inhibitor, L-NNA on ponatinib and nilotinib treated-mice. 
Moreover, an in vivo study was performed to evaluate the effect on soluble cytokines levels. 
The use of these approaches would provide an insight into the effect of pretreatment of CCB 
diltiazem, COX-2 inhibitor, diclofenac and eNOS synthase inhibitor, L-NNA on ponatinib and 
nilotinib platelet phenotype and thrombus formation in vivo under arterial flow in a C57BL/6 
mouse model. 
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  RESULTS 
5.2.1 The effect of pretreatment with calcium channel blocker, diltiazem before ponatinib 
or nilotinib-treated normal human whole blood over type I collagen under in vitro 
arterial flow conditions 
To determine the effect of calcium channel blocker prior of Bcr-Abl inhibition on human 
platelet adhesion and aggregation on type I fibrillar collagen under arterial flow, a comparison 
of ponatinib and nilotinib after pretreatment with calcium channel blocker was done. Assays 
were conducted to examine the dose-dependent effect of TKIs on in vitro platelet thrombus 
formation in blood samples +/- CCB from healthy humans and C57BL/6 mice model. Citrated 
whole blood was treated with ponatinib (0.1 µM), ponatinib (0.1 µM) & Diltiazem (5 µM), 
nilotinib (5 µM) or nilotinib (5 µM) & Diltiazem (5 µM) for 30 minutes at 37oC. Whole blood 
containing rhodamine 6G fluorescently labelled platelets was perfused through a collagen-
coated microcapillary tube flow chamber at an arterial shear rate of 1800s-1. After six minutes 
of sample perfusion, thrombus images for TKIs-treated whole blood +/- CCB were recorded 
and determined in real time. Deconvolved Z-stack images of thrombi recorded in real time 
were analysed for thrombus parameters including thrombus area, thrombus height and 
thrombus volume in the TKI-treated +/- CCB whole blood samples. 
 As shown in Figure 56 and 57, human whole blood treated with ponatinib and nilotinib showed 
increased thrombus formation for in vitro thrombus growth over type I collagen and the 
thrombus height, surface area covered by platelet thrombi and the thrombus volume compared 
to vehicle control. In contrast, the pretreatment with calcium channel blocker showed 22 % 
reduction of thrombus formation with either nilotinib or ponatinib (Figure 56 & 57). These 
results demonstrate that calcium channel blockade prior to ponatinib and nilotinib TKI 
treatment reduced platelet : ECM and platelet : platelet interactions on type I collagen.  
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Figure 56. Calcium channel blockade prior to TKI effect on in vitro thrombus 
formation and growth on Type I collagen under arterial shear flow. Representative 
images of thrombus formation over type I collagen under arterial flow conditions. 
Fluorescently labelled whole blood from human in the presence of PON (0.1 µM), PON 
(0.1 µM) & Diltiazem (5 µM), NIL (5 µM), NIL (5 µM) & Diltiazem (5 µM) and wild type 
(WT) vehicle control were perfused across 500 µg/ml type I collagen at an arterial flow rate 
of 1800s
-1
 in real time over a 6 minute time period.  
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Figure 57. Pre-treatment of whole blood from humans with calcium channel blocker, Diltiazem reduces in vitro 
thrombus formation in the presence of ponatinib or nilotinib. (A) Thrombus height, (B) Thrombus area, (C) 
Thrombus volume. Fluorescently labelled whole blood from human in the presence of PON (0.1 µM), PON (0.1 µM) 
& Diltiazem (5 µM), NIL (5 µM), NIL (5 µM) & Diltiazem (5 µM) and vehicle control were perfused across 500 
µg/ml type I collagen at an arterial flow rate of 1800s 
-1
 in real time over a 6 minute time period. (*P < 0.05, ** P < 
0.01 and *** P < 0.001; n=4) using unpaired student’s t-test.  
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5.2.2 The effect of pretreatment with calcium channel blocker before ponatinib or 
nilotinib treatment subjected to FeCl3-induced vascular injury of the mesenteric 
arterioles to assess in vivo thrombus formation 
Ponatinib and nilotinib TKIs induced a potentiating effect on in vivo thrombus formation under 
arterial flow. In this study, we examined thrombus characteristics in an in vivo FeCl3 induced 
vascular injury of mesenteric arterioles in C57BL/6 mice after pretreatment with calcium 
channel blocker prior to ponatinib or nilotinib treatment. Thrombus formation characteristics 
were analysed in real time by measuring the number of fluorescently-labelled platelets bound 
to injured endothelium. In this model, wild-type mice were treated with ponatinib (3 mg/kg) 
with and without pretreatment of CCB, diltiazem 30 mg/kg and 25 mg/kg nilotinib with and 
without CCB, diltiazem 30 mg/kg or vehicle control 25 mM citrate buffer pH 2.75 by oral 
administration at four hours before surgery. The mice were then completely anaesthetised, the 
ideal diameter of the mesenteric arterioles (80-100 µm) was determined, and the animals were 
administered rhodamine 6G dye. Thrombus growth was observed and compared between TKI-
treated mice with and without diltiazem 30 mg/kg and citrate-treated mice for 10 minutes in 
real time in vivo through intravital microscopy. The rendered Z-stack images were deconvolved 
with Axiovision Rel 4.6 software, to construct 3D-images, and the volume of the thrombi was 
calculated from the area multiplied by the height of each thrombus. Thrombi formed were 
analysed at all time points (0-2, 2-4, 4-6, 6-8 and 8-10 min). As shown in Figure 58 and 59, the 
effect of diltiazem with ponatinib treatment reduced the thrombus volume over time compared 
to ponatinib 3 mg/kg treated-mice by 48% at 10 minutes. 
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Vehicle WT+Diltiazem 3 mg/kg PON 
3 mg/kg PON & 
30 mg/kg Dilt 
2 min 
4 min 
6 min 
8 min 
10 min 
Time/min 
Figure 58. Pre-treatment of C57BL/6 mice with calcium channel blocker, Diltiazem reversed 
the prothrombotic effect of ponatinib. Representative images of thrombus formation in mesenteric 
arterioles (80-100 µm) at 2,4,6,8 and 10 minutes after 7.5% FeCl3 induced vascular injury. Vehicle 
control, WT+ Diltiazem (30 mg/kg), ponatinib (3 mg/kg) or PON (3 mg/kg) & Diltiazem (30 mg/kg) 
treated mice for 24 hours followed by ponatinib or vehicle for 4 hours were appropriate (n=4).  
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Figure 59. Kinetics of thrombus growth in C57BL/6 mice pretreated with calcium channel blocker, 
Diltiazem reversed the prothrombotic effect of ponatinib. (A) Thrombus height, (B) Thrombus area, (C) 
Thrombus volume. The kinetics of thrombus volume were determined over time for thrombi formed in mesenteric 
arterioles of various treatment groups of C57BL/6 mice. 3 dimensional deconvolved thrombi were analysed for 
volume using unpaired student’s t test (*P < 0.05, ** P < 0.01 and *** P < 0.001; n=4). 
B. C. 
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In addition, the same effect is observed with nilotinib treated-mice by pretreatment with 
diltiazem. The result showed reduced thrombus volume over time when mice were pretreated 
with calcium channel blocker before ingestion of nilotinib reversed the prothrombotic 
phenotype by 44% at 10 minutes (Figure 60 & 61). In contrast, the nilotinib-treated mice alone 
showed enhancement of thrombus growth. 
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Vehicle WT+Diltiazem 25 mg/kg NIL 
25 mg/kg NIL & 
30 mg/kg Dilt 
2 min 
4 min 
6 min 
8 min 
10 min 
Time/min 
Figure 60. Pre-treatment of C57BL/6 mice with calcium channel blocker, Diltiazem reversed 
the prothrombotic effect of nilotinib. Representative images of thrombus formation in mesenteric 
arterioles (80-100 µm) at 2,4,6,8 and 10 minutes after 7.5% FeCl3 induced vascular injury. Vehicle 
control, WT+ Diltiazem (30 mg/kg), NIL (25 mg/kg) or NIL (25 mg/kg) & Diltiazem (30 mg/kg) 
treated mice for 24 hours followed by nilotinib or vehicle control for 4 hours were appropriate (n=4).  
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Figure 61. Kinetics of thrombus growth in C57BL/6 mice pretreated with calcium channel blocker, 
Diltiazem reversed the prothrombotic effect on nilotinib. (A) Thrombus height, (B) Thrombus area, (C) 
Thrombus volume. The kinetics of thrombus volume were determined over time for thrombi formed in mesenteric 
arterioles of various treatment groups of C57BL/6 mice. 3 dimensional deconvolved of the thrombi were analysed 
for volume using unpaired student’s t test (* P < 0.05; ** P < 0.01; n=4). 
A. 
 B.     C. 
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5.2.3 The effect of pretreatment with calcium channel blocker, Diltiazem before 
ponatinib and nilotinib treatment for soluble P-selectin level 
 
P-selectin translocated to the surface and is rapidly cleaved in vivo to create soluble P-selectin 
as marker of endothelial and platelet activation [257]. Soluble P-selectin plays an important 
role in the promotion of thrombotic events by exerting procoagulant reactivity [258]. This 
ELISA experiment was used to measure the levels of sP-selectin in mouse plasma.  Plasma 
samples were collected after pretreatment with diltiazem for 24 hours prior to ponatinib and 
nilotinib treatment for 4 hours. As shown in Figure 62, both ponatinib and nilotinib showed 
increased in plasma level of sP selectin compared to vehicle control which reflects proteolytic 
shedding of P-selectin from activated platelets and endothelial cells in vivo in response to 
ponatinib or nilotinib treatment. By contrast, the pretreatment with CCB before treatment with 
ponatinib and nilotinib showed reduced plasma levels of sP-selectin compared to ponatinib and 
nilotinib treatment alone without pretreatment with diltiazem or vehicle control. Thus, these 
results support that ponatinib and nilotinib treatment positively induced platelet and endothelial 
activation via potentiation of P-selectin exposure and cleavage from platelet-endothelial cell 
surface in wild-type mice. However, the pretreatment with CCB diltiazem prevented the 
increase in plasma sP-selectin (Figure 62). 
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Figure 62. Measurement of sP-selectin levels in plasma derived from C57BL/6 mice pretreated with 
diltiazem followed by ponatinib or nilotinib. Plasma obtained from C57BL/6 mice treated with 3 mg/kg 
ponatinib, 25 mg/kg nilotinib, 3 mg/kg ponatinib & 30 mg/kg diltiazem, 25 mg/kg nilotinib & 30 mg/kg diltiazem 
or vehicle control was collected after 4 hours of ingestion. Plasma sP-selectin (ng/mL) levels of C57BL/6 mice 
treated was determined by ELISA. Each experiment were performed in triplicate and represented as mean±SEM 
of four independent experiments (*P < 0.05, ** P < 0.01 and *** P < 0.001; n=4) using unpaired students’ t test. 
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5.2.4 The effect of pretreatment with calcium channel blocker, Diltiazem before 
ponatinib and nilotinib on IL-6, TNF-alpha and IFN-gamma levels in plasma. 
 
Vascular endothelial cells and other cells including monocytes/macrophages produce TNF-
alpha, IL-6 and IFN-gamma cytokines and secreted TNF-alpha is thought to be involved in an 
autocrine activation of endothelial cells with cell-bound TNF-alpha serving to activate target 
cells on endothelial cells [259]. Both TNF-alpha and IL-6 play an important role in the acute 
phase response, inflammation and infection [260]. In this study, ELISA test was used to 
measure the levels of cytokines in mouse plasma. Plasma samples were collected after 
pretreatment of C57BL/6 mice with diltiazem for 24 hours prior ponatinib 3 mg/kg or nilotinib 
25 mg/kg treatment for 4 hours. As shown in Figure 63, 64 and 65, both ponatinib or nilotinib 
treated-mice alone showed increased plasma levels of TNF-alpha, IL-6 and IFN-gamma 
cytokines compared to the vehicle control. By contrast, the pretreatment with CCB, Diltiazem 
prior to treatment with ponatinib or nilotinib showed reduced plasma levels of IL-6, TNF-alpha 
and IFN-gamma. This result indicates that both ponatinib and nilotinib induced a pro-
inflammatory response that can be ameliorated by blockage of calcium flux. 
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Figure 63. Measurement of sIL-6 level in plasma derived from C57BL/6 mice pretreated with diltiazem 
followed by ponatinib and nilotinib. Plasma obtained from C57BL/6 mice treated with 3 mg/kg ponatinib, 25 
mg/kg nilotinib, 3 mg/kg ponatinib & 30 mg/kg diltiazem, 25 mg/kg nilotinib & 30 mg/kg diltiazem or vehicle 
control was collected after 4 hours of ingestion. Plasma IL-6 (pg/mL) levels of C57BL/6 mice treated was 
determined by ELISA. Each experiment were performed in triplicate and represented as mean±SEM of four 
independent experiments (** P < 0.01 and *** P < 0.001; n=4) using unpaired students’ t test. 
sIL-6 
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Figure 64. Measurement of TNF-alpha level in plasma derived from C57BL/6 mice pretreated with 
diltiazem followed by ponatinib and nilotinib. Plasma obtained from C57BL/6 mice treated with 3 mg/kg 
ponatinib, 25 mg/kg nilotinib, 3 mg/kg ponatinib & 30 mg/kg diltiazem, 25 mg/kg nilotinib & 30 mg/kg diltiazem 
or vehicle control was collected after 4 hours of ingestion. Plasma TNF-alpha (pg/mL) levels of C57BL/6 mice 
treated was determined by ELISA. Each experiment were performed in triplicate and represented as mean±SEM 
of four independent experiments (** P < 0.01, *** P < 0.001 and **** P < 0.0001; n=4) using unpaired student’s 
t test. 
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Figure 65. Measurement of IFN-Gamma level in plasma derived from C57BL/6 mice pretreated with 
diltiazem followed by ponatinib and nilotinib. Plasma obtained from C57BL/6 mice treated with 3 mg/kg 
ponatinib, 25 mg/kg nilotinib, 3 mg/kg ponatinib & 30 mg/kg diltiazem, 25 mg/kg nilotinib & 30 mg/kg diltiazem 
or vehicle control was collected after 4 hours of ingestion. Plasma IFN-gamma (pg/mL) levels of C57BL/6 mice 
treated was determined by ELISA. Each experiment were performed in triplicate and represented as mean±SEM 
of four independent experiments (** P < 0.01 and *** P < 0.001; n=4) using unpaired student’s t test. 
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5.2.5 The effect of pretreatment of C57BL/6 mice with COX-2 inhibitor, diclofenac 
inhibitor before ponatinib treatment subjected to FeCl3-induced vascular injury of 
the mesenteric arterioles to induce in vivo thrombus formation 
In this study, we examined thrombosis characterisation in an in vivo FeCl3 induced vascular 
injury of mesenteric arterioles in C57BL/6 mice after pretreatment with COX-2 inhibitor, 
diclofenac. Thrombus growth characteristics were analysed in real time by measuring the 
number of fluorescently-labelled platelets bound to injured endothelium. In this model, wild-
type mice were treated with ponatinib 3 mg/kg with and without pretreatment of COX-2 
inhibitor, diclofenac 10 mg/kg or vehicle control 25 mM citrate buffer pH 2.75 by oral 
administration at four hours before surgery. The mice were then completely anaesthetised, the 
ideal diameter of the mesenteric arterioles (80-100 µm) was determined, and the animals were 
administered rhodamine 6G dye. Thrombus growth was observed and compared between TKI-
treated mice with and without diclofenac 10 mg/kg and citrate-treated mice for 10 minutes in 
real time in vivo through intravital microscopy. The rendered Z-stack images were deconvolved 
with Axiovision Rel 4.6 software, to construct 3D-images, and the volume of the thrombi was 
calculated from the area multiplied by the height of each thrombus. Thrombi formed were 
analysed at all time points (0-2, 2-4, 4-6, 6-8 and 8-10 min). As shown in Figure 66 and 67, the 
effect of COX-2 inhibitor, diclofenac reverses thrombus formation by 35% at 10 minute time 
point compared to ponatinib 3 mg/kg treated-mice only. 
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Figure 66. Pre-treatment of C57BL/6 mice with COX-2 inhibitor, diclofenac reversed the prothrombotic 
effect of ponatinib. Representative images of thrombus formation in mesenteric arterioles (80-100 µm) at 2,4,6,8 
and 10 minutes after 7.5% FeCl3 induced vascular injury. Vehicle control, WT+ diclofenac (10 mg/kg), NIL (25 
mg/kg) or NIL (25 mg/kg) & diclofenac (10 mg/kg) treated mice for 24 hours followed by ponatinib or vehicle for 
4 hours were appropriate (n=4).   
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Figure 67. Kinetics of thrombus growth in C57BL/6 mice treated with COX-2 inhibitor, diclofenac reversed 
the prothrombotic effect of ponatinib. (A) Thrombus height, (B) Thrombus area, (C) Thrombus volume. The 
kinetics of thrombus volume were determined over time for thrombi formed in mesenteric arterioles of various 
treatment groups of C57BL/6 mice. 3 dimensional deconvolved thrombi were analysed for thrombus volume using 
unpaired student’s t test (* P < 0.05, ** P < 0.01 and *** P < 0.001; n=4). 
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5.2.6 The effect of pretreatment of C57BL/6 mice with eNOS synthase inhibitor, L-NNA 
before ponatinib treatment subjected to FeCl3-induced vascular injury of the 
mesenteric arterioles for in vivo thrombus formation 
In this study, we tested thrombosis characterisation in an in vivo FeCl3 induced vascular injury 
of mesenteric arterioles in C57BL/6 mice after pretreatment with eNOS synthase inhibitor, L-
NNA prior to ponatinib treatment. Thrombus growth characteristics were analysed in real time 
by measuring the number of fluorescently-labelled platelets bound to injured endothelium. In 
this model, wild-type mice were treated with ponatinib 3 mg/kg with and without pretreatment 
with L-NNA 10 mg/kg or vehicle control 25 mM citrate buffer pH 2.75 by oral administration 
at four hours before surgery. The mice were then completely anaesthetised, the ideal diameter 
of the mesenteric arterioles (80-100 µm) was determined, and the animals were administered 
rhodamine 6G dye. Thrombus growth was observed and compared between TKI-treated mice 
with and without L-NNA 10 mg/kg and citrate-treated mice for 10 minutes in real time in vivo 
through intravital microscopy. The rendered Z-stack images were deconvolved with 
Axiovision Rel 4.6 software, to construct 3D-images, and the volume of the thrombi was 
calculated from the area multiplied by the height of each thrombus. Thrombi formed were 
analysed at all time points (0-2, 2-4, 4-6, 6-8 and 8-10 min). As shown in Figure 68 and 69, the 
L-NNA reduces thrombus formation by 32% at 10 minute time point compared to ponatinib 3 
mg/kg treated-mice only. In addition, pretreatment with L-NNA inhibitor prior to ponatinib 
TKI treatment reduce thrombus formation by 30% compared to L-NNA alone or ponatinib 
alone. 
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Figure 68. Pre-treatment of C57BL/6 mice with L-NNA prior to ponatinib treatment reduced 
the prothrombotic effect of ponatinib. Vehicle control, WT & L-NNA (10 mg/kg), treated mice for 
24 hours followed by ponatinib 3 mg/kg or vehicle for 4 hours were appropriate. Representative 
images of thrombus formation in mesenteric arterioles (80-100 µm) at 2,4,6,8 and 10 minutes after 
7.5% FeCl3 induced vascular injury.  
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Figure 69. Kinetics of thrombus growth in C57BL/6 mice treated with L-NNA prior to ponatinib treatment 
reduced the prothrombotic effect of ponatinib. (A) Thrombus height, (B) Thrombus area, (C) Thrombus volume. 
The kinetics of thrombus volume were determined over time for thrombi formed in mesenteric arterioles of various 
treatment groups of C57BL/6 mice. 3 dimensional deconvolved of the thrombi were analysed for volume using 
unpaired student’s t test (* P < 0.05 and ** P < 0.01; n=4). 
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 DISCUSSION 
Endothelial cell injury following vascular inflammation leads to shedding of endothelial 
microparticles into the blood circulating system, which can be measured with increased 
fragments of the endothelium cells in association with endothelial dysfunction [261]. 
Imbalanced release of vasodilators and vasoconstriction-related elements results in endothelial 
dysfunction. Notably, endothelial dysfunction is a core effect of hypertension. Normal 
functioning endothelial cells stiffen and loose vasorelaxation [262]. This makes it an important 
feature to identify hypertension. Studies on regulation of the vascular muscle that relies on 
nitric oxide with regards to physical and pharmacological response has been achieved in the 
past ten years [263]. Evidently, reduced availability of NO is caused by endothelial 
dysfunction, which causes the oxidative stress within the cells to increase. Disturbances in the 
endothelial physiology have been linked to certain cardiovascular risks [264]. Based on 
epidemiological studies, endothelial dysfunction can occur because of chronic inflammation or 
infection.  
 
Currently, there are some proposals of how ponatinib promotes arterial occlusive events. For 
instance, the medication produces targeting effects on the multiple receptor pathways, which 
include fibroblast growth factors receptor kinases (FGFR), vascular endothelial growth factor 
receptor (VEGFR) and angiopoietin receptor (Tie-2), which produces some of targeting effects 
that can predispose to a condition of hypertension. The ponatinib has also been associated with 
thrombotic and proteinuria microangiopathy [265].  
 
According to recent research, ponatinib inhibition of VEGFR is essential since it reduces 
migration, viability and the functionality of the human umbilical vein endothelial cells 
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(HUVEC) [266]. Ponatinib also uses blocking VEGFR to exert some anti-angiogenic activity 
in HUVEC and zebrafish model by delaying VEGFR signaling pathway in either an AKT or 
P13 kinase-dependent manner [267]. A study on ponatinib TKI further revealed that it 
controlled vasomotor function, endothelial cell growth, and blood flow recovery, as evident in 
an ischaemia reperfusion mouse model [268].  
 
The blockade of Ang/Tie-2 pathway, using nilotinib or ponatinib, could upregulate the cytokine 
levels, resulting in pro-inflammatory effects [269].  These TKIs could promote cell-to-matrix 
or cell-to-cell interactions, which activates the platelets and advance the vascular effects over 
time. An analysis of the CML patients’ treated at MD Anderson with nilotinib indicated about 
2.1% of vascular events was associated with vasospasm which did not show any evidence of 
atherosclerotic lesions [230]. This vasospasm effect was enhanced with higher doses of 
nilotinib of 400 mg QD compared to the previous 300 mg QD [270].  
 
The early acute vascular effects point to ponatinib as the cause of vasospasm effects, which 
according to research, results from the dosage and later produce chronic effects of increased 
atherosclerosis, which majorly affects the CML patients with some known cardiovascular risk 
factors. Research also indicates that ponatinib cause attenuates vasorelaxation and 
vasoconstriction in the mouse aortic rings [231]. To reverse this, the use of either COX-2 or 
eNos synthase or calcium channel inhibitors, was applied to modulate vasoconstricting 
prostanoids to reduce the ponatinib effect. 
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L-type calcium channels mediate calcium flux from extracellular to intracellular space. 
Calcium influx is associated with release of calcium stores into the cytoplasm, resulting in cell 
contraction [271]. However, diltiazem is a L-type calcium channel blocker. It enhances 
vasodilatory tone by inhibiting Ca2+ flux into the vascular smooth muscle cells and enhances 
eNOS protein expression and production of endothelium derived NO [272]. Thus, bioactive 
NO is a potent inhibitor of platelet activation that could explain the reversal of ponatinib or 
nilotinib induced prothrombotic state. 
 
The regulation of COX-1 and COX-2 enzymes is different despite sharing high homology 
levels of 65 percent [273]. The two COXs can work independently despite being in the same 
cell type. COX-1 preferred substrates include fatty acids including arachidonic acid as COX-
2’s preferred substrate include 2-arachidonyl glycerol and fatty acids [274]. In addition, some 
products generated by COX-2 cannot be synthesised by COX-1. In both cases, lipid peroxides 
are required for activation purposes though COX-2 needs lower hydroperoxide concentrations 
by ten fold that its counterpart. This means that COX-2 can be used in the COX-I environments 
without being activated [275]. Moreover, Helliwell et al., identified that COX-2 is expressed 
on inflammation sites while COX-1 is expressed in most tissues even during shear stress [276].   
 
Normal functioning blood vessels express COX-1 and COX-2 through the vascular smooth 
muscle cells and endothelial cells with the former COX-2 as the predominant isoform. Despite, 
the fact that COX-2 plays a significant role in the generation of prostacyclin in humans, COX-
1 also contributes to the production of PGs in platelets. Thromboxane A2 within the 
cardiovascular system functions as a thrombogenic factor that aids in vasoconstriction through 
its generation from COX-1 and the endothelial cells. However, COX-1 disruption can result in 
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the decrease of PG synthesis though the inducible synthesis is not affected. This means normal 
survival can be achieved with severe consequences such as aggregation of impaired platelets 
and increased pain tolerance with airway hypersensitivity [277]. COX-2 deletion phenotype is 
arguably more severe since it is closely associated with an impaired inducible synthesis and 
normal PG synthesis [278]. Furthermore, prostacyclin is a powerful vasodilator and anti-
aggregating factor in blood vessels. It also functions as the main arachidonic acid metabolite 
through synthesis at the endothelium site. Nonetheless, the spread of inflammation in most 
cardiovascular diseases is often accompanied with oxidative stress that facilitates eicosanoids 
production [279]. In effect, it changes production from anti-thrombosis to a prothrombotic state 
and vasodilation to vasoconstriction.  
 
The exciting part of the study was pretreatment using L-type calcium channel blocker, 
diltiazem or COX-2 inhibitor, diclofenac or endothelial eNos synthase inhibitor, L-NNA before 
exposing to TKI treatment. The research revealed blockade of calcium flux was able to reverse 
the pro-inflammatory and prothrombotic phenotype for ponatinib. Similarly, calcium channel 
blockade also reduced the prothrombotic phenotype for nilotinib. The evidence supports the 
concept that nilotinib and ponatinib may produce a vasospastic effect, which activates 
dysregulation or contributes to endothelial and platelet activation. These actions suggest a 
direct impact on the blood vessel wall, which results in platelet and endothelial activation. Also, 
any dose of ponatinib, even at 15 mg QD, can still potentially produce fatal consequences 
[280]. The study examined ponatinib treatment in ex vivo and in vivo mouse models over a 
dose, dependent range from 3, 10 and 30 mg/kg. The study concluded that the 3 mg/kg of 
ponatinib was also sufficient to produce a prothrombotic phenotype, equivalent to 45 mg QD 
given to CML human patients.  
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The current safety measures were introduced in 2014 to counter ponatinib treatment’s adverse 
vascular effects in nilotinib and ponatinib treated patients. This will be a subject for future 
investigations. It is important to correlate the results from the single acute mouse model with 
chronically treated CML patients. Along with the safety measures were recommendations to 
reduce the amount of dosage from 45 to 30 to 15 mg QD for some patients to decrease dose-
related prothrombotic risks. Ph+ refractory leukemias or CML patients using the drug may 
require concurrent anti-inflammatory or calcium channel anti-hypersensitive or antiplatelet 
medicines or anticoagulants that reduce reduction adverse vascular events in nilotinib and 
ponatinib treated patients in further investigation.   
 
 
 
 
 
 
 
 
 
 
 
  
175 
 
 
 
 
 
 
 
 
 
Chapter 6: THE EFFECT OF TKIs ON PLATELET AND 
ENDOTHELIAL ACTIVATION AND THROMBUS 
FORMATION IN CHRONICALLY TREATED CML 
PATIENTS 
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 INTRODUCTION 
 
There is an emerging occurrence in cardiovascular disease where the TKIs which are used in 
the treatment of patients with CML trigger events of arterial thrombosis and PAOD over time. 
While most CML patients who receive either imatinib or dasatinib for treatment have not 
shown any thrombotic side effects of such, there have been increasing reports of myocardial 
infarctions and PAOD on those who have received ponatinib or nilotinib treatment over time 
[281]. 12.5% of patients with CP-CML on nilotinib, as per a study by Kim et al, who used the 
treatment was reported to have developed PAOD [230].    
 
Initial use of ponatinib was associated with increased incidence of severe arterial thrombotic 
events of 19%, thus requesting the need for careful patient selection, including consideration 
of co-morbidities and thromboembolic risks and dose reduction strategies, as the risk appeared 
to be dose dependent [282]. In addition to this, reports from different groups indicated that 
there was an increased occurrence of myocardial infarction and vascular adverse events on 
patients who were treated with 400 mg QD compared to those treated with 300 mg QD dose of 
nilotinib. This was indicated with a 12.5% and 6.1% occurrence rate on the respective doses 
[283]. Nilotinib therapy was reported to affect the lower limbs of the patients necessitating 
stent implantations, angioplasty and in severe cases, complete amputation [284]. However, 
incident reports of prothrombotic events are rare on patients receiving imatinib or dasatinib 
treatment when compared to untreated healthy patients [283]. 
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The common events reported on patients during ponatinib or nilotinib treatment were 
associated with cardiovascular risk factors such as smoking, obesity, dyslipidaemia, and 
hypertension of the arteries [285]. There are heightened risks of vascular events on CP-CML 
patients who, through clinical trials, are switched from imatinib treatment to ponatinib or 
nilotinib therapy [282]. Other metabolic effects as a result of changing to nilotinib therapy 
included increased low density lipoprotein (LDL) and hypercholesterolemia [286]. 
 
One common cause of health issues that often lead to death in the western world today is arterial 
thrombosis. This can be associated with atherosclerosis caused by narrowing of blood vessels 
with the accumulation of fatty deposits and development of atherosclerotic lesions. Following 
rupture of atherosclerotic lesions, platelets stick to exposed thrombogenic proteins such as type 
I collagen to develop blood clots. Platelets have the ability to stick together and combine with 
the injured or diseased endothelium. This characteristic makes their activation an essential 
component for thrombus growth. This can better be clinically explained using the stages of 
formation of the atherosclerotic plaque. In the early stages of the atheroma process with 
narrowing of blood vessels with increased shear flow rate, platelets are activated [287]. They 
stick together and combine with the constituents of the ECM which have been exposed in 
arterial shear conditions. This gradually initiated the growth of local thrombus inside the walls 
of the blood vessels. An amplified arterial thrombosis is thereafter caused by an activated 
platelets in conjunction with activation and assembly of coagulation complexes.  
 
According to various research studies, leukaemia treatment using anti-cancer therapy evidently 
affects the functioning of platelets. In some occasions, there is an increased aggregation of the 
platelets which end up creating pathologic thrombi [288]. Vast amounts of data obtained from 
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clinical trials indicate that there may exist other prothrombotic effects due to treatment using 
nilotinib, which is not evident with other TKIs. According to data, however, an adverse 
vascular risk profile does not fully explain the increased risk. This is because there is evidence 
of such events occurring on patients with low-risk profiles, contrary to expectations [289].  
 
Hence, this study findings provides a first-hand demonstration, of how ponatinib or nilotinib 
affects the activation of platelets and endothelium to enhance thrombus formation in ex vivo 
studies with CML patients. In contrast, the study shows how imatinib and dasatinib prevented 
the processes of platelet activation, aggregation and final formation of thrombus when 
administered to chronically TKI treated CML patients. The characteristics of these TKI-treated 
CML patients as shown in Table 4. 
 
This study focuses on the effect of ponatinib and other TKIs on platelet and endothelial 
activation, pro-inflammatory cytokines and thrombus formation in both healthy humans and 
CML patients in order to determine the ability of TKIs to induce or inhibit a prothrombotic 
state. 
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Table 4. The characteristics of TKI-treated CML patients & normal human controls. 
PVD- prinzmetal’s variant angina (coronary artery vasospasm); CVA-cerebrovascular accident; 
IHD-ischaemic heart disease. 
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 RESULTS 
6.2.1 Assessment of ex vivo platelet thrombus growth in TKI-treated CML patients over 
type I collagen under arterial flow conditions 
 
The effects of TKIs on human platelets were investigated further by comparing thrombus 
growth under arterial shear conditions by whole blood derived from CML patients treated with 
TKIs with blood from normal age matched healthy human donors (not on any antiplatelet or 
anticoagulant therapy). Rhodamine fluorescently labelled in whole blood were perfused over 
type I collagen at an arterial shear rate of 1800s-1 over a 6 minute time frame and real time 
imaging recorded. 
 
 As shown in Figure 70, blood from ponatinib or nilotinib-treated patients formed larger 
thrombi over time compared to blood from normal donors and from imatinib or dasatinib-
treated patients. A Z-stack analysis undertaken at 2, 4 and 6 minutes of thrombus growth clearly 
showed that the thrombus height and area of blood from ponatinib or nilotinib-treated patients 
was significantly larger and thrombus volume was significantly increased when compared to 
blood from healthy donors (Figure 71).  
 
By contrast, blood from patients treated with imatinib displayed a reduction in thrombus height, 
area and in thrombus volume when compared to the thrombi formed by blood from normal 
donors (Figure 71). Blood from dasatinib-treated patients showed a significant reduction in 
thrombus height, area and volume when compared to normal human donors, consistent with 
previous observations [238] (Figure 71). 
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Figure 70. The effect of TKI-treated CML patients on ex vivo thrombus formation 
and growth. Venous blood obtained from normal human donors or CML patients treated 
with ponatinib 15 mg QD, nilotinib 300 mg QD, imatinib 300 mg QD or dasatinib 100 
mg QD prior to blood collection. Platelet count was normalised to 200×109/L. 
Fluorescently-labelled platelets in whole blood from normal human donors or CML 
patients treated with ponatinib, nilotinib, imatinib or dasatinib were perfused through a 
Type I collagen-coated microcapillary (500 µg/mL) at a shear rate of 1800s-1 for 6 
minutes. Z-stack images were captured in real time with a digital Axiocam mRm camera 
(Carl Zeiss) and analysed with Zeiss Axiovision Rel4.6 software.  
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Figure 71. The kinetics of TKI-treated CML patients on ex vivo thrombus formation and growth. (A) 
Thrombus height, (B) Thrombus area (µm2) in real time was determined for thrombi formed on immobilised in type 
I collagen flow perfused with whole blood from healthy normal controls, ponatinib, nilotinib, imatinib or dasatinib 
treated CML patients. (C) Thrombus volume (µm3) over time was calculated from thrombus area (µm2)×thrombus 
height (µm) and determined at 2, 4, 6 minute time points for healthy normal controls, ponatinib, nilotinib, imatinib 
or dasatinib treated CML patients. 3D deconvolved reconstructions of thrombi formed were analysed for surface 
coverage of platelet aggregates (µm2), thrombus height (µm) and thrombus volume (µm3). Results shown are 
mean±SEM from three independent experiments. (*P<0.05, **P<0.01 and ***P<0.001) using unpaired student’s t 
test. 
A. 
B. C. 
Thrombus Height  
Thrombus Area Thrombus Volume 
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Collectively, whole blood derived from ponatinib or nilotinib-treated patients showed a 
significant increase in thrombus growth under flow conditions, which provided strong evidence 
that ponatinib and nilotinib treatment leads to an increased thrombus growth phenotype. By 
contrast, imatinib or dasatinib inhibited thrombus formation on immobilised type I collagen 
under ex vivo arterial shear flow rate. Taken together, these results indicate that the 
prothrombotic consequence of ponatinib or nilotinib treatment of CML patients is potentiated 
by the presence of the endothelium and priming of the platelets in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
184 
 
6.2.2 Measurement of soluble P-selectin 
 
P-selectin is translocated to the surface and is rapidly cleaved in vivo to create soluble P-selectin 
as a consequence of endothelial and platelet activation [290]. To examine whether ponatinib 
and other TKIs treatment altered plasma levels of sP-selectin in TKI-treated CML patients, the 
levels of sP-selectin were measured in patient plasma using sandwich ELISA. As shown in 
Figure 72, CML patients treated with ponatinib or nilotinib demonstrated a significant increase 
in plasma levels of sP-selectin, compared to normal control. By contrast, as shown in Figure 
72, levels of sP-selectin in plasma derived from patients treated with either imatinib or dasatinib 
were decreased when compared to vehicle human control. Notably, the plasma levels of sP-
selectin of normal control in this study is consistent with previous studies of random normal 
human donors (18.3-45.4 ng/ml)  [291]. Based on these results, elevated plasma levels of sP-
selectin in ponatinib or nilotinib-treated patients indicated that nilotinib induces the exposure 
of P-selectin in vivo, resulting in cleavage of P-selectin from activated platelets and/or 
endothelial cells leading to accumulation of circulating sP-selectin in patient’s plasma. 
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Figure 72. sP-selectin levels were determined in TKI-treated patients. Ponatinib-, nilotinib-, imatinib- or 
dasatinib-treated patients versus human control. Venous blood was collected from CML patients chronically 
treated with various TKI’s. Plasma sP-selectin (ng/mL) levels of CML patients treated with ponatinib, nilotinib, 
imatinib or dasatinib TKIs was determined using commercial ELISA. Plasma samples were tested in triplicate 
and presented as mean±SEM comparing to control (**P<0.01; n=2) using unpaired student’s t test. 
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6.2.3 The effect of TKI-treated patients on soluble plasma IL-6, TNF-alpha, IFN-gamma 
sICAM-1 and sVCAM-1 levels. 
 
Vascular endothelial cells and other cells including monocytes/macrophages produced TNF-
alpha, IL-6, IFN-gamma, sICAM-1 and sVCAM-1 cytokines and secreted TNF-alpha is 
thought to be involved in an autocrine activation of endothelial cells with cell-bound TNF-
alpha serving to activate target cells on endothelial cells [292]. Both TNF-alpha and IL-6 play 
an important role in the acute phase response, inflammation and infection [293]. In this study, 
ELISA test was used to measure the levels of cytokines in TKI-treated CML patient’s plasma. 
Whole blood was collected from TKI-treated CML patients and plasma by centrifugation. As 
shown in Figure 73, 74, 75, 76 and 77 both ponatinib and nilotinib treated-CML patients 
showed increased plasma levels of all cytokines compared to the normal control. By contrast, 
imatinib or dasatinib-treated patients showed a reduction in plasma levels of IL-6, TNF-alpha, 
IFN-gamma, sICAM-1 and sVCAM-1 compared to healthy normal controls. This result 
indicates that both ponatinib and nilotinib induced a pro-inflammatory response with platelet 
and endothelial activation and increased pro-inflammatory cytokines levels in chronically 
treated CML patients. 
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Figure 73. Measurement of IL-6 level in plasma derived from TKI-treated CML patients. Ponatinib-, 
nilotinib-, imatinib- or dasatinib-treated patients versus normal human controls. Venous blood was collected from 
CML patients chronically treated with TKIs. Plasma IL-6 (pg/mL) levels of patients treated with ponatinib, 
nilotinib, imatinib or dasatinib vs healthy normal controls was determined using commercial ELISA. Plasma 
sample were tested in triplicate and presented as mean±SEM comparing to control (****P<0.0001; n=2) using 
unpaired student’s t test. 
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Figure 74. Measurement of TNF-alpha level in plasma derived from TKI-treated CML patients. Ponatinib-
, nilotinib-, imatinib- or dasatinib-treated patients versus normal human controls. Venous blood was collected 
from CML patients chronically treated with TKIs. Plasma TNF-alpha (pg/mL) levels of patients treated with 
ponatinib, nilotinib, imatinib or dasatinib vs healthy normal controls was determined using commercial ELISA. 
Plasma sample were tested in triplicate and presented as mean±SEM comparing to control (****P<0.0001; n=2) 
using unpaired student’s t test. 
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Figure 75. Measurement of IFN-gamma level in plasma derived from TKIs-treated patients. Ponatinib-, 
nilotinib-, imatinib- or dasatinib-treated patients versus normal human controls. Venous blood was collected from 
CML patients chronically treated with TKIs. Plasma IFN-gamma (pg/mL) levels of patients treated with 
ponatinib, nilotinib, imatinib or dasatinib vs healthy normal controls was determined using commercial ELISA. 
Plasma sample were tested in triplicate and presented as mean±SEM comparing to control (****P<0.0001; n=2) 
using unpaired student’s t test. 
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Figure 76. Measurement of sICAM-1 level in plasma derived from TKI-treated CML patients. Ponatinib-, 
nilotinib-, imatinib- or dasatinib-treated patients versus normal human controls. Venous blood was collected from 
CML patients chronically treated with TKIs. Plasma sICAM-1 (ng/mL) levels of patients treated with ponatinib, 
nilotinib, imatinib or dasatinib vs healthy normal controls was determined using commercial ELISA. Plasma 
sample were tested in triplicate and presented as mean±SEM compared to control (***P<0.001; n=2) using 
unpaired student’s t test. 
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Figure 77. Measurement of sVCAM-1 level in plasma derived from TKI-treated CML patients. Ponatinib-, 
nilotinib-, imatinib- or dasatinib-treated patients versus normal human controls. Venous blood was collected from 
CML patients chronically treated with TKIs. Plasma sVCAM-1 (ng/mL) levels of patients treated with ponatinib, 
nilotinib, imatinib or dasatinib vs healthy normal controls was determined using commercial ELISA. Plasma 
sample were tested in triplicate and presented as mean±SEM compared to control (**P<0.01; n=2) using unpaired 
student’s t test. 
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 DISCUSSION 
According to several research studies, ponatinib increased the adverse side effect of arterial 
thrombosis [294]. In addition, the administration of nilotinib over time causes development of 
PAOD possibly due its direct effect of vasospasm of the blood vessels. This is an effect which 
imatinib treatment has not displayed [295]. The induction of vasospasm maybe the reason as 
to why younger patients who have very low cardiovascular risk factors end up developing a 
PAOD form that is rapidly progressive over time. 
 
This chapter sheds light on how the treatment of CML patients using ponatinib affects the 
functioning of platelets and endothelial cells. The first results of this study show that using 
intravital microscopy real-time imaging, it can be observed that unlike imatinib or dasatinib, 
ponatinib or nilotinib treatment significantly increased ex vivo thrombus formation on Type I 
collagen. In addition to this, results in this chapter confirmed that unlike the other TKIs, CML 
patients chronically treated with ponatinib and nilotinib increased the level of soluble plasma 
derived cytokines. It was evident that common cardiovascular risk factors significantly 
increased the chances of occurrence of vascular events. In addition, it confirmed the previous 
study of TKIs treated CML patients which showed increased of thrombus growth with nilotinib 
[238]. 
 
The ex vivo thrombus formation, as discussed in this chapter, was analysed using blood samples 
derived from healthy normal donors and CML patients chronically treated with ponatinib, 
nilotinib, imatinib or dasatinib TKI’s. This was an approach taken to correlate with TKI-treated 
C57BL/6 mice that received a single acute dose of ponatinib or nilotinib produced the same 
prothrombotic phenotype. The results showed that under ex vivo flow conditions, increased 
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adhesion of the platelets and thrombi formed on the fibrillar Type I collagen under arterial 
shear flow in ponatinib and nilotinib- treated CML patients. There was a two-fold increase in 
surface coverage of platelets, and the volume of the thrombus in CML patients who were 
chronically treated using ponatinib and nilotinib. However, in the ex vivo adhesion of the 
platelets and thrombus growth, there was an evident limited thrombus formation on CML 
patients chronically treated using either imatinib or dasatinib TKIs. This was done in 
comparison to samples from healthy humans who acted as normal controls. Similar 
observations were also made in the fourth chapter of the study where C57BL/6 mice treated 
with ponatinib and nilotinib TKIs, showed significantly increased thrombus formation, unlike 
those under imatinib and dasatinib treatment, which was seen to act as inhibitory modulators 
of thrombus growth. 
 
Results from the previous studies relate to our initial findings which showed that chronically 
treating CML patients with ponatinib and nilotinib increased under arterial flow ex vivo 
thrombus growth Type 1 collagen. In contrast, treatment using imatinib and dasatinib evidently 
reduced thrombus formation. Together, both these findings show that there is a very close 
relationship between the effects of TKIs on a single acute dose TKI treatment of wild-type 
C57BL/6 mice and on chronically treated CML patients. Both subjects showed that the TKIs 
influenced their platelet adhesion and ex vivo thrombus formation in real time under arterial 
flow conditions. 
 
The uncontrolled accumulation of the activated platelets in situations of damaged endothelial 
or ruptured atherosclerotic lesions exposed type I collagen, triggering pathologic thrombosis 
and the resultant responses could include myocardial infarction, PAOD or cerebral ischaemic 
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stroke. This happens due to the leukocytes' adhesion to the endothelium and the rolling that is 
mediated by P-selectin which enhances the condition of atherothrombosis and increased 
inflammation [296]. 
 
Various subclasses of cardiovascular diseases have described increased levels of soluble 
plasma P-selectin in vivo. In this chapter, the focus was to define in vivo endothelial and platelet 
activation by various biomarkers including sP-selectin, sICAM-1 and sVCAM-1. Plasma was 
isolated from CML patients who were treated using the four TKIs namely ponatinib, nilotinib, 
imatinib and dasatinib. Our data indicated that there was an elevated soluble plasma P-selectin 
levels in the plasma of CML patients who were treated using ponatinib or nilotinib. On the 
other hand, soluble plasma P-selectin levels showed no significant changes in CML patients 
chronically treated using imatinib or dasatinib. Most patients with PAOD have been reported 
to have high levels of sP-selectin in their plasma [297]. This was the same for those suffering 
from thrombosis, where sP-selectin is derived primarily from activated platelets and to a lesser 
extent activated endothelial cells [298]. The tethering role of GPIbα in capturing P-selectin on 
activated endothelium is clearly shown by the interaction between platelets and the 
endothelium [136]. The results of this chapter correspond to those of chapter four which 
showed that through cleavage of P-selectin and the resultant increase in soluble plasma P-
selectin of wild-type C57BL/6 mice, ponatinib and nilotinib TKIs induced activation of the 
platelets and endothelium in vivo.  
 
From recent observations, it has been confirmed that ponatinib and nilotinib increased 
production and secretion of pro-inflammatory cytokines. These TKI’s also increased release of 
soluble adhesion molecules including sICAM-1 and sVCAM from activated vascular 
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endothelium. These observations show that ponatinib and nilotinib have the potential to 
influence the formation of platelet thrombus and the release of adhesive molecules into the 
blood. There may be other contributory factors triggered by ponatinib or nilotinib TKI therapy 
that may also lead to the development of the pathological thrombi. It is however evident that 
ponatinib or nilotinib stimulates an event which is very important for platelet and vascular 
endothelial cell activation. Thereby predisposing to a prothrombotic inflammatory phenotype. 
 
In conclusion, investigative studies on the effects of TKIs in CML patients on modulating the 
formation of arterial thrombus are highly warranted. This study, despite having a limited 
sample size provides substantial evidence on the potential role of ponatinib or nilotinib in 
inducing the formation of platelet thrombus, which leads to increase of thrombotic events with 
CML patients treated with TKIs, and increased secretion of sP-selectin, proinflammatory 
cytokines and soluble adhesion molecules levels which may potentiate atherogenesis via the 
global effects on physiological function of platelets and endothelial cells. 
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Chapter 7: GENERAL DISCUSSION 
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 DISCUSSION 
 
Tyrosine kinase inhibitors are a relatively new treatment for Chronic Myeloid Leukemia 
(CML) and have improved the 10 years survival rate of CML patients in the chronic phase to 
80 percent [299]. The first TKI that was introduced in 2000 for treating CML was Imatinib 
(Gleevac) as a frontline therapy which revolutionised CML chronic phase treatment thereby 
improving survival outcomes and quality of life significantly. Nilotinib and dasatinib were 
developed as second generation TKIs for treatment to address issues of imatinib resistance and/ 
or intolerance [300]. Despite the increase in survival rate of the patients who were treated using 
the TKIs like imatinib, issues have emerged regarding the use of TKIs to treat CML [301]. One 
of the issues arising is the increase in resistance to dasatinib, nilotinib, and imatinib. Due to the 
side effects and challenges linked to dasatinib, imatinib, and nilotinib, ponatinib which is a new 
third generation TKI inhibitor multi-kinase drug has been developed to deal with mutational 
resistance for T315I. Ponatinib can inhibit T315I Bcr-Abl mutant kinases selectively, 
especially those that are not sensitive to new Bcr-Abl inhibitors obtainable at clinics [302, 303]. 
Being a third generation TKI, ponatinib uses a distinct mode of interaction in comparison to 
the other TKIs because it binds with superior affinity compared to other TKIs [304]. However, 
it was initially withdrawn due to serious vascular adverse effects [304]. 
 
The main intention of this study was to evaluate the effects of other TKIs and ponatinib in both 
mouse and human models in vitro, ex vivo and in vivo to establish its capability to provoke a 
prothrombotic condition. Thus, this study gives numerous novel insights on the results of other 
TKIs compared to ponatinib on platelet and endothelial activation together with thrombus 
growth under physiological conditions of arterial shear. The findings have broadened the 
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comprehension of the effect of ponatinib on the function of platelets and the endothelium and 
have exposed potential mechanism used by ponatinib to stimulate a prothrombotic situation. 
Differences in the modulation by ponatinib that involve the formation of platelet thrombus in 
vivo have also been established. Furthermore, the influence of dasatinib and imatinib on the 
thrombus growth over time where the two TKIs have inhibitory consequences on the 
platelet:ECM and platelet:platelet interactions involved in thrombus formation in mice and 
humans. 
 
Nilotinib and ponatinib enhance arterial thrombotic occurrence in blood vessels and the 
introduction of PAOD over time according to clinical studies [285, 305]. On the other hand, 
dasatinib and imatinib do not produce this outcome. The study gives an insight into the 
consequence of ponatinib as an activator of platelets in vitro and indicates one of the 
mechanisms which increases the risk of vascular events. This study showed that a single acute 
dose of ponatinib treatment contributed to the potentiation of platelet activation. 
 
Compared to CRP and collagen, ADP is a known weak agonist in the development of platelet 
aggregation. In chapter three, ponatinib was shown to potentiate the ADP-mediated response 
of platelet aggregation. In addition, activation of platelets takes place in reaction to vessel 
injury which is caused by various receptors like thrombin, PAR-4, and thrombin receptors 
PAR-1. PAR-1 has been discovered to be the central thrombin receptor and has a high affinity 
on human platelets whereby it links to a separate sets of heterotrimeric G-proteins to control 
signaling pathway [306]. The PAR-1 mediated α-granule release in normal healthy platelets of 
donors is potentiated by nilotinib and ponatinib. Despite the mechanism being unclear, there is 
a possibility that it has off target effects that act on PAR-1 mediated α-granule pool secretion 
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of P-selectin [307]. Therefore, this study demonstrates ponatinib as promoting aggregation of 
platelets in response to adenosine diphosphate (ADP) which was not seen with dasatinib, 
imatinib, and nilotinib. Besides, ponatinib and nilotinib were both shown to enhance exposure 
of platelet activation marker, P-selectin (CD62) from the alpha particle (α-granule) following 
PAR-1 stimulation, although there was no effect after stimulation of CRP and thrombin. 
 
Once platelets have been activated, α- granules secrete their contents where P-selectin is 
exposed and quickly translocated to the surface of platelets [308]. It takes part in causing 
inflammation by mediating the interaction. Ponatinib is connected to the reactions to 
endothelial injury or stimulating vascular tissue and also enhances exposure of P-selectin which 
implies the activation of platelets. However, the release of α-granules was not enhanced in 
PAR-4 mediated activation of platelets. Previous studies have shown that human platelets have 
different α-granule pools that are; PAR-1 mediated α-granule which releases fibrinogen 
comprising pro-angiogenic proteins and vascular endothelial growth factor (VEGF) while  
PAR-4 mediated α-granule on the other hand, releases vWF-entailing anti-angiogenic proteins 
and Endostatin [309].  This explains the differences in the releases of platelets in α-granule 
protein pools in the two autonomous groups. It is well recognised that thrombin is the most 
potent physiological stimuli and has a prominent pro-inflammatory nature [310].  
 
Nonetheless, ponatinib did not demonstrate any enhancing effect on the release of α-granule 
by thrombin-mediated exposure of activating platelets and this can be made clear by the fact 
that thrombin is associated with many receptors like PAR-4, platelet glycoprotein (GP)1b-IX-
V receptor and PAR-1.  It is important to note that GP1b binding spot for thrombin is abundant 
on platelet membrane; thus, full activation of platelets by thrombin is necessary.   
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In chapter three, the effect of TKI’s to modulate platelet:ECM and platelet: platelet interactions 
under arterial flow conditions was examined using both human and mouse model. Ponatinib's 
effect on the formation of thrombus under in vitro conditions of arterial shear flow had not 
been studied entirely unlike imatinib, dasatinib, and nilotinib in previous studies [238]. The 
study tested the ability of other TKIs versus ponatinib to modulate the growth of thrombus 
under in vitro arterial flow conditions by intravital microscopy which permitted the capture of 
real time images from C57BL/6 mouse and human samples. The experiments showed that 
nilotinib and ponatinib TKIs facilitated the growth of thrombus under in vitro arterial flow 
conditions on immobilised type I collagen over time tested at all doses. In contrast, dasatinib 
and imatinib reduced platelet adhesion and thrombus formation on immobilised type I collagen 
with the thrombus height, area and volume thrombus was significantly reduced at 4 and 6 
minutes of perfusion when compared against vehicle control of whole blood.   
 
The work done previously by Loren et al., appears to disagree with my results of in vitro 
thrombus formation that was stimulated by ponatinib [222]. The cause of this difference is not 
completely clear but it likely due to variation in test systems. These workers used a shear flow 
rate of 2200s-1 on type I collagen and blocked the collagen-coated surface with denatured BSA 
while this study used arterial shear flow rate of 1800s-1 on type 1 collagen without coating 
blocked by BSA. Another factor relates to solubilisation of ponatinib [222]. In this study, 25 
mM citrate buffer pH 2.75 achieved maximal solubilisation of ponatinib. For this solubilisation 
it provides optimal bioactive ponatinib for stimulation of platelet activation and thrombus 
formation under arterial flow conditions. 
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A study by Gratacap et al., showed that CML patients treated with imatinib reduced thrombus 
formation significantly on immobilised type I collagen under physiologic arterial shear 
condition whereas patients treated with dasatinib formed smaller thrombi than imatinib. The 
similar group of research also accounted that blood from mice treated with dasatinib formed 
smaller thrombi on type 1 collagen under arterial shear flow conditions [47]. 
 
TKIs have a different impact on the thrombus platelet formation with emerging evidence of a 
direct effect of ponatinib producing vascular arterial occlusive events [311]. Furthermore, for 
CML patients, ponatinib and nilotinib appear to trigger PAOD over time in a dose-dependent 
manner [312]. In mice treated with ponatinib a single acute dose of 3, 10 or 30 mg/kg or 25 
mg/kg of nilotinib, various methods were used to evaluate the development of thrombi in vivo 
in C57BL/6 mice, and they comprised evaluation after FeCl3 vascular induced injury of both 
the carotid artery and mesenteric arterioles.  
 
In chapter four, the potentiation of ponatinib versus the other TKIs was examined under ex vivo 
arterial shear flow rates to induce thrombus growth, was of interest in this chapter. Both 
ponatinib and nilotinib TKIs had potentiated a significant increase in thrombus growth over 
time as compared to vehicle control. In contrast, thrombus growth type 1 collagen was limited 
by dasatinib and imatinib treatment at 4 and 6 minutes of perfusion which was similar to vehicle 
control. Our results showed that a single acute dose of ponatinib of 3, 10 and 30 mg/kg or 
nilotinib 25 mg/kg enhanced thrombus ex vivo growth on mobilised type 1 collagen in contrast 
to vehicle control over time.  
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GPIb-IX-V, integrin α2β1, integrin αIIbβ3, CD9 and GPVI are the main glycoprotein receptors 
which exist on the surface of the platelets, and they play an important role in platelet regulation 
[313]. Dasatinib, however, does impair the platelet association with collagen and leads to 
downregulation of collagen GPVI/FcR γ chain ITAM coupled signaling pathway giving rise to 
bleeding events and limiting the growth of thrombus [314]. 
 
Since ponatinib treatment of C57BL/6 mice resulted in a prothrombotic phenotype, it was 
necessary to check if ponatinib modulated expression of platelet glycoproteins or the 
conformational change of integrin αIIbβ3 to an activated state in vivo. The studies showed that 
3 mg/kg ponatinib did not affect platelet glycoprotein expression or modulate the agonist 
induced conformational change of integrin αIIbβ3 in vivo. The study demonstrated similar 
capability of binding to JON/A mAb from both treated and untreated C57BL/6 mice. 
 
In chapter four either intravital microscopy or laser doppler flow probe to examine the effect 
of TKIs on FeCl3 induced vascular injury of carotid artery or mesenteric arterioles in vivo. The 
findings indicated that mice that underwent nilotinib and ponatinib treatment increased the rate 
at which the thrombus growth occurred in vivo at six, eight and ten minutes. This study and 
others proved that mice treated with dasatinib or imatinib reduced thrombus growth [221]. 
Thus, this study emphasises that dasatinib and imatinib TKIs have the capacity to limit platelet 
thrombus growth in vivo.  
 
Haemoglobin oxidation was induced by FeCl3, resulting to haemolysis of erythrocytes 
producing endothelium denudation and as a consequence exposure of the ECM molecules 
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including type I collagen [315]. It is recognised that dysfunctioning of the endothelial cells  
plays a major role in arterial thrombus growth, linked with disfunctioning of platelet, the bond 
of engaged  leukocytes, and promoting the proinflammatory cytokines release [316]. After 
platelet stimulation, adhesive proteins like CD40L and P-selectin are produced to support the 
platelets activation and enhance the arterial thrombus formation in vivo [290]. This study 
showed a reduction in thrombus growth after FeCl3 induced vascular injury in C57BL/6 mice 
treated with dasatinib as compared to the sham control indicating a major variance in 
comparison to nilotinib, ponatinib or vehicle control.  
 
In chapter four, my study showed that mice treated with dasatinib and imatinib, led to a delay 
in achieving 95% occlusion of the carotid artery when compared to vehicle control following 
induction of FeCl3 injury of the carotid artery. The induction of FeCl3 thrombosis involves 
adhesion and activation of platelets at site of vascular damage via contact with sub-endothelial 
adhesive proteins including type 1 collagen and vWF connected to their respective receptors. 
Nilotinib and ponatinib TKIs induced a prothrombic state in in vitro, ex vivo and in vivo after 
induction of FeCl3 injury as shown by preceding studies whereas both dasatinib and imatinib 
TKIs limited thrombus development. In contrast, ponatinib and nilotinib potentiated thrombus 
growth over time.  
 
Apart from the vasodilators such as calcium channel blockers regulating and making sure that 
there is enough blood flow, it is evident that the endothelium also plays a significant role [317]. 
The primary function of the vasodilators is to prevent the aggregation of the platelets [318].  
When the vasodilator secretion increases, the anti-thrombotic and anti-aggregation of the 
platelets is achieved which in turn raises the activities of adenylate cyclase and guanylate 
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cyclase which increase the levels of c-AMP and c-GMP. Apart from thromboxane A2, 
angiotensin II, ROS, and endothelin-1 are also vasoconstrictors that are secreted by the 
endothelium. Through the cell surface expression of thrombomodulin, the endothelial cells 
regulate coagulation by interaction with thrombin that leads to binding and activation of protein 
C to downregulate coagulation through inactivation of FVa and FVIIIa. [247].  
 
The endothelial cells are indeed delicate, and this makes them susceptible to injury or disease 
which may affect wound repair processes. Detaching of the endothelial microparticles into the 
blood circulation system results from endothelial cell injury after a vascular inflammation 
[319]. The rise in the fragments of the endothelial cells, as well as endothelial dysfunction, are 
what is used to quantify the shedding of the endothelial microparticles [320]. Remarkably, 
hypertension is a core cause of dysfunctioning of the endothelium [321]. The blood vessels 
lose their capacity to vasodilate which is a way to identify if a person has hypertension [322]. 
Endothelial dysfunction leads to the lower accessibility of NO, and therefore the oxidative 
pressure escalates within the cells. Cardiovascular risk is linked with any disturbance 
experienced in the endothelium [323]. According to previous studies, the dysfunctioning of the 
endothelium can also be influenced by chronic inflammation [324].  
 
Specific possible mechanisms of how ponatinib stimulates arterial occlusive events are being 
proposed.  These include fibroblast growth factors receptor kinases (FGFR), the vascular 
endothelial growth factor receptor (VEGFR) and angiopoietin receptor (Tie-2) are potential 
targets of ponatinib TKI on multiple receptor pathways that may be capable of predisposing to 
vasospastic or hypertensive conditions. There is also the apparent association between 
thrombotic and proteinuria microangiopathy with the ponatinib TKI drug [325]. 
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Ponatinib inhibition of VEGFR is vital because it reduces migration and the functioning of the 
HUVEC [312]. Moreover, to exert some anti-antigenic activity in HUVEC and zebrafish, 
ponatinib blocks VEGFR in a AKT and P13 kinase-dependent manner [326].  From these 
studies, there arose a question on the function of VEGFR pathway in preventing unfavourable 
vascular occurrences. 
 
The use of either nilotinib or ponatinib to block the Ang/Tie-2 pathway could block the pro-
inflammatory effects due to the up-regulation of the cytokine levels. Cell-to-cell interactions 
or cell-to matrix can also result from the blockade, and they activate the platelets while at the 
same time progressing the vascular complications with time. A retrospective CML's patient 
study at MD Anderson showed that 2.1% vascular events of patients treated with nilotinib were 
linked with vasospasm and thus lacking macro evidence of atherosclerotic lesions [327]. 
Higher doses of nilotinib to 400 mg QD as compared to the former 300 mg QD heightened the 
vasospasm influence [230]. According to the early acute vascular effects, the cause of 
vasospasm is seen to be nilotinib, ponatinib or possibly dasatinib therapy [327]. However, 
research has shown the chronic effects of TKIs over time of amplified atherosclerosis, which 
primarily affects patients with cardiovascular risk factors [328]. Interestingly, ponatinib TKI 
has been shown to have the capacity to attenuate vasorelaxation and vasoconstriction of mouse 
aortic rings in vitro [231]. COX-2 inhibitor, diclofenac, eNOS synthase inhibitor, L-NNA as 
well as CCB, nifedipine were able to reverse this process and these observations suggested that 
vasoconstriction prostanoids are associated with ponatinib treatment [231]. 
While COX-1 and COX-2 share about 65 percent of homology, the two COXs are quite diverse 
in function [329]. For COX-1, fatty acids and arachidonic acid are the chosen substrates while 
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2-arachidonyl glycerol and fatty acid are the preference for COX-2 [330]. Even though COX-
2 requires secondary absorptions of hydrogen peroxide than its counterpart, both need lipid 
peroxides for activation [331]. Therefore, in the presence of COX-1, COX-2 can be used to 
treat the conditions that cause inflammation without being stimulated.  
 
It is through the smooth vascular muscle cells and the endothelial cells, that the blood vessel 
usually operates by expression of COX-1 and COX-2 with the latter being the major isoform. 
COX-1 contributes to the production of PGs while the COX-2 is attributed majorly with the 
generation of prostacyclin in human beings [332]. Within the cardiovascular system, 
thromboxane A2 purposes as an accumulating factor which helps in the vasoconstriction in its 
production from COX-1 in platelets as well as the endothelial cells [333]. Although the 
inducible synthesis is never affected, the interruption of COX-1 can lead to the reduction of the 
integration of PG and in the blood vessels, prostacyclin is considered to be a potent vasodilator 
and an anti-aggregating cause [334]. It is arguable that COX-2 deletion phenotype is further 
severe because of its close association with an impaired inducible synthesis of  PG [335]. Also, 
in the endothelium, prostacyclin is the main arachidonic acid metabolite [336].  
 
Before the exposure to TKI, the interesting part of this study was to test if the prothrombotic 
state could be ameliorated by pretreatment with the use of either L-type calcium channel 
blocker, diltiazem, COX-2 inhibitor, diclofenac or eNos synthase inhibitor, L-NNA. The pro-
inflammatory and prothrombotic phenotype could be reversed by pretreatment with the calcium 
channel inhibitor, diltiazem prior to nilotinib or ponatinib treatment as shown in this study. 
According to the evidence produced, a vasospastic effect may be produced by nilotinib and 
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ponatinib as this could trigger dysregulation or aid towards endothelial activation. However, 
platelet and endothelium are activated as a result of the impact on the blood vessel wall. 
 
Diltiazem belongs to the benzothiazepine class of calcium channel blockers. It has the capacity 
to enhance vasodilatory tone by inhibiting calcium influx into vascular smooth muscle cells 
and increasing by endothelial eNOS expression. Diltiazem also increases the production of 
endothelial derived NO which would explain the potent inhibition of thrombus growth 
potentiated by either ponatinib or nilotinib TKIs. NO is a known potent bioactive inhibitor of 
platelet activation released from activated endothelial cells. 
 
Consistent with this prothrombotic finding  of ponatinib dose, any dose of ponatinib even as 
little as 15 mg QD can result in some severe vascular consequences [281]. Ponatinib treatment 
in ex vivo and in vivo mouse models are examined in this study over a single acute dose range 
between 3, 10 and 30 mg/kg.  The conclusion of the study showed that prothrombotic 
phenotype could be produced by 3 mg/kg of ponatinib which equated to 45 mg QD applied to 
CML human patients. In 2014, there was introduction of protective actions to reduce the 
adverse vascular effects of ponatinib treatment.  This included a reduction in prothrombotic 
risks related to the dose, lowering the dose intake from 45 to 30 to 15 mg QD. Patients with 
CML or Ph+ refractory leukemia use drugs that may expose them to a thrombo-inflammatory 
phenotype over time. Therefore, to lower the risks associated with these medicines and to lower 
vascular occurrences with nilotinib and ponatinib, investigating the use of anti-inflammatory 
or calcium channel anti-hypersensitive or anti-platelet measures should be considered.  
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The adverse events (AEs) of the arterial thrombotic status are said to be increased by ponatinib  
TKI as shown by numerous clinical studies [282]. Additionally, incidents of PAOD with the 
use of nilotinib overtime as a direct consequences on vasospasm of the blood vessels [295]. 
The effect was not observed  by imatinib treatment but vasospasm has been reported with 
dasatinib use [337]. The reason above explains why young patients with low cardiovascular 
risk end up getting a form of PAOD that progresses quickly over time. 
 
Therefore, this study intends to bring to light how treating patients with ponatinib influences 
the way platelets and endothelial cells function. Using intravital microscopy real-time imaging 
according to the first findings of the study, it can be noted that using nilotinib and ponatinib 
for treatment increased of ex vivo thrombus formation on type I collagen, unlike dasatinib and 
imatinib. Furthermore, the results according to this study proved that using nilotinib or 
ponatinib treatment increased soluble cytokines levels in chronically treated CML patients 
which are different from other TKIs. It was clear that common cardiovascular risk factors 
significantly increased incidence of vascular events. However, arterial vascular events were 
reported on CML patients who exhibited low-risk factors indicated the direct effect of ponatinib 
and nilotinib treatment [338].  
 
The ex vivo thrombus formation as discussed in this study was examined blood samples from 
healthy normal donors, compared to chronically TKI-treated CML patients receiving dasatinib, 
imatinib, nilotinib, or ponatinib therapy. This approach was performed to compare results of 
chronically treated CML patients using TKIs or with a single acute dose of TKI treatment in a 
mouse C57BL/6 model.  Under ex vivo flow conditions, the interaction between platelets with 
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type I collagen was enhanced in thrombus height, surface coverage (area) and thrombus volume 
in CML patients who had undergone nilotinib or ponatinib treatment. 
 
On the other hand, in the ex vivo interaction of the platelets and type I collagen, there was 
inhibition in the thrombus formation over time on patients who have are treated with either 
dasatinib or imatinib TKIs compared to healthy human controls. Similar observations were 
made in chapter four of this study where nilotinib or ponatinib TKIs treated C57BL/6 mice, 
displayed great potential for thrombus formation unlike those being treated with dasatinib and 
imatinib, which acted as inhibitory modulators of thrombus formation and growth. 
 
Importantly this study highlighted that single acute dose of ponatinib or nilotinib in C57BL/6 
correlated with a prothrombotic phenotype demonstrated in chronically treated CML patients. 
In contrast, dasatinib and imatinib treatment reduced thrombus formation. The two findings 
showed a close correlation between the outcomes of TKIs on human beings and wild-type mice 
where the two subjects indicated that TKIs affected platelet: ECM and platelet: platelet 
interactions to modulate and thrombus formation over time under arterial flow conditions. 
 
The unrestrained buildup of the activated platelets in circumstances of injured endothelium or 
ruptured atherosclerosis lesions in blood vessels where increased levels of type 1 collagen 
occur, can induce pathological thrombosis and which may result in myocardial infarction or 
cerebral ischaemic stroke. During this process, leukocytes interact with the endothelium, as a 
consequence of leukocyte rolling mediated by P-selectin which increases the inflammatory 
response and may predispose to atherothrombosis [339]. 
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A variety of subclasses of cardiovascular diseases have showed increased levels of soluble P-
selectin in plasma as a consequence of endothelial and platelet activation. In this study, plasma 
was obtained from chronically TKI treated CML patients on either dasatinib, imatinib, 
ponatinib, and nilotinib. My study showed that higher soluble plasma P-selectin levels were 
present in CML patients chronically exposed to nilotinib and ponatinib treatment. Nonetheless, 
there were no significant changes in patients on dasatinib or imatinib treatment compared to 
healthy controls.  
 
The role of GPIbα of tethering to capture P-selectin on endothelium that is activated is shown 
in the interaction between the endothelium and platelets [340]. These results match up with the 
ones from chapter four which indicated that P-selectin cleavage with subsequent rise in soluble 
P-selectin plasma levels in wild-type mouse treated with either nilotinib or ponatinib 
highlighted platelet and endothelial activation in vivo. Based upon on these results, the rise in 
sP-selectin plasma levels in TKI treated mice or human CML patients, the activation of 
platelets and endothelium in vivo is influenced by nilotinib and ponatinib TKI therapy. This 
study highlighted that nilotinib and ponatinib TKIs increased secretion and production of 
cytokines known to be pro-inflammatory. This study demonstrated that nilotinib and ponatinib 
have great potential to influence platelet thrombus formation and secretion of soluble adhesion 
molecules, sVCAM-1 and sICAM-1 and pro-inflammatory cytokines (IL-6, TNF-alpha and 
IFN-gamma). 
7.1.1 CONCLUSION 
To conclude, chronically treated CML patients on ponatinib therapy is linked with augmented 
rates of atherothrombotic occurrences as evidenced by clinical data. Various effects and 
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insights of different TKIs on the role of platelet profiles resulting from human blood and murine 
samples have shown by this study. Imatinib and dasatinib treatments have inhibitory effects on 
platelet aggregation as proved by experiments in my study and from studies in other 
laboratories  on platelet granule exocytosis and in vitro thrombus formation [237].  Ponatinib 
and nilotinib potentiated platelet alpha-granule release (P-selectin exposure) selectively as 
depicted by the studies in chapter three in reaction to PAR-1 in the human platelets and this 
implies that nilotinib and ponatinib have the ability to potentiate agonist induced platelet 
activation.    
 
What is confirmed in the study is the possible association of ponatinib treatment for both human 
and murine platelets on platelet type I collagen in the enhancement of in vitro thrombus growth. 
Both nilotinib and ponatinib TKIs potentiated the growth of arteriolar thrombus growth over 
time. These TKIs modulated the platelet activation, adhesion and aggregation steps of 
thrombus formation. This may explain why ponatinib or nilotinib TKIs have the capacity to 
increase thrombus formation in settings of atherosclerosis and vascular disease.   
 
Novel insights on how the formation of an arteriolar thrombus is influenced by TKIs via various 
models in vivo have also been highlighted. After a single acute dose of ponatinib or nilotinib 
selectively produced a prothrombotic state in vivo in the context of different vascular beds. 
Analysis of formation of platelet thrombus included FeCl3 induced vascular injury of either 
mesenteric arterioles (80-100 µm in diameter) or of the carotid artery.  
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The study concluded that ponatinib 3 mg/kg was sufficient to reduce a prothrombotic 
phenotype which is equivalent to CML patients receiving 45 mg QD. In order to counter the 
prothrombotic effects of ponatinib treatment, altered measures were introduced in 2014. 
Recommendations were made together with safety actions to lower the amount of dose from 
45 mg QD to 15 mg QD to reduce the dose-related prothrombotic effect for CML treated 
patients. Typically, these patients with CML and Ph+ refractory leukemia and receiving drug 
treatment with ponatinib developed a thrombo-inflammatory phenotype over time. To 
minimise these adverse effects of ponatinib TKI or nilotinib and lower the vascular events on 
patients treated with these TKIs, there is a possibility to implement the use of anti-inflammatory 
or anti-platelet drugs, or calcium channel blockers or direct oral anti-coagulant drugs. 
 
Reducing the side effects of arterial thrombus development in ponatinib or nilotinib treated 
CML patients is warranted. This study provided substantial evidence on modulatory function 
of ponatinib or nilotinib to enhance the development of thrombus formation. It indicates a rise 
in the occurrence of thrombosis in patients with CML and who are treated with TKIs could 
potentially occur because of the increasing of levels of sP-selectin and cytokine secretion from 
endothelial cells and platelets. Based on these results, ponatinib and nilotinib TKIs have a 
prothrombotic effect that leads to thrombotic complications which can be reversed by 
pretreatment with L-type calcium channel blocker, diltiazem and by COX-2 inhibitor, 
diclofenac and to a lesser extent eNOS synthase inhibitor, L-NNA. 
 
7.1.2 FUTURE DIRECTIONS 
Data obtained from this study was from a small group of chronically treated CML patients 
treated with either ponatinib, nilotinib, imatinib or dasatinib therapy and thus a significant 
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constraint is the patient number. Further studied should explore the relationship between raised 
blood glucose and levels of xLDL and the thrombogenic potent in patients undergoing through 
the TKI treatment over time. 
 
The ponatinib dose of 15 mg QD is currently administered in haematology clinics to CML 
patients or 300 mg QD nilotinib or 400 mg QD imatinib or 100 mg QD dasatinib. However, in 
research experiments involving animals, an acute single dose of TKIs was given orally to 
C57BL/6 mice to examine thrombus growth equated with the same dose given to CML patients. 
Thus, the requirement of advanced studies to analyse the TKIs effects on various mechanisms 
of thrombus growth and stability in a mouse model with bcr-abl Ph+ treated using TKI therapies 
is warranted. 
 
The fact that the CCB diltiazem was able to reverse the prothrombotic and pro-inflammatory 
phenotype in a C57BL/6 mouse model it would be valuable to apply the CCB in human clinical 
trials. A clinical trial in nilotinib-treated or ponatinib treated CML patients with treatment arms 
of nilotinib or ponatinib alone versus treatment with calcium channel blocker, diltiazem in 
conjunction with TKI therapy. In addition, nilotinib or ponatinib-treated CML patients who 
develop vascular complications of coronary artery vasospasm or cerebrovascular accident 
could be treated in conjunction with L-type calcium channel blocker to reduce arterial occlusive 
events. 
 
Further studies should examine the effect of other anti-platelet agents including ticagrelor or 
clopidogrel (P2Y12 antagonists) or new anti-coagulants such as apixaban and rivaroxaban (FXa 
  
214 
 
inhibitors) to see whether the acute effects of ponatinib or nilotinib could be prevented. In 
addition, examine the effect of statins which seem to ameliorate a proinflammatory state. 
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